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Summary 
Gene regulation in higher eukaryotes is a complex and dynamic process involving the 
coordinated action of several transcription factors and coregulators. The assembly of multi-
protein complexes at promoter or enhancer elements modulates the activity of whole biological 
pathways and contributes to the physiological plasticity of cells and tissues. However, given their 
complexity and the high number of players involved, these regulatory processes are still poorly 
understood. In this context, next generation sequencing methods like the chromatin 
immunoprecipitation sequencing technique (ChIP-Seq) provide a novel approach for mapping 
the interactions between protein complexes and DNA elements on a genome-wide scale. 
In this project, we perform a comprehensive coregulator-tailored ChIP-Seq data analysis to 
study the global recruitment of the peroxisome proliferator-activated receptor γ coactivator 1 α 
(PGC-1α) and of the nuclear estrogen-related receptor α (ERRα) in skeletal muscle. Moreover, 
by integrating this information with microarray expression data, we infer the direct and indirect 
effects of our proteins of interest on their downstream target genes and, thus, on the regulated 
biological pathways. In addition, by combining several computational techniques, including 
binding site prediction and principal component analysis, we identify the activator protein 1 (AP-
1) and the specificity protein 1 (SP1) as novel transcriptional partners in the PGC-1α- and 
ERRα-mediated regulation of energy metabolism in skeletal muscle. Our study provides a new 
approach for the genome-wide analysis of coregulators and sheds light on the transcriptional 
network controlling skeletal muscle plasticity. 
The content of this thesis is organized as follows. In chapter 1 we depict the state-of-the-art 
regarding nuclear receptors (and in particular ERRα), coregulators (with a focus on PGC-1α) 
and next generation sequencing technologies; moreover, we present the aims that motivated the 
projects described in this thesis. Chapter 2 illustrates our ChIP-Seq data analysis procedure, 
starting from the raw reads till the peak calling step. As every maturing technique, ChIP-Seq is 
accompanied by a number of issues that still need to be addressed; for this reason, we focus 
particularly on the artifacts we found and on our computational approaches to solve them. In 
chapter 3 we describe the downstream analysis steps of ChIP-Seq studies, including peak 
annotation, motif search and principal component analysis of peak binding site predictions. The 
results of the computational techniques described in the previous chapters to dissect PGC-1α 
regulatory network in skeletal muscle are illustrated in chapter 4, whereas in chapter 5 we focus 
on the interplay between PGC-1α and ERRα and in particular we examine to which extent ERRα 
7 
is required for PGC-1α-mediated effects on skeletal muscle cells. Finally, the discussion will 
review the main findings of the present thesis and provide an outlook on the possible future 
developments of this study. 
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1. Introduction 
1.1. Nuclear receptors 
Nuclear receptors (NRs) are a class of transcription factors that modulate several major 
physiological processes, ranging from development to reproduction, inflammation, and 
metabolism [1]. As for all transcription factors, this regulatory capacity of NRs relies on their 
ability to recognize specific DNA sequences at the promoter of their target genes and to affect 
the rate of RNA polymerase II-directed transcription by interacting with other components of the 
general transcriptional machinery [2]. The next sections will provide a detailed description of NR 
different types and functions, as well as an in-depth portrait of the ERR family of nuclear 
receptors and in particular of ERRα. 
1.1.1. Classification, structure and function 
The nuclear receptors superfamily is encoded by a set of 49 genes in mouse (48 in human and 
47 in rat) [3] and consists of two distinct groups of transcription factors: the first includes the 
“ligand-activated” NRs, which transduce thyroid hormones, steroid hormones, retinoids and 
vitamin D signals into physiological responses; the second, namely the “orphan receptors”, is a 
group of factors for which no known endogenous ligands have been identified so far [4]. 
Because of their specific response to small molecules, the ligand-induced family of NRs has 
been more extensively studied to develop drugs for the treatment of several pathological states, 
including obesity, diabetes, cancer and cardiovascular or metabolic diseases; the growing 
interest in these therapeutic targets has led to the creation of numerous databases and web 
resources containing the set of all transcription factor binding sites on a genome-wide scale, also 
called “cistrome” (for some examples, see [5, 6]). 
As illustrated in Figure 1.1, the domain structure common to most of the NR superfamily 
members consists of four functional units: an amino-terminal activation domain (named AF1), a 
central DNA binding domain (or DBD) and a carboxy-terminal ligand binding domain (also known 
as LBD), which hosts a second activation function domain (AF2). The most conserved region is 
the DBD, which consist of two zinc finger domains to recognize specific NR-responsive elements 
(NRREs) in the regulatory regions of their target genes [7]. The LBD domain, whose function is 
to provide a hydrophobic pocket for binding recognition, is also a target for post-translational 
11 
modifications, which alter the NR stability and binding affinity, resulting in a modulated target 
gene expression. 
 
Figure 1.1 Nuclear receptors structural domains. From [8]. 
Nuclear receptors can be classified according to several criteria; for example, on the basis of the 
ligand-binding properties, NRs can be subdivided in hormone receptors, metabolic receptors and 
orphan receptors (Fig.1.2). NRs belonging to the first group – such as the androgen receptor 
(AR) or the glucocorticoid receptor (GR) – generally bind to the DNA as homodimers and are 
usually located in the cytosol; upon binding to their ligands, they translocate to the nucleus and 
recognize their cognate NRRE sequences on the DNA. Metabolic receptors – like for example 
the farnesoid X receptor (FXR), the liver X receptor (LXR) and the peroxisome proliferator-
activated receptors (PPARs) – are instead located in the nucleus and often bound to the DNA in 
heterodimers with the retinoid X receptor (RXR). The third group of receptors – which include the 
steroidogenic factor 1 (SF1) and the liver receptor homolog-1 (LRH-1) – are generally regulating 
transcription through changes in their expression or post-translational modifications and can 
work either as heterodimers or as monomers [7]. 
Chromatin accessibility to DNase I and histone modifications contribute to nuclear receptors 
binding to the DNA both before and after the interaction with their cognate ligands: John and 
colleagues have shown that the glucocorticoid receptor often binds to pre-existing regions of 
open chromatin [9], while Hurtado et al. reported that a significant fraction of estrogen receptor 
alpha sites were accessible before estrogen induction [10]. On the other hand, chromatin 
remodeling continues also post-induction, as it has been shown that the binding of certain 
nuclear receptors, as well as some nuclear factors – like the forkhead box protein A1 (FOXA1) – 
can act as “pioneer factors” to facilitate the binding for a second NR through recruitment of 
nucleosome remodeling complexes (such as the SWitch/Sucrose NonFermentable complex 
SWI/SNF), in a process called “assisted loading” [11, 12]. 
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Nuclear receptors can regulate transcription, both positively and negatively, by multiple 
mechanisms. In the absence of a ligand, NRs are often part of complexes including corepressor 
proteins such as the nuclear receptor co-repressor 1 (NCoR1) or the nuclear receptor co-
repressor 2 (also called SMRT). However, this ligand-independent repression is not the only way 
to diminish target genes expression: several NRs (e.g. GR or LXRs) can also repress 
transcription in a ligand-dependent manner (named “transrepression”) by antagonizing and 
inhibiting the activity of other signal-dependent transcription factors; one example is the nuclear 
factor-κB (NF-κB), which plays a crucial role as effector of pro-inflammatory signaling pathways. 
Differently from other transcription factors, several NRs are able to activate transcription only 
upon the binding of their cognate ligand, which: (i) triggers the dissociation of the corepressor, 
(ii) induces a conformational change in the α-helical region of the C terminal domain AF2 and (iii) 
stabilizes the binding of the receptor with the DNA. This ligand-dependent transactivation has 
the role of recruiting the coactivator proteins and, through these, of modifying the local chromatin 
structure to facilitate the assembly of the transcriptional complex [13]. 
 
Figure 1.2 Nuclear receptors can be classified in three groups on the basis of their ligand-binding 
properties: (A) hormone receptors, (B) metabolic receptors and (C) orphan receptors. From [8]. 
1.1.2. The ERR family of nuclear receptors 
One interesting group of nuclear receptors is represented by the estrogen-related receptor 
(ERR) subfamily. All the three members of this family, ERRα, ERRβ and ERRγ belong to the 
orphan receptor category, as no endogenous ligands have been identified to date. Based on its 
high sequence homology with the estrogen receptor alpha (ERα), ERRα was the first of the 
three NRs, together with ERRβ, to be identified [14]. However, differently from ERα, neither 
ERRα nor the other two members of the family were shown to bind estrogen [14], as confirmed 
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by crystallographic and functional studies indicating that the ERRs are constitutively active 
without a natural ligand [15, 16]. On the other hand, several synthetic ligands have been found 
to modulate the activity of the ERRs. One of these is the synthetic nonsteroidal estrogen 
diethylstilbestrol (DES), widely used to prevent spontaneous abortion in women until it was 
withdrew by the United States Food and Drug Administration in the 70s, as it was shown to 
cause a rare vaginal tumor. Other synthetic ligands are tamoxifen (TAM) and its derivative 4-
OHT, which act as estrogen antagonists in mammary glands and are clinically used for breast 
cancer treatment. Although the in vitro effects of DES and TAM were documented for ERRβ and 
ERRγ, no endogenous ERRα-interacting molecule has been identified to date [17], while the 
synthetic compound XCT-790 has been shown to act as a selective inverse agonist of ERRα 
[18]. 
The DNA sequence recognized by all the three family members is the extended half site 
TNAAGGTCA, which is present either single or repeated and to which the ERRs can bind as 
monomers or dimers, respectively; in the latter case, although several groups have suggested 
that the orientation and spacing between the two half sites might determine the specificity of 
recognition, an in-depth study on ERRγ reported instead no clear relationships between the 
spacing and the binding affinity of the nuclear receptor [19]. Furthermore, Zhang and others 
have demonstrated that ERRs can bind and compete with ERα to the classical estrogen 
response element sites (EREs) [20], which is a 13 bp-long palindromic sequence composed by 
two inverted repeats separated by a 3 bp-long central spacer [21]. 
Concerning the biological functions of ERRs, a number of studies have established a central role 
of these nuclear receptors in the regulation of energy metabolism and mitochondrial biogenesis 
[22], as confirmed by their expression patterns: in fact, although they are ubiquitously expressed, 
their level is much higher in tissues with high energy demands, like brain, heart, kidney, retina, 
brown adipose tissue and skeletal muscle [23]. Albeit they have overlapping functions, the ERRs 
carry also distinct biological roles. For example, ERRβ plays crucial roles in placental 
development [24], inner ear maturation [25], photoreceptor survival [26] and type I muscle fiber 
formation together with ERRγ [27]. On the other hand, ERRγ was shown by a loss-of-function 
study to be specifically important for the maintenance of cardiac, gastric, and renal potassium 
homeostasis [28]. Moreover, ERRγ muscle-specific transgenic mice showed increased 
expression of genes promoting fat metabolism, TCA cycle and vascularization [29]. 
Similarly to ERRγ, ERRα also plays a relevant role in the regulation of energy metabolism and in 
particular of fatty acids metabolism, as it induces the pyruvate dehydrogenase kinase 4 (PDK4), 
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a negative regulator of glucose oxidation [30]. Although no phenotypic change in skeletal muscle 
(apart from reduced fat mass) has been observed in whole-body ERRα knockout animals [31], 
the over-expression of ERRα in C2C12 myoblasts accelerated their differentiation to myotubes 
via modulation of the mitogen-activated protein kinase (MAPK) signaling pathway, highlighting 
the importance of ERRα in promoting muscle growth [32]. Several studies have shown that the 
peroxisome proliferator activated receptor γ coactivator 1α (PGC-1α) is a strong inducer and 
coactivator of ERRα, which in turn promotes its own transcription in a positive feedback loop and 
regulates mitochondrial function [33-35]. 
 
Figure 1.3 Schematic model for regulation of ERRα and PGC-1α target genes. Adapted from [36]. 
1.2. Coregulators of transcription 
The efficacy of nuclear receptor-mediated transcription strongly depends on coregulators, a 
group of proteins that associate with NRs and alter the state of the chromatin to either enhance 
(“coactivators”) or inhibit (“corepressors”) NRs ability of regulating the expression of hormone-
responsive genes [37]. The abundance of these coregulators – which include also the receptor-
interacting protein 140 (RIP140) and the nuclear receptor co-repressor 1 (NCoR1) – is regulated 
in response to a variety of physiological stimuli, (such as exercise, cold and fasting) and in 
pathological conditions [38]. 
1.2.1. Types and molecular mechanism of action 
Apart from their final effect as activators or repressors of transcription, coregulators can be 
distinguished on the basis of their mechanism of action in two main groups: the ATP-dependent 
remodeling factors and the histone acetyltransferases (HATs). 
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Coregulators belonging to the first group use the energy produced from the hydrolysis of ATP to 
introduce a superhelical torsion into the chromatin, thus actively altering nucleosome positions 
(by sliding or ejecting them) and rendering the DNA either more or less accessible to 
transcription factors [39]. The yeast SWI/SNF complex was the first remodeling factor to be 
identified, followed by the imitation SWI (ISWI) proteins and the RSC (remodeling the structure 
of chromatin) complex, whose corresponding human orthologs are the SMARC proteins. 
Many coactivator proteins either possess intrinsic histone acetyltransferase enzymatic activities 
or recruit other proteins with this activity to regulatory regions. At physiological pH, the 
electrostatic interactions between the deprotonated phosphates of the DNA backbone (hence, 
positively charged) and the protonated lysine residues of the histones (negatively charged) are 
responsible for the binding of the DNA to the histones. The function of the HAT proteins is to 
acetylate the side chains of the histone lysines, thus weakening the tight bond that keeps the 
DNA wrapped around them. As a consequence, the chromatin becomes more accessible to 
transcription factors and to the general transcriptional machinery. Conversely, several 
corepressor proteins possess histone deacetylase properties or recruit histone deacetylases 
(HDACs) to remove the acetyl groups from lysines and, thus, restoring the condensed and 
inaccessible state of the DNA. Some examples of corepressors belonging to this group are the 
REST corepressor proteins (RCoR 1, 2 and 3) and the nuclear receptor co-repressor proteins 
(NCoR1 and 2); in skeletal muscle, NCoR1 can repress ERRα under basal conditions, thereby 
decreasing metabolic genes transcription, while it is significantly reduced upon exercise and 
caloric restriction [40, 41]. On the other hand, examples of coactivator proteins include the p300 
protein, which plays an essential role in regulating cell growth, and the peroxisome proliferator 
activated receptor γ coactivator 1 proteins (PGC-1α and β). 
1.2.2. The PGC-1 family of coactivators 
The peroxisome proliferator activated receptor (PPAR) γ coactivator 1 (PGC-1) protein family is 
composed of three members: PGC-1α, PGC-1β and the PGC-1-related coactivator (PRC). The 
structure features common to all the three proteins are: (i) an N-terminal activation domain (AD), 
(ii) one or more LXXLL or LLXXL motifs (where L stands for leucine and X for any amino acid), 
which are used to interact with nuclear receptors, (iii) a serine-rich domain and (iv) a C-terminal 
RNA recognition and splicing motif (for a detailed description, see [42]). Similarly to other 
coactivators, due to the lack of a DNA binding domain, the PGC-1 members do not interact 
directly with the DNA, but rather act as scaffolds for the recruitment of other proteins containing 
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enzymatic activities and of NRs [43]. With these, they form multi-protein complexes that 
positively regulate the expression of their target genes.  
PRC can be found ubiquitously, whereas PGC-1α and PGC-1β are highly expressed in organs 
with high energy demands (in terms of oxygen and ATP consumption), like skeletal muscle, 
heart, kidney, brain and brown adipose tissue. While PRC has not been extensively studied, 
PGC-1β is known to play a role in muscle endurance capacity and angiogenesis [44, 45], in liver 
lipogenesis [46], osteoclast activation [47] and brown fat differentiation [48]. In the next sections 
we will focus on the modulation of PGC-1α expression and activity, as well as on the 
transcriptional network regulated by this coactivator in skeletal muscle. 
1.2.3. Modulation of PGC-1α expression and activity 
The most studied member of the PGC-1 family is undoubtedly PGC-1α. As it is a potent inducer 
of transcription, its regulation is tightly controlled by several mechanisms (Fig.1.4), including 
intracellular signaling cascades and post-translational modifications (PTMs). 
Some examples of the several intracellular events that control the synthesis of PGC-1α mRNA 
are: (i) the cyclic AMP response element-binding protein (CREB), which binds to the PGC-1α 
promoter when phosphorylated upon exercise-induced calcium release [49]; (ii) the AMP-
activated protein kinase (AMPK), following muscle contraction [50]; (iii) the MEF2C and MEF2D 
transcription factors, which trigger an auto-regulatory feed-forward loop [51]; (iv) the FOXO1 
transcription factor, that inhibits PGC-1α expression in liver [52]; (v) the orphan nuclear receptor 
SHP, shown to reduce PGC-1α transcription in brown adipose tissue [53]. 
 
Figure 1.4 Regulation of PGC-1α transcription. The promoter of PGC-1α hosts binding sites for the 
transcription factors MEF2, FoxO1, ATF2 and CREB, which enhance PGC-1α transcription in response to 
distinct signaling pathways (insulin, cytokines, exercise, cold and blood glucagon levels). From [54]. 
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Several PTMs of PGC-1α have been reported, including methylation, phosphorylation, 
sumoylation, acetylation and ubiquitination. For example, phosphorylation of its serine and 
threonine residues by AMPK and p38/MAPK are able to stabilize the relatively short half-life (2 
or 3 h) of PGC-1α [50, 55]; on the contrary, poly-ubiquitination is a signal for proteosomal 
degradation of the protein [56]. The acetylation of PGC-1α lysine residues determines its activity: 
in fact, while the acetylation by the general control of amino acid synthesis protein 5 (GCN5) 
inactivates PGC-1α [57], the deacetylation by the protein sirtuin 1 (SIRT1) re-activates PGC-1α 
in response to the NAD+/NADH ratio [58]. 
1.2.4. Transcriptional network regulated by PGC-1α in skeletal muscle 
Originally discovered as thermogenic regulator in brown adipose tissue (BAT) upon cold 
exposure [59], PGC-1α has later been shown to play different roles in other tissues. For 
example, it is required to reduce neurodegeneration caused by reactive oxygen species (ROS) 
in brain [60], for protection against light-induced damages in retina [61] and for gluconeogenesis, 
ketogenesis, heme and bile acids biosynthesis in liver [49, 62-64].  
However, the tissue in which PGC-1α shows the most remarkable effects is skeletal muscle (for 
an overview, see Fig.1.5). In this organ, the nodal functions of PGC-1α are the coordination of 
oxidative metabolism and the promotion of mitochondrial biogenesis, which are key 
determinants of skeletal muscle plasticity and are required to meet higher energy demands [65]. 
Mitochondrial biogenesis is a long-term adaptive process that results in the increase of the 
mitochondrial content of a tissue and in the change of mitochondrial protein-to-lipid ratio [66]. 
This process requires the coordinated transcription of a large number of nuclear mitochondrial 
genes, the synthesis of new proteins and lipids and the replication and transcription of the 
mitochondrial DNA, which encodes some essential components of the oxidative phosphorylation 
(OXPHOS) complexes [67]. In response to exercise, PGC-1α mRNA and protein levels increase, 
enabling this coactivator to integrate physiological signals and to enhance mitochondrial 
biogenesis [68, 69]. For this process, several transcription factors cooperate with and are 
coactivated by PGC-1α. The nuclear respiratory factor 1 (NRF-1), NRF-2 (also called GA-
binding protein or GABP) and ERRα are some well-known examples; upon induction of their 
genes, PGC-1α stimulates the expression of mitochondrial genes including the cytochrome c 
oxidase subunit 4 (COX4) enzyme and the mitochondrial transcription factor A (Tfam) which, in 
turn, regulates transcription of the mitochondrial DNA genes [33, 68]. A direct consequence of 
mitochondrial biogenesis is an increase in ROS production, which is addressed by PGC-1α 
through the enhanced expression of the ROS detoxifying enzymes, although this has been 
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shown so far only for the brain [60]. Moreover, to provide an adequate energy supply to the cell, 
PGC-1α also promotes lipid refueling through activation of de novo lipogenesis and increases 
fatty acids oxidation by coactivating PPARα [70, 71]. 
PGC-1α is highly expressed in skeletal muscle and particularly enriched in the slow-twitch type I 
fibers, which are more oxidative, vascularized and rich in mitochondrial content than the fast-
twitch type II fibers. Transgenic expression of PGC-1α showed to drive a shift in fiber type from 
fast to slow-twitch fibers and the transition from a resistance phenotype (i.e. with high muscle 
strength and mass) to a more aerobic endurance phenotype [72]. In rodents, PGC-1α was 
shown to be transiently induced after a single bout of low-intensity swimming exercise [73]; 
accordingly, chronically elevated levels of PGC-1α mRNA were observed upon endurance 
exercise training in humans [69]. In contrast, muscle-specific deletion of PGC-1α resulted in 
reduced resistance to fatigue and elevated markers of inflammation [74] , thereby providing a 
link between metabolic and immune signaling pathways (for an extensive review, see [42]).  
 
Figure 1.5 Overview of the multiple pathways in skeletal muscle regulated by PGC-1α through distinct 
TFs. Green and red arrows represent up- and down-regulation, respectively. Adapted from [65]. 
1.3. Next generation sequencing techniques 
1.3.1. The ChIP-Seq procedure 
DNA sequencing is the process used to precisely determine the exact order of nucleotides 
(adenine, cytosine, guanine and thymine) composing a fragment of deoxyribonucleic acid (DNA). 
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As this molecule encodes the genes of a living organism and the instructions to express them in 
time and space, the determination of its sequence has become of crucial importance in Biology 
for a better understanding of an organism's characteristics and diseases. 
Since the "chain-termination method" was developed by Frederick Sanger in 1977, it has 
become the method of choice for almost three decades and, thanks to its low error rate (per-
base accuracy as high as 99.999%) [75], it is still in use for small-scale experiments and to 
confirm de novo sequences. Briefly, the method consists into four separate sequencing 
reactions, each of which containing a chemically-altered deoxynucleotide (dATP, dCTP, dGTP, 
dTTP). Every time the enzyme DNA polymerase incorporates at random one of these molecules 
into the growing DNA chain, the copying process is stopped. The resulting DNA fragments are 
loaded on a gel electrophoresis chamber, where the original sequence can be deduced by 
reading from the smallest to the largest piece of DNA. 
Over the past ten years, the "next generation sequencing" (NGS) has progressively replaced 
Sanger sequencing and has become the gold-standard to obtain millions of DNA sequenced 
fragments in a much more time- and cost-effective manner. In fact, although every NGS platform 
employs a different technology, the key difference with traditional Sanger sequencing is that 
these new methods are able to massively parallelize the sequencing process and to perform, for 
example, the "high-throughput" sequencing of an entire human genome in less than one day 
[76].  
A multitude of NGS applications have arisen in the last decade. For example, NGS techniques 
can be used to detect large structural variations as copy-number variants (CNVs) as well as 
single-nucleotide polymorphisms (SNPs) and other chromosomal rearrangements [77]. Likewise, 
NGS methods are intensively used for whole transcriptome profiling analysis (RNA-Seq) to take 
a snapshot of the RNA presence and quantity at a given moment in time; mRNA studies in 
particular have begun to replace the use of microarrays to determine expression profiles. Other 
methods, like the photoactivatable-ribonucleoside-enhanced crosslinking immunoprecipitation 
(PAR-CLIP), can be used to analyze protein interactions with RNA and are particularly useful to 
detect miRNA target sites [78]. Finally, ChIP-sequencing (or ChIP-Seq) is a widespread 
procedure to analyze protein interactions with DNA. 
By combining chromatin immunoprecipitation (ChIP) with massively parallel sequencing, ChIP-
Seq can be used to precisely map binding sites for a protein of interest genome-wide. Since it 
was developed in 2007 [79, 80], this method has suddenly replaced the ChIP-on-chip technique 
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(i.e. ChIP on a microarray) thanks to the higher resolution and genome coverage. The sensitivity 
of this technology depends on several factors, including the sequencing platform employed and 
the sequencing depth (or coverage), which corresponds to the number of reads representing a 
given basepair in the reconstructed sequence. The method, which can be applied both to 
transcription factors and to epigenetic histone modifications, consists of two steps (Fig.1.6). 
 
Figure 1.6 ChIP-Seq technique combines chromatin immunoprecipitation (ChIP) with next-generation 
sequencing to map all protein–DNA interactions genome-wide. From [81]. 
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The first is the ChIP, which enriches particular DNA-protein complexes by selecting them with a 
specific antibody against the protein of interest; the quality of the final results will strongly 
depend on this first step and, in particular, on the affinity of the antibody for the protein of 
interest. The second part begins with the purified DNA fragments, which are sequenced 
simultaneously through a genome analyzer; millions of sequenced reads are then aligned to the 
reference genome and the IP-enriched regions, or “peaks” – corresponding to the sites where 
the protein of interest was originally recruited to – are identified. 
1.3.2. Data processing issues from sequencing experiments 
As every new technology, also ChIP-Seq has certain limitations, many of which arise during the 
experimental part of the procedure, with a huge impact on the downstream data analysis and 
therefore on the final results. One example is the amount of starting material. Standard ChIP-
Seq protocols typically require large quantities of starting material, in the range of 107 cells, in 
order to obtain a quantity comprised between 1 and 10 ng of immunoprecipitated DNA. Gilfillan 
and colleagues have reported that a lower cell number risks the involvement of too many cycles 
of polymerase chain reaction (PCR) to obtain the desired quantity of DNA [82]. The direct 
consequence of these extra-amplification runs is a drastic reduction of the sensitivity of the 
method and the rise of PCR duplicates artifacts (that show up as “stacks” of sequences on the 
genome), which can be wrongly interpreted as binding sites during the peak calling step of the 
analysis. Conversely, loading too much material on the slide (in the case of Illumina sequencing) 
can result in fluorescent labels too close to each other to be correctly distinguished, causing 
lower data quality [83]. 
Another critical determinant of the quality of the ChIP-Seq experiment is the antibody. Choosing 
a specific antibody will result in a high level of IP enrichment over the background, while using a 
non-specific antibody will give rise to false positive peaks. Therefore, apart from testing the 
enrichment obtained at known binding sites prior the sequencing, it is recommendable to always 
couple the IP to a control sample, which will ease the peak calling step and avoid misleading 
enrichment events. Commonly used control samples are: (i) the “input” DNA, that is, DNA prior 
immunoprecipitation, (ii) the “mock” IP, treated like the IP sample but without any antibody, or 
(iii) a non-specific antibody, such as anti-IgG. 
The choice of using a limited number of sequencing cycles – for example, resulting in DNA 
sequences (usually called “tags”) 25 or 36 basepairs long – can also be problematic during the 
mapping step of the analysis, as short sequences can be ambiguously mapped to repeated or 
22 
low-complexity regions of the reference genome. Moreover, as the number of sequencing cycles 
increases, there is an exponential decay (or “fading”) in the fluorescent signal intensity, which 
often results in wrongly called bases [84] and, therefore, in errors during the mapping step of the 
analysis. Using longer reads (e.g. 50 basepairs long) or paired-end sequencing, in combination 
with a quality filter of the sequenced tags, can help to reduce this type of problems. 
1.3.3. Computational challenges of coregulator ChIP-Seq data analysis 
The growing interest in the molecular function of nuclear receptors and coregulator proteins has 
led to an increase in the number of ChIP-Seq studies to identify their binding sites genome-wide. 
However, coregulators do not bind DNA directly, but rather exert their function by interacting with 
several other proteins, such as nuclear receptors and chromatin remodeling complexes. 
Therefore, this indirect action of coregulators poses additional challenges to the analysis of 
ChIP-Seq data. 
First of all, this technique will detect only indirect protein-DNA interactions, making it difficult to 
trace back which transcription factor was mediating the interaction of the coregulator with the 
DNA. Moreover, since coregulators are able to control several distinct factors, it is highly 
probable that different peaks will correspond to different transcription factor instances, albeit 
bound to the same coregulator. Hence, a de novo motif analysis of the ChIP-Seq peaks will be 
dominated by the most enriched transcription factor (TF), although other TFs might be bound as 
well, even if to a minor extent, by the chipped coregulator. 
Another challenge in coregulator ChIP-Seq data analysis is a direct consequence of the fact that 
coregulators can bind to enhancer regions and bring these in contact with promoters – which 
might be located farther away from the enhancer – to increase the gene transcription rate. As 
ChIP-Seq blocks the whole DNA-protein complex through formaldehyde, it might happen that an 
enhancer peak will be wrongly assigned to its nearest gene, rather than to the truly regulated 
gene, located next to the promoter in contact with the enhancer. 
1.4. Genome-wide studies on ERRα and PGC-1α 
Based on genetic and molecular approaches in highly oxidative tissues, a number of ERRα and 
PGC-1α target genes involved in carbohydrate, lipid and mitochondrial metabolism have been 
identified during the last decade. However, although specific characteristics of both ERRα and 
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PGC-1α have been thoroughly analyzed by several studies, only a few of them have explored to 
date the recruitment and the downstream effects of these two proteins on a genome-wide scale. 
By performing ChIP-on-chip assay and microarray analysis on wild-type and ERRα null mice 
hearts, the group of Vincent Giguère showed that ERRα is involved in the uptake, production 
and transport of energy substrates across mitochondrial membranes, as well as in the 
intracellular sensing of altered Ca2+ levels, which represent the signal of an increased demand of 
energy sources [85]. Using a similar genome-wide approach, the same group later identified 
ERRα as a regulator of renal Na+/K+ homeostasis and of the renin-angiotensin pathway in mice 
kidneys [86]. In liver, a ChIP-Seq experiment on endogenous ERRα showed that the mammalian 
target of rapamycin (mTOR) regulates ERRα activity by repressing its ubiquitin-mediated 
degradation; in fact, rapamycin treatment, as well as genetic ablation of ERRα, reduced ERRα 
ability to control TCA cycle and lipid biosynthesis, causing the development of nonalcoholic fatty 
liver disease [87]. Finally, a ChIP-on-chip study on ERRα in mouse liver showed a significant 
overlap between its metabolic target genes and the recruitment sites of the homeobox protein 
prospero-related homeobox 1 (Prox1); moreover, Prox1 was shown to interact with both ERRα 
and PGC-1α and to inhibit their activity in the context of energy production [88]. 
Regarding PGC-1α, the first genome wide study was conducted in 2004 by the Spiegelman’s 
group [35]. By combining a microarray of PGC-1α-induced transcriptional profiles with a 
computational approach to detect cis-regulatory motifs in genome-wide promoter regions, the 
authors identified ERRα and GABPA as key transcription factors for the regulation of the 
OXPHOS pathway. In particular, the software they developed, MotifADE, identified the two TFs 
by (i) ranking all array genes expression fold changes, (ii) performing a k-mer search in their 
promoter regions and (iii) using the Mann-Whitney rank sum statistic to determine whether the 
distribution of fold changes for the subset of genes containing a given k-mer was significantly 
different from the genes lacking the k-mer. Another genome-wide study, conducted in the group 
of Jiandie Lin, identified the BRG1-associated factor 60a (BAF60a) as a novel partner of PGC-
1α in the regulation of hepatic lipid metabolism [89]; through a coactivation reporter screen, the 
authors created a collection of 1146 transcriptional regulators (corresponding to ~48% of all 
predicted human TFs and cofactors) and tested whether the activity of individual TFs was 
enhanced in presence or absence of PGC-1α. To our knowledge, the only ChIP-Seq analysis of 
PGC-1α was performed by Charos and colleagues in human hepatic carcinoma cells (HepG2) 
treated with forskolin, an inducer of PGC-1α [90]. A de novo motif search in the top 250 peaks 
identified heat shock factor 1 (HSF1), ERRα and the CCAAT/enhancer-binding protein β 
(CEBPB), although no experimental validation of these predictions was reported; moreover, the 
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association of regulator-occupancy with gene expression revealed a stronger correlation of 
PGC-1α with down-regulated than with up-regulated genes, which is in contrast with the well-
known coactivatory function of PGC-1α. 
In conclusion, despite some studies have started to explore the regulatory networks controlled 
by ERRα and PGC-1α, the exhaustive set of partner TFs and of the corresponding downstream 
targets, in particular for the skeletal muscle tissue, is still far from complete. 
1.5. Aims of the thesis 
The coactivator PGC-1α and the nuclear receptor ERRα have been extensively shown to 
regulate key biological processes related to energy metabolism in higher eukaryotes. However, 
a rigorous and complete genome-wide analysis of their DNA recruitment in skeletal muscle and 
of their downstream effects on directly-controlled pathways has not been described so far. In this 
thesis, using a combination of several computational techniques for the analysis of high-
throughput sequencing data, we aimed to unravel the complex transcriptional network of skeletal 
muscle and to identify novel functional partners for PGC-1α and ERRα. Moreover, we sought to 
elucidate to which extent are PGC-1α-mediated effects dependent or not on ERRα and which 
are the biological pathways they regulate together, directly and indirectly, in skeletal muscle 
cells. Furthermore, we tried to definitely answer the long-debated question of a possible PGC-1α 
role as corepressor by looking at the direct and indirect regulatory effects of PGC-1α on the 
activity of all known transcription factors. In addition, the lack of a well-defined analysis pipeline 
for the study of coregulator ChIP-Seq data motivated us to optimize every step of the NGS data 
processing method and to provide a solution to the numerous artifacts of this recently developed 
technique. 
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2. ChIP-Seq data analysis – From raw data to peaks 
identification 
2.1. ChIP-Seq platforms and technologies 
Nowadays, the most commonly used ChIP-Seq platforms are provided by Illumina, Ion Torrent 
and Roche 454 Pyrosequencing. In the latter technique, each DNA fragment (up to 1 kilobase, 
or kb) is fixed, through a generic adaptor, to a DNA-capture bead and amplified. Each bead is 
then placed, together with DNA polymerase and sequencing buffers, into a single well of a slide, 
where the reaction of synthesis takes place; every time the slide is flooded with one of the four 
nucleotides, the successful incorporation of the base in the DNA releases a light signal, whose 
density is detected and used to reconstruct the sequence. 
In contrast, Ion Torrent technology does not make use of any optical signal; instead, it 
determines how many nucleotides (if any) are added at each cycle by measuring the change in 
pH which happens upon the release of an H+ ion following the addition of a base to the DNA 
polymer. 
The procedure adopted by the Illumina Genome Analyzer is the most alike to the classical 
Sanger sequencing, as it also exploits terminator bases to stop the PCR reaction as soon as 
they are incorporated in the growing DNA. However, the biggest novelty of the Illumina 
technology consists in the fact that these nucleotides are "reversible terminator bases" (RT-
bases) and, as such, once the fluorescent dye is chopped by the cleavage enzyme, they revert 
to normally functioning nucleotides [1]. This property of the reagent allows to speed up the so 
called process of "sequencing-by-synthesis" and to reach a significantly higher throughput 
compared to Sanger sequencing (Fig.2.1). 
More in detail, the Illumina sequencing process, which is the one we chose to generate most of 
the data contained in this thesis, begins with the library preparation. During this phase, which 
takes about 6 hours, the protein of interest is cross-linked by formaldehyde to the DNA and the 
genomic material is sheared by sonication into fragments that, ideally, should result in a range 
between 100 and 1000 basepairs (bp) long [2]. This range can be further reduced and become 
much tighter after the size selection process. The following step consists in the addition of bead-
attached antibodies, raised against the protein of interest, to immunoprecipitate specific DNA-
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protein complexes; in parallel, a sample of the whole cell extract (WCE, also called "Input DNA") 
is put aside and later used as the background to determine the enrichment of the target protein. 
After purification of the DNA-protein complexes, generic adapter sequences are ligated to the 
ChIP DNA and to the WCE, and both samples undergo a PCR amplification step in order to get 
enough starting material for the sequencing reaction.  
 
Figure 2.1 The Illumina sequencing method. From [3]. 
Single strand ChIP DNA and WCE oligos are loaded on individual lanes of an Illumina slide, 
named "flowcell", and hybridized to it through the previously ligated adapters. Next, DNA oligos 
32 
undergo about 5 hours of automated cluster generation. During this process, called "bridge 
amplification", the DNA templates are repeatedly: (i) denatured, (ii) hybridized (or "bridged") to a 
complementary primer, (iii) extended through forward and reverse primers which are covalently 
attached to the flowcell and (iv) linearized again. Through this solid-phase amplification, single 
DNA molecules are turned into clonal clusters of up to 1000 identical copies, ending with the 
production of 100-200 millions of spatially separated clusters across the flowcell surface. 
To determine the sequence of each of these clusters, the four previously mentioned RT-bases 
are added to the flowcell so that the DNA polymerase enzymes can start incorporating them in 
the nascent DNA strands simultaneously. Cycle after cycle, a new nucleotide is added to each 
synthesized strand (based on the sequence of the template) and the fluorescence emitted by the 
dye bound to the incorporated base is detected by a camera. The sequential images captured 
during this sequencing-by-synthesis are processed in the following image analysis step, which 
includes clusters identification, background correction and finally base calling, through which the 
fluorescence signals are converted into actual data (the sequenced "reads" or "tags") together 
with the corresponding quality scores. 
2.2. Quality filter of sequenced reads 
The most commonly used file format to store raw sequencing reads obtained from an Illumina 
instrument is the "FASTQ format". Similarly to the classical FASTA format, a FASTQ file is a 
text-based human readable format, which consists of a set of biological sequences, each 
preceded and represented by a one-line header. However, the fundamental difference with 
FASTA files is the possibility to store also reads' corresponding quality scores, as calculated by 
the sequencing instrument. This new piece of information is listed right after the read's 
sequence, such that each biological sequence in the FASTQ file is composed of the following 
four lines: 
- line 1 begins with the "@" character, followed by a sequence identifier; for Illumina data, the 
identifier usually contains: the instrument name, the flowcell lane number, the tile number with 
'x'- and 'y'-coordinates, and, in some cases, a "Y" or "N" whether the read failed the instrument's 
filter or not, respectively; 
- line 2 is the sequence of the read, which consists of the symbols "A", "C", "G", "T", "N" 
according to the IUPAC notation; 
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- line 3 begins with the "+" character and is an optional identifier; 
- line 4 encodes the quality values of the read in ASCII characters and its length correspond to 
that of line 2. 
The quality score 𝑄 associated to a given nucleotide is a value related to the probability 𝑝 that 
the corresponding base call is incorrect [4]. Since quality scores were introduced, two different 
equations have been used to define the value of 𝑄. The first, adopted for Sanger sequencing 
and named after the PHRED software, was defined in terms of the estimated probability of error: 
𝑄𝑃𝐻𝑅𝐸𝐷 = −10𝑙𝑜𝑔10𝑝 
To translate quality scores in single characters (or bytes), FASTQ files used ASCII 33-126 to 
encode PHRED qualities from 0 to 93, thus adopting an offset of 33. 
The second equation, introduced by the Solexa pipeline in 2004, substituted the simple 
probability 𝑝 with the odds 𝑝/(1 − 𝑝): 
𝑄𝑆𝑂𝐿𝐸𝑋𝐴 = −10𝑙𝑜𝑔10 � 𝑝1 − 𝑝� 
For this new formula, an offset of 64 was chosen to translate quality scores in ASCII characters 
from 59 to 126. Values obtained using the two equations above could be mapped to each other 
through the following conversions, as defined in [5]: 
𝑄𝑃𝐻𝑅𝐸𝐷 = −10𝑙𝑜𝑔10�10𝑄𝑆𝑂𝐿𝐸𝑋𝐴/10 + 1� 
𝑄𝑆𝑂𝐿𝐸𝑋𝐴 = −10𝑙𝑜𝑔10�10𝑄𝑃𝐻𝑅𝐸𝐷/10 − 1� 
Finally, after Solexa Inc. was acquired by Illumina in 2006, the original PHRED equation was 
reintroduced; however, to be interchangeable with the earlier Solexa files, an offset of 64 (rather 
than 33) was adopted. For an overview of the different mappings of quality scores to ASCII 
characters, see Figure 2.2. 
Since Li & Homer showed in 2010 that using a base quality filter halves the frequency of 
incorrect read alignment errors [6], several research groups are becoming more and more aware 
of the importance of filtering low-quality reads to improve the accuracy of the downstream 
analysis steps [7-9]. 
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Figure 2.2 Base quality convertion to ASCII characters. From Wikipedia, retrieved March 25, 2014, from 
http://en.wikipedia.org/wiki/FASTQ_format. 
Because of the different versions of quality encodings, the most arduous part of the filtering is 
the determination of the instrument version that was used to sequence the data. Once this 
obstacle is overcome, the filtering algorithm consists in translating back the ASCII characters of 
each sequenced read into qualities and deciding whether to keep, discard or trim the read (i.e. 
cut bases off from the low-quality end) according to specified cutoffs. To filter our ChIP-Seq 
datasets, we decided to keep only those reads with: (i) a minimum length of 25 basepairs, (ii) an 
average minimum quality of Q = 20 (corresponding to an error rate of 1%) and (iii) no more than 
2 undefined bases (reported in the FASTQ file as "N").  
Essentially, the algorithm we developed analyses the first million tags in the input file and 
collects from these the numerical values corresponding to minimum and maximum ASCII 
characters, in order to decipher the codification which was used by the instrument. Once this is 
accomplished, the program parses the file one record (i.e. one read) at the time and scans its 
quality string symbol by symbol; whenever the average quality falls below the user-defined 
cutoff, if the length of the read till the current basepair is bigger than the defined length cutoff, 
the read is trimmed and written in the output file; otherwise, it is skipped. Also, if the DNA 
sequence contains more than 2 Ns, that read is not reported in the output file. 
A useful way to visualize the quality of the sequenced reads before and after the filtering 
process, is provided by software like FastQC 
(www.bioinformatics.babraham.ac.uk/projects/fastqc), which provide a set of useful quality 
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checks (like "Basic Statistics", "Per base GC content" or "Sequence Duplication Levels") on raw 
sequence data coming from high throughput experiments. To visualize and confirm the results of 
our quality filter, we looked in particular at the "Per base sequence quality" feature, as shown in 
Figure 2.3. 
 
Figure 2.3 Bar plot showing the quality scores of reads of the second IP replicate from the PGC-1alpha 
sequencing before (A) and after (B) the quality filter. The y axis is the quality score; colored regions 
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represent low (red), medium (orange) and high (green) qualities. Each bar represents the quantiles and 
average quality of the first to the nth base over all reads in the input file. It can be noticed that, as usual, 
quality degrades toward the end of the sequence. 
2.3. Mapping to the reference genome 
The next step after the quality filter is the mapping of the sequenced reads to the reference 
genome. Nowadays, there are several programs to performs this task; in case of reads obtained 
from a Solexa/Illumina instrument, the currently most used tools are MAQ [10], SOAP [11], 
Bowtie [12] and BWA [13]. Bowtie in particular, which we chose to align reads from our datasets, 
has the advantage of being particularly fast, space efficient and at the same time very accurate, 
thanks to the implementation of an algorithm called "Burrows-Wheeler transform". This method, 
originally developed for data compression, rearranges a character string by sorting all 
lexicographic rotations of the original text, then sorting all rows in alphabetical order and finally 
extracting from this matrix the last column. In this way, it is possible to create an index of a 
whole mouse genome that occupies only about 2.4 GB on disk and that requires less than 2 GB 
of RAM for the alignment. 
Bowtie has many command-line options that can be tuned according to the desired result; the 
most commonly used options are described in [14]. For our purpose, we decided to avoid the 
common practice of discarding multi-mappers, as it leads to a significant loss of information in 
case, for example, the reads map to duplicated regions of the genome or the protein of interest 
binds frequently to repeated DNA sequences. For this reason, we used the combination of 
parameters "--best --strata -a -m 100" to report all valid alignments per read which were "best" in 
terms of stratum (i.e. number of mismatches) and in terms of the mismatched position(s) quality 
values; moreover, the option "-m" suppressed all reads which had more than 100 reportable 
alignments. In the following steps, for those tags mapped to more than one position (i.e. multi-
mappers) we assigned to each locus a weight corresponding to the fraction of all alignments 
reported for that particular read, that is 1/number of positions the read maps to.  
Table 2.1 shows the percentages of reads, from our PGC-1alpha datasets, which were 
successfully mapped using Bowtie. It is worth noting that, in general, for mouse ChIP-Seq data a 
percentage of uniquely mapped reads higher than 70% is considered normal, while a 
percentage lower than 50% might indicate problems with the sequencing platform or that the 
chipped protein might bind frequently in repetitive DNA regions [4]. 
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Table 1 Bowtie report for the 4 samples of the PGC-1α sequencing. 
 
2.4. Removal of ChIP-Seq artifacts 
Right after the mapping step, the mappings can be transformed into genomic densities and 
visualized in a genome browser, like for example the University of California at Santa Cruz 
(UCSC) Genome Browser [15] or the Integrative Genomics Viewer (IGV) from the Broad Institute 
[16]. Specifically, the file containing the mapped alignments per read, usually stored in a "SAM" 
or "BAM" (i.e. the binary version of SAM) format [17], need to be converted to a "WIG" or 
"BigWIG" file [15], which contains the number of reads per position at single basepair resolution. 
Viewing the data in the context of its genomic region can turn out to be quite informative; in fact, 
a visual inspection of the data can help to identify particular artifacts like Kb-large regions with 
an enrichment that is many orders of magnitude higher than the surrounding density, or like 
"stacks" of reads (Fig.2.4). 
 
Figure 2.4 Most common ChIP-Seq artifacts. The upper panel depicts an entire chromosome where two 
regions stand out as highly sampled. (A) False enrichment caused by repeated or low-complexity regions 
(shown by the thick black lines). Red and blue represent reads on forward and reverse strand, 
Reads subset IP 1st repl. WCE 1st repl. IP 2nd repl. WCE 2nd repl.
Processed 6'711'717 17'899'074 36'580'431 35'525'221
With at least one reported alignment 5'699'648 (84.92%) 16'053'370 (89.69%) 21'448'059 (58.63%) 32'244'584 (90.77%)
Failed to align 628'807 (9.37%) 755'365 (4.22%) 13'863'112 (37.90%) 1'140'329 (3.21%)
With alignments suppressed due to -m 383'262 (5.71%) 1'090'339 (6.09%) 1'269'260 (3.47%) 2'140'308 (6.02%)
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respectively. (B) Probable PCR amplification error causing a “stack” of reads. Dark blue lines represent 
the single reads mapped on the genome and piled on each other, producing the profile in light blue. Upper 
and lower panel illustrate the “stack” before and after duplicates removal and shows that the light blue 
profile disappears. From [18]. 
For the first case (schematized by panel A in figure 2.4, from [18]), the principal sources of error 
might be mapping mistakes around low-complexity regions or genomic repeated locations 
whose length have been underestimated at the moment of the assembly, while the second 
artifact (schematized by panel B in figure 2.4, from [18]) originates mainly from PCR 
amplification errors arising during the sample preparation step. 
To disentangle the first type of artifact, we used a 2 kb long sliding window and counted the 
amount of control reads (from the WCE sample) genome-wide; the distribution of these counts 
(Fig.2.5) helped us to set a sample-specific cutoff to the maximum number of background reads 
which was used in the following peak finding step. This way, we prevented calling as (false 
positive) peaks enriched regions located in repeated or low-complexity regions (Fig.2.6). 
 
Figure 2.5 Control reads distribution in the first replicate sample from the PGC-1α sequencing. 
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Figure 2.6 Example of a set of false positive peaks (blue distributions) in a region overlapping repeated 
DNA. Read distributions come from the PGC-1α sequencing data (upper track: WCE, lower track: IP). 
Our solution to the second type of artifact was to assign a weight of 1 to any pile of tags starting 
at the same genomic position, as if that locus was covered just by one read. The rationale for 
this procedure is that it would be very unlikely for the sonication step to break DNA at the exactly 
same location more than twice by chance; hence, if we see more than one read per locus, it was 
most probably caused during the PCR amplification step. 
An example of a PCR amplification error next to a bona fide tag enrichment is illustrated in 
Figure 2.7, while Figure 2.8 shows the distribution of the IP reads from the ERRα sequencing 
experiment, in which it can be clearly noticed that most of the loci in the genome were covered 
by around 100 reads, corresponding to the average height of the observed stacks. 
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Figure 2.7 Example of “stacks” of reads (blue vertical lines) next to a real peak (in the right portion of the 
picture). Read distributions come from the ERRα sequencing data (upper track: IP, lower track: WCE). 
 
Figure 2.8 Reverse cumulative distribution of the number of reads per loci in the IP sample from the 
ERRα sequencing experiment. 
2.5. Fragment size estimation and read shift 
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Typically, ChIP-Seq library preparation protocols require a selection step to choose the most 
appropriate DNA fragment size to use for cluster generation. In the Illumina platforms, only one 
end of a fragment is read by the instrument and the final size of the sequenced tag is in general 
much smaller than the one of the original fragment. As a consequence, the distribution of tags 
on the genome will show two enrichment peaks (on opposite strands) in the surroundings of 
each actual recruitment site of the chipped protein, with the distance between these peaks being 
about half of the selected fragment size (Fig.2.9). 
A precise identification of the specific sequenced fragment size is thus essential to accurately 
determine the binding site locations of the protein of interest. However, although recent 
technologies like the Agilent Bioanalyzer provide a highly precise sample sizing and quantitation, 
a still commonly used method for size selection is to manually cut out from an electrophoresis 
gel a band of genomic material which is approximately in the desired size range. Moreover, the 
estimated fragment size is often not known to the bioinformatician and it needs to be inferred 
from the data. 
 
Figure 2.9 Tags distribution around an enriched site of a ChIP-Seq experiment result in two peaks on 
opposite strands flanking the actual binding location of the protein of interest. Adapted from [19]. 
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Our approach to tackle this problem was to find, for each dataset, the maximum value of the 
cross-correlation 𝐶(𝑑) between reads on opposite strands, calculated as: 
𝐶(𝑑) = �𝑟𝑒𝑎𝑑+(𝑖) ∗ 𝑟𝑒𝑎𝑑−(𝑖 + 𝑑)
𝑖
 
where 𝑟𝑒𝑎𝑑+(𝑖) and 𝑟𝑒𝑎𝑑−(𝑖 + 𝑑) are indicator functions that equal 1 if a read starts at position 𝑖 
on the plus strand, or if a read starts at position 𝑖 + 𝑑 on the minus strand, respectively. The 
cross-correlation 𝐶(𝑑) was computed for a range of distances 𝑑 between 1 and 500 bp. 
Accordingly, all reads belonging to a given dataset were shifted towards the 3’ direction by half 
of the estimated fragment length, 𝑑/2, to better represent the precise location of the actual 
protein recruitment site. As an example, Fig.2.10 shows the cross-correlation or the second 
replicate IP from the PGC-1α sequencing experiment, whose reads were shifted by 70 bp.  
 
Figure 2.10 Estimation of the average fragment size, measured as the cross-correlation between reads 
mapped on the plus and minus strands, as a function of their distance. The data is referred to the second 
replicate IP dataset from the PGC-1α sequencing and the maximum cross-correlation (i.e. the peak of the 
distribution) was found at a distance of 141 bp. 
2.6. Peak calling 
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A crucial step in ChIP-Seq analysis is to identify the regions in the genome (also called “peaks”) 
where the protein of interest was significantly enriched. The availability of a sequenced control 
sample (in our case the whole cell extract or WCE) might help to decrease the number of false 
positives and, thus, to improve the accuracy of the prediction, although this is not an easy task to 
prove experimentally on a genome-wide scale. However, when comparing the IP sample to the 
control dataset, it is important to consider that the total number of reads can differ between 
samples and, hence, a normalization method must be applied.  
In our approach, to make the reads from different samples comparable, we estimate the fraction 
𝑓𝐼𝑃 of all IP reads that are contained in each 200 bp window genome-wide as: 
𝑓𝐼𝑃 = 𝑛𝐼𝑃𝑁𝐼𝑃 
and, similarly, the fraction 𝑓𝑊𝐶𝐸 of all WCE reads that are contained in each 2000 bp window, 
centered on the ChIP one, as: 
𝑓𝑊𝐶𝐸 = 𝑛𝑊𝐶𝐸𝑁𝑊𝐶𝐸 
where 𝑛𝐼𝑃 and 𝑛𝑊𝐶𝐸 are the number of reads in the window from IP and WCE, respectively, 
while 𝑁𝐼𝑃 and 𝑁𝑊𝐶𝐸 are the total number of reads in the IP and WCE samples, correspondingly. 
In particular, we use a wider window for the control sample to take into account the influence of 
local fluctuations and we model the tag sampling noise along the genome by a Poisson 
distribution. The ChIP enrichment of each consecutive window is calculated as: 
𝑍 = 𝑓𝐼𝑃 −  𝑓𝑊𝐶𝐸
�𝜎2𝐼𝑃 +  𝜎2𝑊𝐶𝐸 
where 𝜎2𝐼𝑃 and 𝜎2𝑊𝐶𝐸 represent the IP and WCE read frequency variances, given by: 
𝜎2𝐼𝑃 =  𝑓𝐼𝑃∗ (1− 𝑓𝐼𝑃)𝑁𝐼𝑃  and 𝜎2𝑊𝐶𝐸 =  𝑓𝑊𝐶𝐸 ∗ (1 − 𝑓𝑊𝐶𝐸)𝑁𝑊𝐶𝐸  
respectively. To speed up the algorithm, we use sliding windows and we move them in steps of 
25 bp (Fig.2.11). All consecutive windows having a Z score greater than the chosen cutoff are 
merged in clusters and the top scoring one (the summit) is called as a peak and used in the 
following steps. 
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Figure 2.11 Schematic representation of the principle behind the sliding window approach used in the 
peak finder. “d” and “D” indicate the IP and the WCE sliding windows, respectively.  
For the case in which the ChIP-Seq experiment was repeated in biological duplicate, prior to the 
peak calling step, it is worth looking at the correlation between replicates to evaluate the 
reproducibility of the ChIP enrichment. One way to proceed is to identify the top peaks in one 
dataset (using the above formula), to examine the correlation between their Z scores and the Z 
values of the corresponding regions in the other dataset and to repeat this procedure switching 
the two duplicates. Figure 2.12 shows the correlation between the first and the second biological 
replicate of the PGC-1α sequencing. 
Once evaluated the correlation between duplicates, the reads can be pulled together to identify 
the final set of peaks. To this purpose, we defined the combined Z score for the two biological 
replicates as:  
𝑍 =  𝑓𝐼𝑃1+ 𝑓𝐼𝑃2− 𝑓𝑊𝐶𝐸1− 𝑓𝑊𝐶𝐸2
�𝜎2𝐼𝑃1+ 𝜎2𝐼𝑃2+ 𝜎2𝑊𝐶𝐸1+ 𝜎2𝑊𝐶𝐸2. 
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Figure 2.12 The ChIP enrichment was reproducible across biological replicates from the PGC-1α 
sequencing dataset. (A) Correspondence between the Z scores of the peaks called for the first 
sequencing experiment and the Z scores of the corresponding regions in the second sequencing and (B) 
viceversa. Colors indicate the density of the points (grey:low, black:high). “r” indicates the Pearson 
correlation coefficient. 
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3. ChIP-Seq data analysis – From peaks to the 
downstream analysis 
3.1. Peak annotation to genomic elements 
The major goals of a ChIP-Seq experiment are to determine all locations genome-wide where 
the protein of interest is recruited to and to relate these binding positions to one or more cellular 
functions in which the protein might be involved. To address these objectives, ChIP-Seq peaks 
are usually “annotated” to functionally relevant genomic elements, which include transcripts, 
promoters, enhancers, intergenic regions, miRNAs, etc. In the absence of a more detailed 
chromatin conformation caption experiment – which can identify chromosomal regions folded to 
bring interacting regulatory regions together, for example enhancers and genes – it is common 
practice to associate ChIP-Seq peaks to their nearest genomic annotation, assuming that the 
closer the distance, the more likely the association is correct. 
Accordingly, we annotated the peaks from our datasets to their closest RefSeq Mus musculus 
(mouse) transcripts [1] and we defined binding regions as “Intergenic”, “Intronic”, “Exonic”, 
“Upstream of TSS” or “Downstream of TSS” in case they were, respectively, further than 10 kb 
from the nearest RefSeq transcript, inside an intron, inside an exon, comprised between a 
distance of -10 to 0 kb from the nearest transcription start site (TSS), or located between a 
distance of 0 to 10 kb from the closest transcription end site (TES). In addition, to compare the 
observed peak location distributions with the expected ones, we generated 100 random peak 
sets of the same length, checked their positions in relation to the RefSeq transcripts and 
averaged the results. As shown by Figure 3.1, PGC-1α binding peaks occur twice as often in the 
proximal promoter region and about 1.3 times more frequently inside the gene body, compared 
to random peaks. These numbers are even higher in ERRα peaks, which are located more often 
in the region upstream of TSS (22%) and less frequently in intergenic regions (41%) than the 
PGC-1α peaks. 
In parallel to the above described annotation procedure, which helped us to get an insight about 
the genomic distribution of PGC-1α and ERRα peaks, both peak sets were also assigned by 
proximity to the closest promoter regions, which were downloaded from the SwissRegulon 
database [2]. Each peak was assigned to the nearest promoter (and, thus, to the associated 
gene) in case the distance between the centers of the two elements was smaller than 10 kb. 
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Figure 3.1 Comparison of the percentages of PGC-1α, ERRα and random peaks locations with respect to 
the nearest RefSeq transcript. 
Moreover, taking advantage of the availability of an expression array for PGC-1α over-
expression in C2C12 muscle cells, we could make a functional link between the occupancy of 
PGC-1α along the genome and the regulatory effect on its downstream target genes. In fact, we 
found that out of the ~30% of our peaks associated to a promoter, 1720 were assigned to a non-
changing promoter, 532 to a significantly up-regulated promoter (log2 foldchange ≥ 2, z-score ≥ 
3) and only 43 to a significantly down-regulated promoter (log2 foldchange ≤ -2, z-score≤ -3), as 
shown in Figure 3.2. 
 
Figure 3.2 Pie chart depicting the number of PGC-1α peaks associated to a mouse promoter (grey, 
green, red) or not associated to any promoter within the distance of 10 kb (blue). 
Non-changing promoter
Down-regulated promoter
Up-regulated promoter
No promoter assigned
5217
1720
43
532
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3.2. Peak co-occurrence with histone modifications 
Intriguingly, the vast majority of PGC-1α peaks was not assigned to any promoter within the 
distance of 10 kb. Our interpretation of these results is that, considering its role as a coregulator, 
PGC-1α might be recruited to enhancer regions and, thus, be involved in long-range interactions 
with its downstream target genes. A key limitation of our peak-to-gene assignment, in fact, is that 
this functional link was restricted to the nearest annotation; although promoter regions are likely 
to contain a significant number of regulatory sites, it is well known that an important fraction of 
these, estimated in hundreds of thousands by the ENCODE Project Consortium [3], reside in 
enhancer regions, also called cis-regulatory modules (CRMs). Albeit the experimental 
identification of these regions is a challenging task, recent developments in high-throughput 
sequencing have proved that distal regulatory regions can also be recognized by a series of 
other genomic features, including the methylation pattern, the DNase I hypersensitivity and 
certain histone modification marks [4-6]. 
Thanks to the availability of high-throughput data for these genomic traits, we could investigate 
to which extent our distal peaks were co-occurring with histone modifications by measuring the 
overlap between the two pieces of information. We downloaded from the GEO database 
(http://www.ncbi.nlm.nih.gov/geo/) several ChIP-Seq datasets from the Dynlacht lab for histone 
mark sequencing experiments conducted in C2C12 muscle cells (GEO accession numbers: 
GSM721289, GSM721291, GSM721293, GSM721295, GSM721297, GSM721301, 
GSM721303, GSM721305). Although the experimental conditions were not exactly the same as 
the ones we used for our experiment (in particular the lack of adenoviral infection), the cells used 
for the histone mark sequencing were at the myotube differentiation stage.  
Intriguingly, as shown in Table 3.1, a large fraction of the PGC-1α peaks was indeed overlaying 
one or more histone marks for open chromatin and active enhancers, strongly suggesting a 
distal coactivatory role of this protein in the context of skeletal muscle cells. In particular, the 
histone modifications which PGC-1α peaks were most overlapping to were H3K4me1 and 
H3K18ac, both found to be present at both active and inactive/poised enhancers [7]. Although 
H3K4me1 is the most abundant modification among those that were analyzed, the fact that we 
obtained about half of PGC-1α peaks overlapping a histone marks that occupies only 7.6% of 
the genome, is most likely not by chance. Similar considerations can be made for the other 
enhancer marker, H3K18ac, which covers only 3.3% of the genome but is overlapping ~33% of 
our peaks. 
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Table 3.1 Overview of the histone modifications for which we evaluated the overlap with the 5217 PGC-1α 
peaks that were not assigned to any mouse promoter. The histone mark genome coverage was calculated 
as the ratio between the number of bp covered by the histone mark and the total length of the genome. 
 
An example of a PGC-1α peak overlapping some histone modification from the ENCODE 
Project, performed on C2C12 cells at the myoblast stage, is shown in Figure 3.3. 
 
Figure 3.3 A PGC-1α peak overlapping the histone marks sequenced by the ENCODE Consortium. 
Histone 
modification
Features and functions PGC-1α peaks 
overlapping with 
the histone mark
Histone mark 
genome 
coverage
Ratio 
(fold)
H3K4me1 Marker of for active/poised enhancers at distal loci. 48.5% 7.6% 6.4
H3K4me2 15.4% 1.8% 8.6
H3K4me3 6.5% 2.0% 3.3
H3K27me3 Marker associated with repressed regions and promoters. 4.9% 3.4% 1.4
H3K36me3 Marker for actively transcribed regions and transcriptional elongation. 4.0% 2.4% 1.7
H3K9ac Marker of active chromatin at promoters and enhancers. 8.3% 0.6% 13.3
H3K18ac Marker for functional enhancers. Has been linked to activation of nuclear hormone receptors. 33.6% 3.3% 10.2
H4K12ac Marker enriched at the TSS and along gene bodies. Required for unperturbed progression to S phase. 11.3% 1.0% 11.3
Markers for active/poised promoters. Stimulate the 
recruitment of chromatin remodeling factors and 
histone acetyltransferases.
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3.3. De novo motif finding 
In Computational Biology, a sequence motif is a mathematical representation of the DNA-binding 
specificity of proteins such as nucleases and transcription factors [8]. Briefly, a motif can be built 
by aligning the known binding sites for a given factor and counting the frequencies of each 
nucleotide at each position; this matrix of frequencies is then converted in a matrix of probability 
scores, the Position Weight Matrix (PWM), whose logarithmic values are proportional to the 
binding energy contribution of the single bases [9] and can be represented by a sequence logo 
[10]. 
Motif analysis of the genomic regions identified by peak calling is a multi-purpose step in ChIP-
Seq studies. In fact, when the motif of the chipped protein is already known, motif search can be 
used to validate the success of the experiment and to create a refined version of the motif, using 
the top scoring peaks to build a new one. On the other hand, when a motif of the chipped protein 
is not known, this analysis step can be useful for the determination de novo of the protein’s 
binding specificity; likewise, in case of a co-regulator that does not bind DNA, motif analysis can 
provide an extremely valuable hint to: (i) discover new binding partners for the protein of interest, 
(ii) to verify the presence of binding sites for transcription factors that are known to work in 
complex with the chipped protein, and (iii) to identify which of the known partners are co-binding 
at each peak. 
In the context of our ChIP-Seq experiments, since PGC-1α does not bind DNA directly, the goal 
of the motif analysis was rather focused on the identification of known and novel binding 
partners for the chipped coactivator. To this purpose, we used a de novo motif finder, 
PhyloGibbs [11], which combines a Gibbs motif sampler approach with phylogenetic footprinting 
into one integrated Bayesian framework. More in detail, the algorithm takes into account the 
phylogenetic relationships in an input set of aligned sequences to assign posterior probabilities 
to all possible configurations of an arbitrary number of binding sites for a user-specified number 
of unknown transcription factors.  
When we used PhyloGibbs on the top scoring PGC-1α peaks, we identified a motif strongly 
resembling that of ERRα as the most enriched motif in the input dataset (for more details, see 
chapter 4). This result was confirmed when PhyloGibbs was run on the top ERRα peaks using 
different setting configurations; the combination of parameters z=1 y=200 m=10 – with “z” 
indicating the expected number of different motifs, “y” the number of expected sites and “m” the 
length of the expected motif – was the one that produced the motif with the most significant p-
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value, 6.09726e-28. This motif was very similar to the one coming from the PGC-1α peaks and 
was recognized as highly similar to ESRRA.p2 (the weight matrix of ERRα) by the motif 
comparison software STAMP [12], as shown in Figure 3.4. 
 
Figure 3.4 The motif (top sequence logos) produced by PhyloGibbs using the top 200 ERRα peaks was 
recognized by the software STAMP as most similar to the SwissRegulon weight matrix ESRRA.p2 (bottom 
right sequence logo). 
Although we expected to find this motif as the top result of the de novo search in ERRα peaks, 
we were surprised to observe it emerging uncontested from the PGC-1α peaks as well; in fact, 
although for ERRα the most notable partner is PGC-1α, this coactivator is known to interact with 
numerous other nuclear receptors, including PPARG, GR, NRFs, TFAM and RXRs (for a review 
on PGC-1α partners, see [13]), which nevertheless were not as dominant as ERRα. However, it 
needs to be considered that, since the high similarity between nuclear receptor binding 
preferences is also reflected in their motifs, it is likely that at least some fraction of the ESRRA 
binding sites were actually belonging to other similar nuclear receptors. 
3.4. Binding sites prediction and motif over-representation compared 
to a shuffled background 
In addition to the de novo motif search, we also performed binding site prediction for known 
transcription factors using the software MotEvo [14]. Briefly, by taking as input a multiple 
alignment of orthologous DNA sequences from different species, a collection of PWMs and a 
phylogenetic tree relating the species to the reference, MotEvo estimates the posterior 
probability for a given transcription factor binding site (TFBS) to occur at each position within the 
input sequences. The main advantage of this software consists in improving the accuracy of 
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binding site predictions by incorporating conservation information and by introducing a novel 
model, named “unknown functional element” (UFE), that takes into account the probability for an 
unknown factor for which we do not yet have a motif, to occur and compete with any of the input 
motifs. 
As described more in detail in chapter 4, we aligned the peak regions to six other mammalian 
species and run MotEvo on this multiple alignment using a collection of 190 regulatory motifs 
downloaded from the SwissRegulon portal [2]. In parallel, we built a background set of random 
peaks to assess the significance of our predictions and to identify the over-represented motifs in 
our dataset. Instead of using a random set of genomic regions, which might not have had the 
same conservation pattern of our peaks, we shuffled the columns of the peak multi-alignments, 
in order to maintain both the gap and the conservation pattern of the original sequences. 
Moreover, because of the shuffle, the output regions were also size- and number-matched to the 
input peaks. As for the original peaks, we ran MotEvo on the shuffled peaks and we kept only 
those binding sites with a posterior probability greater than 0.1. 
For each motif 𝑥, we calculated the sum of its binding site posterior probabilities in the peak 
alignments and in the shuffled dataset as: 
𝑛𝑥 =  �𝑃(𝑥𝑖)
𝑖
 
and: 
𝑛′𝑥 =  �𝑃(𝑥𝑗)
𝑗
 
where 𝑖 and 𝑗 are the 𝑖-th and 𝑗-th binding sites found in the original peaks and in the shuffled 
peaks, respectively. For both sets of peaks, we calculated the quantities 𝑓𝑥 and 𝑓′𝑥, 
corresponding to the fraction of basepairs occupied by the motif 𝑥 and weighted by its TFBSs 
posterior sum, as: 
𝑓𝑥 =  𝑛𝑥𝑙𝑥𝐿𝑥  
and: 
𝑓′𝑥 =  𝑛′𝑥𝑙𝑥𝐿′𝑥  
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where 𝑙𝑥 is the length of motif 𝑥, while 𝐿𝑥 and 𝐿′𝑥 are the total lengths of the original and shuffled 
peaks. Finally, the enrichment of TFBSs for each motif 𝑥 was computed as: 
𝑍 =  𝑓𝑥 −  𝑓′𝑥
�𝑓𝑥 ∗
(1 −  𝑓𝑥)
𝐿𝑥
+ 𝑓′𝑥 ∗ (1 −  𝑓′𝑥)
𝐿′𝑥
 
Interestingly, when we checked which motifs were the most enriched in three subsets of PGC-1α 
peaks assigned to up-regulated, non-changing and down-regulated promoters, ESRRA turned 
out to be the most enriched motif for every subset (see Table 3.2), suggesting a key role of the 
ERRα nuclear receptor in the PGC-1α-controlled regulatory network. In addition, it is worth to 
notice that the group of leucine zipper transcription factors including FOS, JUN, BACH2, NFE2, 
NFE2L2 and FOSL2 were among the top over-represented motifs only in peaks assigned to up-
regulated and to non-changing promoters, indicating that they might not be involved in the 
repression of PGC-1α downstream targets. Two transcription factors enriched in PGC-1α peaks 
assigned to down-regulated promoters, FOXJ2 and TFAP4, were previously found to play a role 
in preventing and contrasting the deleterious effects of inflammation [15, 16]. However, since the 
Z-scores are much smaller than in the other two peak sets, we believe that these peaks might be 
“spurious” and, thus, that the associated promoters are not direct targets of PGC-1α. 
Table 3.2 Top over-represented motifs in three subsets of the PGC-1α peaks. Binding site predictions 
were compared to those predicted in a background set built by shuffling the original peak alignments. 
 
Motif name Z-score Motif name Z-score Motif name Z-score
ESRRA 30.81 ESRRA 46.71 ESRRA 8.93
NR5A1,2 26.20 NR5A1,2 40.87 NR6A1 5.92
NR6A1 20.43 BACH2 38.78 FOX{I1,J2} 5.81
BACH2 16.48 NR6A1 35.64 NFIX 5.78
FOS_FOS{B,L1}_JUN{B,D} 15.36 FOSL2 34.15 TFAP4 5.77
FOSL2 14.87 FOS_FOS{B,L1}_JUN{B,D} 33.31 NR5A1,2 5.73
SP1 13.18 NFE2 29.15 CDX1,2,4 5.12
NFE2L2 12.67 CTCF 26.30 MYFfamily 4.72
NFE2 12.67 HNF4A_NR2F1,2 25.20 BPTF 4.71
CTCF 12.54 NFE2L2 25.18 NFE2 4.59
HNF4A_NR2F1,2 12.44 REST 21.31 TLX1..3_NFIC{dimer} 4.07
NR1H4 11.84 NR1H4 19.22 ETS1,2 4.04
NFY{A,B,C} 11.65 PPARG 18.75 PPARG 4.03
PPARG 11.29 MZF1 18.65 TFCP2 3.99
MAZ 11.18 RREB1 17.89 PATZ1 3.90
ELF1,2,4 11.14 TFAP4 17.19 ATF2 3.69
EBF1 10.88 PATZ1 16.87 AIRE 3.59
PATZ1 10.65 ESR1 16.60 MZF1 3.56
TFCP2 10.37 SPI1 16.36 NFE2L2 3.48
RXRG_dimer 10.33 RXRA_VDR{dimer} 15.86 PDX1 3.43
PGC-1α peaks assigned to
up-regulated promoters
PGC-1α peaks assigned to
non-changing promoters
PGC-1α peaks assigned to
down-regulated promoters
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3.5. Principal Component Analysis on the peaks site count matrix 
Usually, the outcome of motif analysis provides an overview of all the motifs for which at least 
one binding site was predicted within the input regions of interest. In the case of ChIP-Seq data, 
considering that peaks are in general much wider than the actual protein binding site, this 
translates in the possibility of finding a TFBS for almost any known sequence motif. However, 
even by defining a score for motif over-representation versus a background set of regions, it is 
not trivial where to set the cutoff for the identification of the critical group of transcription factors 
responsible for the major effects observed in a dataset. Moreover, it has to be considered that 
the results of the motif enrichment analysis will be strongly influenced by the chosen background 
dataset. 
For these reasons, we decided to use a background-independent approach, Principal 
Component Analysis (PCA), to grasp the most relevant information contained in our multi-
dimensional dataset, at nearly no computational cost. Although PCA has been previously used 
for gene selection in microarrays and to compare two biological conditions in ChIP-Seq data [17, 
18], to our knowledge it has not been employed so far to identify the structure of binding site 
occurrences in ChIP-Seq peaks. To this purpose, we built a “site count matrix” 𝑋 containing the 
total number of predicted binding sites 𝑋𝑝𝑚 for each of the 190 mammalian weight matrices 
(columns) downloaded from SwissRegulon [2] in each peak 𝑝 (rows). For each motif, the 
average site count was subtracted from every value, in order to mean-center the columns of the 
matrix: 
𝑋�𝑝𝑚 = 𝑋𝑝𝑚 − 〈𝑋𝑚〉 
Then, a Singular Value Decomposition (SVD) was applied to the 𝑋�𝑝𝑚 matrix, to factorize it as: 
𝑋�𝑝𝑚 = 𝑈 ∙ 𝑆 ∙  𝑉𝑇 
where 𝑈 is a 𝑚 × 𝑛 matrix whose columns are the left singular vectors (in our case, the 
“eigenpeaks”) of 𝑋�𝑝𝑚; 𝑆 is a 𝑛 × 𝑛 diagonal matrix containing the singular values, and 𝑉𝑇 (the 
transpose of 𝑉) is an 𝑛 × 𝑛 matrix whose rows are the right singular vectors (in our case, the 
“eigenmotifs”), with 𝑚 the number of peaks, and 𝑛 the number of motifs (Fig.3.5). The singular 
vectors of singular values are called principal components, which are linear combinations of 
uncorrelated variables and correspond to the number of original variables. Usually, only a few 
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components, accounting for most of the variation observed in the original dataset, are retained 
for further interpretation of the results. 
 
Figure 3.5 Schematic representation of the singular value decomposition. Adapted from [19]. 
In our context, before applying the PCA on PGC-1α and ERRα peaks (see chapters 4 and 5), we 
tested its effectiveness on a group of ChIP-Seq experiments for several well studied 
transcription factors from the ENCODE Project, in order to confirm the results with the known 
interacting partners from the literature. To this end, we downloaded 20 peak sets in the 
GM12878 human lymphoblastoid cell line from the Crunch webserver 
(http://crunch.unibas.ch/ENCODE_REPORTS/), a recently developed and completely automated 
tool for the analysis of ChIP-Seq data which implements the read quality control algorithm 
described in chapter 2 and performs read mapping, peak detection and de novo motif analysis. 
After running MotEvo [14] on the peaks, we created a site count matrix as previously described 
and used R [20] to perform the PCA through SVD. In most of the cases, we could identify some 
already known partners of the chipped protein among the outliers of the PCA analysis. For 
example, Figure 3.6 shows the result of the PCA for the peaks of c-MYC, a member of the basic 
Helix-Loop-Helix (bHLH) family of transcription factors; as illustrated by the plot, the 
bHLH_family motif and the ARNT_ARNT2_BHLHB2_MAX_MYC_USF1 motif (which includes c-
MYC, but also its well-known partner MAX) are pointing out of the motif cloud as the top relevant 
ones, followed by the motifs of other known c-MYC partner proteins, such as SP1 [21], MAZ 
[22], SREBP1 and 2 [23], HIF1α [24]. In conclusion, these results suggest that the PCA can be 
successfully applied to identify transcription factors which can be chosen for follow-up 
experiments as putative partners for the protein of interest. 
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Figure 3.6 Principal Component Analysis of the peaks analyzed using Crunch on the c-Myc ENCODE 
ChIP-Seq data. The sequence logo of c-MYC is indicated by the arrow. 
3.6. Evaluation of motif pairs preferred distances and geometries 
Several recent studies have shown that pairs of interacting factors often co-occur along the 
genome with precise spatial preferences, which can be used as a criterion to predict cis-
regulatory elements [25-27]. In order to determine whether certain transcription factors have a 
recurring or preferred distance from the chipped protein, we collected the distances within our 
peaks between binding sites for different motif pairs and calculated the entropy of the resulting 
distribution. As the entropy is a measure of the uncertainty of a variable, in general, the less 
uniform is a distribution, the lower will be its entropy; in our context, we expect to obtain a low 
entropy for the case a given transcription factor will occur at a preferred distance, rather than at 
random intervals. 
In particular, since for some motifs we observed too few pair distances to use the classical 
Shannon entropy formulation, we adopted a Bayesian approach to estimate the predictability of 
the observed distances distribution. More in detail, to circumvent the case of having zero 
occurrences for certain distances (which would be incompatible with Shannon entropy), we need 
to introduce a pseudo-count. 
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Considering the discrete variable 𝑑 of distances between motif pairs, the likelihood 𝑃(𝑑|?⃑?) of 
observing a certain distance 𝑑 given a vector of probabilities ?⃑?, can be modelled as a 
multinomial distribution: 
𝑃(𝑑 = 𝐷𝑎𝑡𝑎|?⃑?) = �𝜌𝑖𝑛𝑖𝑀
𝑖=1
 
where 𝜌𝑖𝑛𝑖 is the probability of observing 𝑛𝑖 times the distance 𝑑 = 𝑖, with 𝑖 ranging from 1 to the 
maximum distance 𝑀. The likelihood of the distances independent on ?⃑? is called “evidence” and 
is calculated as: 
𝑃(𝑑) = �𝑃(𝑑|?⃑?) 𝑃(?⃑?) 𝑑?⃑? 
where 𝑃(𝜌) is the prior probability, that reflects our initial belief before having observed any data. 
We modelled the prior by a Dirichlet distribution: 
𝑃(?⃑?|𝛼) ≈ 𝐷𝑖𝑟(𝛼) = 1B(𝛼) �𝜌𝑖𝛼i−1𝑀
𝑖=1
 
where B(𝛼) is the beta function, which can be expressed in terms of the gamma function: 
B(𝛼) = ∏ Γ(𝛼𝑖)𝑀𝑖=1
Γ(∑ 𝛼i𝑀𝑖=1 ) , 𝛼 = (𝛼𝑖, … ,𝛼𝑀) 
and is dependent on the hyperparameter 𝛼, which can be interpreted as a pseudo-count 
representing the expected number of distance counts a priori. When 𝛼 = 1 for all 𝑖, the prior 
corresponds to a uniform distribution. 
Combining 𝑃(𝑑|?⃑?) and 𝑃(?⃑?), we have: 
𝑃(𝑑) = �Γ(𝑀𝛼)��(𝜌𝑖)𝑛𝑖+𝛼−1
Γ(𝛼) �
𝑖
 𝑑?⃑? 
which can be solved analytically as: 
𝑃(𝑑) = Γ(𝑀𝛼) 
Γ(𝑛 + 𝑀𝛼)��Γ(𝑛𝑖 + 𝛼)Γ(𝛼) �
𝑖
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If we take the logarithm of the above formula, it becomes: 
𝑙𝑜𝑔[𝑃(𝑑)] = 𝑙𝑜𝑔[Γ(𝑀𝛼)] − 𝑙𝑜𝑔 [Γ(𝑛 + 𝑀𝛼)] −𝑀𝑙𝑜𝑔[Γ(𝛼)] + �𝑙𝑜𝑔[Γ(𝑛𝑖 + 𝛼)]
𝑖
 
Considering the uniform parameter prior (𝛼 = 1) and the Stirlings’ approximation: 
𝑙𝑜𝑔[Γ(𝑥 + 1)] ≈ 𝑥𝑙𝑜𝑔(𝑥) − 𝑥 
then, by replacing 𝜌𝑖 with (𝑛𝑖 𝑛⁄ ), we can approximate the logarithm of the evidence as the 
negative entropy of the maximum likelihood (ML) estimate [28]: 
𝑙𝑜𝑔[𝑃(𝑑)] ≈ −𝑛𝐻(𝑛𝑖 𝑛⁄ ) 
which can be derived such that the entropy 𝐻 can be calculated as: 
𝐻 = −�𝑙𝑜𝑔[Γ(𝑀𝛼)] − 𝑙𝑜𝑔 [Γ(𝑛 + 𝑀𝛼)] −𝑀𝑙𝑜𝑔[Γ(𝛼)] + �𝑙𝑜𝑔 [Γ(𝑛𝑖 + 𝛼)]
𝑖
�
1
𝑛
 
The value of 𝐻 will be higher for more disordered distributions and lower for distributions 
showing a preferred distance. Indeed, as shown in Figure 3.7, we observed that motifs with very 
low entropy, like NF-κB, show a “spiked” distribution of distances from a reference motif (in this 
case, ESRRA), while motifs more ubiquitous like YY1 show a wider distribution, with higher 
entropy. 
 
Figure 3.7 Examples of distributions of the distances between ESRRA and (A) NF-κB (H=5.23) or (B) 
YY1 (H=5.86). 
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However, even using this estimation of the entropy does not avoid labeling some distributions as 
less entropic than others simply because of a lower number of predicted binding sites, which 
favors random spikes with respect to real preferred distances. A possible solution to this 
problem, which we will work on in the next steps of this study, would be smoothing these counts 
by distributing the number of observed pair distances to their neighboring positions, either using 
an exponential kernel or by a simple discrete approximation. 
Another interesting analysis of motif pairs is the study of the preferred geometries between their 
coupled binding sites. Several studies have shown that TFs bound to the same side of the DNA 
helix are much more likely to interact with each other and are more stable than proteins bound 
on opposite sides (for example, see [29, 30]). Moreover, a study on the Drosophila transcription 
factors Bcd and Kr showed that the maximal correlation between the two motifs was observed 
when the two TFs were located on the same DNA strand and shifted by two bases [31]. 
Considering that a complete turn of the DNA helix is composed of 10 nucleotides [32] and that 
zinc finger proteins (e.g. FOXP3) show enhanced binding to DNA when their dimers are located 
at regular turns [33], we studied which TFs were more often located at regular 10 bp distances 
from ERRα sites, up to four turns of the DNA helix. We decided to not consider longer distances, 
as higher-order conformations of the DNA helix might arise, thereby altering this short-range 
regularity. In order to count only TFBS pairs on the same face of the DNA, we considered only 
sites located on the same DNA strand.  
Table 3.3 shows the results obtained using the “only ERRα” peaks (i.e. ERRα sites not directly 
co-activated by PGC-1α). Several motifs (KLF4, ZNF148, NR1H4, KLF12, FOX(C1,C2), SP1) 
are characterized by zinc finger domains, like ESRRA. KLF4 in particular, might occupy the 
same sites of SP1, as it was shown to compete with SP1 for binding to the DNA [34]. 
Interestingly, we noticed that most of the factors were more often found at a distance of 1 or 2 
turns rather than at further distances, suggesting that these intervals reflect the appropriate 
distance for protein dimerization. Moreover, the fact that several TFs (for instance NR1H4 in turn 
1) showed distinct preferences regarding binding before or after ESRRA sites might suggest a 
preferred orientation of their binding sites in concomitance with ERRα ones; these different 
preferences were present also when considering the group of zinc finger, despite their common 
domain type. In conclusion, we started investigating the patterns in which couples of binding 
sites are distributed; in the future developments of this project, we could explore these patterns 
more in depth and on a bigger set of sequences, in order to get more insights into transcription 
factor pair co-recruitment to DNA. 
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Table 3.3 TFBS occurrences at regular DNA turns relative to the center of the ESRRA binding sites in 
“only ERRα” peaks. “A” and “B” indicate whether the TFBS of the motif is after or before the TFBS of 
ESRRA, respectively. One turn corresponds to a distance of 10 bp, with a tolerance of ±2 bp. Counts are 
sorted by the column “turns 1+2”, which should reflect the appropriate distance for dimerization. 
 
  
MOTIF 1 turn B 1 turn A 2 turn B 2 turn A 3 turn B 3 turn A 4 turn B 4 turn A turns 1+2 turns 1+2+3 turns 1+2+3+4
KLF4 5 1 11 36 3 4 7 2 53 60 69
ZNF148 14 30 4 3 3 2 3 2 51 56 61
NR1H4 28 7 4 6 7 5 6 3 45 57 66
KLF12 6 29 2 6 5 7 6 6 43 55 67
FEV 5 7 17 6 6 4 1 1 35 45 47
FOX{C1,C2} 2 28 2 2 2 5 1 0 34 41 42
NFE2L1 24 2 2 5 3 2 3 5 33 38 46
SP1 5 2 13 12 3 3 6 1 32 38 45
TP53 0 29 3 0 1 0 0 1 32 33 34
SPIB 8 4 17 2 3 6 13 7 31 40 60
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4.1. Abstract 
Skeletal muscle tissue shows an extraordinary cellular plasticity, but the underlying molecular 
mechanisms are still poorly understood. Here we use a combination of experimental and 
computational approaches to unravel the complex transcriptional network of muscle cell 
plasticity centered on the peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α), 
a regulatory nexus in endurance training adaptation. By integrating data on genome-wide 
binding of PGC-1α and gene expression upon PGC-1α over-expression with comprehensive 
computational prediction of transcription factor binding sites (TFBSs), we uncover a hitherto 
underestimated number of transcription factor partners involved in mediating PGC-1α action. In 
particular, principal component analysis of TFBSs at PGC-1α binding regions predicts that, 
besides the well-known role of the estrogen-related receptor α (ERRα), the activator protein-1 
complex (AP-1) plays a major role in regulating the PGC-1α-controlled gene program of hypoxia 
response. Our findings thus reveal the complex transcriptional network of muscle cell plasticity 
controlled by PGC-1α. 
4.2. Introduction 
A sedentary life style can lead to an imbalance between energy intake and expenditure and 
favors the development of a number of chronic diseases like obesity and type 2 diabetes. 
Regular exercise on the other hand is an effective way to reduce the risk for these lifestyle-
related pathologies [1]. The health benefits of exercise are at least in part induced by changes in 
skeletal muscle tissue. Muscle cells exhibit a high plasticity and thus a remarkably complex 
adaptation to increased contractile activity. For example, endurance training induces 
mitochondrial biogenesis, increases capillary density and improves insulin sensitivity [1, 2]. To 
achieve such a complex plastic response, a number of different signaling pathways are activated 
in an exercising muscle, for example p38 MAPK-mediated protein phosphorylation events, 
increased intracellular calcium levels or the activation of the metabolic sensors AMP-dependent 
protein kinase (AMPK) and sirtuin-1 (SIRT1) [3].  
While the temporal coordination of the numerous inputs is not clear, all of the major signaling 
pathways converge on the peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) 
to either induce Ppargc1a gene expression, promote post-translational modifications of the 
PGC-1α protein, or by doing both [4, 5]. Upon activation, PGC-1α mediates the muscular 
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adaptations to endurance exercise by coactivating various transcription factors (TFs) involved in 
the regulation of diverse biological programs such as mitochondrial biogenesis, angiogenesis, 
ROS detoxification or glucose uptake [3]. Accordingly, transgenic expression of PGC-1α in 
mouse skeletal muscle at physiological levels not only induces mitochondrial biogenesis but also 
drives a fiber type conversion towards a more oxidative, slow-twitch phenotype [6] while muscle-
specific Ppargc1a knockout animals exhibit several symptoms of pathological inactivity [7, 8]. 
Coregulators are part of multicomponent regulatory protein complexes that are well suited to 
translate external stimuli into changes in promoter and enhancer activities by combining various 
enzymatic activities to modulate histones and chromatin structure, and recruit other TFs [9]. 
Thus, dynamic assembly of distinct coregulator complexes enables the integration of many 
different signaling pathways leading to a coordinated and specific regulation of entire biological 
programs by multiple TFs [10, 11]. For example, PGC-1α not only recruits histone acetylases 
[12], the TRAP/DRIP/Mediator [13] as well as the SWI/SNF protein complexes [14], but also 
binds to and coactivates a myriad of different transcription factors, even though a systematic 
inventory of TF binding partners has not been compiled yet [15]. Thus, the specific control 
exerted by the PGC-1α-dependent transcriptional network might provide an explanation for the 
dynamic and coordinated muscle adaptation to exercise. Since PGC-1α in skeletal muscle not 
only confers a trained phenotype, but also ameliorates several different muscle diseases [16], 
the unraveling of the PGC-1α-controlled transcriptional network in skeletal muscle would be of 
great interest to identify putative therapeutic targets within this pathway. 
Therefore, we aimed at obtaining a global picture of the co-regulatory activity of PGC-1α in 
skeletal muscle cells. More precisely, by combining data on the genome-wide binding locations 
of PGC-1α and the gene expression profiles in response to PGC-1α over-expression with 
comprehensive computational prediction of transcription factor binding site (TFBS) occurrence, 
we sought to unveil the biological processes that are regulated by PGC-1α, to identify the 
transcription factors that partner with PGC-1α, and to determine the mechanistic details of PGC-
1α-regulated transcription. We not only mapped the locations on the DNA where PGC-1α was 
bound, but also delineated the target genes whose expression is either directly or indirectly 
affected by PGC-1α and identified novel putative transcription factor partners that mediated 
PGC-1α’s action. In particular, our results strongly suggest that the activator protein-1 (AP-1) 
complex is a major regulatory partner of PGC-1α, with AP-1 and PGC-1α together regulating the 
hypoxic response gene program in muscle cells in vitro and in vivo. 
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4.3. Materials and methods 
4.3.1. Cell culture and siRNA transfection 
C2C12 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 
10% fetal bovine serum (FBS), 100 Units/ml penicillin and 100ug/ml streptomycin. To obtain 
myotubes, the C2C12 myoblasts were allowed to reach 90% confluence and the medium was 
changed to DMEM supplemented with 2% horse serum (differentiation medium) for 72 hours. 
The siRNAs for the knockdown of NFE2L2, FOS, JUN, ATF3, NFYC, ZFP143, GTF2I, the non-
targeting siRNA pool and the DharmaFECT1 transfection reagent were purchased from 
Dharmacon (Fisher Scientific) and the siRNA transfection was performed according to the 
Thermo Scientific DharmaFECT Transfection Reagents siRNA Transfection Protocol. Briefly, 
after three days of differentiation, the respective siRNAs (50nM final concentration) was added 
to the medium. 24h after siRNA transfection, the cells were infected with either the PGC-1α or 
GFP adenovirus. Then, 48h after adenoviral infection, the cells were harvested. 
Differentiated C2C12 cells were infected with adenoviral (AV) shERRα (kindly provided by Dr. 
Anastasia Kralli, Scripps Research Institute, La Jolla, CA, USA) to knockdown and inactivate 
ERRα or shGFP as a control. The infected cells were kept in culture for 4 days. Afterwards, cells 
were infected with the AV-flag-PGC-1α or AV-GFP and kept in culture two additional days. As a 
supplement to the previously infected AV shERRα cells, 2µM of the ERRα inverse agonist XCT-
790 were added. To the remaining cells, 0.02% DMSO as a vehicle was added to the 
differentiated medium. All the experiments have been performed in biological triplicates. For 
RNA isolation, TRIzol® was used according to the TRIzol® reagent RNA isolation protocol 
(Invitrogen). Three conditions were used for further analysis: AV-shGFP + AV-GFP + vehicle, 
AV-shGFP + AV–flag-PGC-1α + vehicle, AV-shERRα + AV-flag-PGC-1α + 2µM XCT-790. 
4.3.2. ChIP and ChIP Sequencing 
ChIP was performed according to the Agilent Mammalian ChIP-on-chip Protocol version 10.0. 
For each immunoprecipitation, approximately 1x108 C2C12 cells were differentiated into 
myotubes and infected with AV-flag-PGC-1α. For cross-linking protein complexes to DNA 
binding elements, the cells were incubated in a 1% formaldehyde solution for 10 minutes, 
followed by the addition of glycine to a final concentration of 125mM to quench the effect of the 
formaldehyde. The cells were rinsed in 1xPBS, harvested in ice-cold 1xPBS using a silicone 
scraper and pelleted by centrifugation. The pelleted cells were either used immediately or flash 
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frozen and stored for later. The cells were then lysed at 4°C using two lysis buffers containing 
0.5% NP-40/0.25% Triton X-100 and 0.1% Na-deoxycholate/0.5% N-lauroylsarcosine, 
respectively. The chromatin was then sheared by sonication to obtain DNA fragments of about 
100-600bp in length. 50μl of the sonicated lysate was saved as input DNA. The 
immunoprecipitation was performed overnight at 4°C using magnetic beads (Dynabeads® 
Protein G, Invitrogen), which were previously coated with monoclonal antibodies like the 
monoclonal ANTI-FLAG® M2 Antibody, Sigma for the ChIP of PGC-1α or with the monoclonal 
anti-c-Fos (9F6) rabbit antibody #2250, Cell Signaling for the ChIP of FOS. The beads carrying 
the precipitate were washed five times for the c-Fos antibody and six times for the flag antibody 
with RIPA buffer and once with TE that contained 50mM NaCl to eliminate unspecific binding of 
DNA to the beads. For elution, the beads were resuspended in elution buffer containing 1% 
SDS, placed in 65°C water bath for 15 minutes and vortexed every 2 minutes. To reverse the 
cross-links, the samples were incubated at 65°C overnight. The following day, the RNA and the 
cellular proteins were digested using RNase A and proteinase K. The DNA was precipitated and 
the success of the chromatin immunoprecipitation was validated by semiquantitative real-time 
PCR. The ChIP experiments were performed in triplicates. The ChIP of PGC-1α was further 
used for sequencing. The ChIP-Seq experiment of over-expressed PGC-1α in C2C12 cells was 
performed in biological duplicates. At the joint Quantitative Genomics core facility of the 
University of Basel and the Department of Biosystems Science and Engineering (D-BSSE) of the 
ETH Zurich in Basel, DNA libraries were prepared using the standard Illumina ChIP-Seq 
protocol, as described by the manufacturer, and the immunoprecipitated samples sequenced on 
the Genome Analyzer II. In order to keep only high quality data, the sequenced reads were 
filtered based on the quality score of each read and its alignments. Reads were retained when 
Phred score >= 20, read length >= 25 bps and number of wrongly called nucleotides (Ns) <= 2. 
Those reads that passed the filter, (6’711’717 for the first immunoprecipitated sample (IP), 
36’580’431 for the second IP, 17’899’074 for the first Whole Cell Extract (WCE), and 35’525’221 
for the second WCE), were aligned to the mouse genome, UCSC mm9 assembly, using Bowtie 
version 0.12.7 [17] using parameters --best --strata -a --m 100. The number of aligned reads 
equaled 5’699’648 for the first IP sample, 16’053’370 for the first WCE, 21’448’059 for the 
second IP, and 32’244’584 for the second WCE. 
4.3.3. Identification of bound regions 
To identify regions that were significantly enriched in the ChIP, we passed a 200 bps long sliding 
window along the genome, sliding by 25 bps between consecutive windows, and estimated the 
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fraction of all ChIP reads fIP that fall within the window, as well as the fraction fWCE of reads from 
the whole cell extract that fall in the same window (which we estimate from a 2000 bps long 
window centered on the same genomic location). A Z-score quantifying the enrichment in the 
ChIP of each window was computed as: 
𝑍 = 𝑓𝐼𝑃 −  𝑓𝑊𝐶𝐸
�𝜎2𝐼𝑃 +  𝜎2𝑊𝐶𝐸 
where 𝜎2𝐼𝑃 and 𝜎2𝑊𝐶𝐸 are the variances of the IP and WCE read frequencies, which are given 
by: 
𝜎2𝐼𝑃 =  𝑓𝐼𝑃∗ (1− 𝑓𝐼𝑃)𝑁𝐼𝑃  and 𝜎2𝑊𝐶𝐸 =  𝑓𝑊𝐶𝐸 ∗ (1 − 𝑓𝑊𝐶𝐸)𝑁𝑊𝐶𝐸  
respectively. 
The enrichments were reproducible across biological replicates. Using only the first sequencing 
dataset, we called peaks at a Z cutoff of 4.5; we then compared these with the Z scores from the 
corresponding regions of the second dataset and the Pearson correlation coefficient was found 
to be 0.778. Similarly, we called peaks at a Z cutoff of 4.5 using only the second sequencing 
dataset; when we compared these peaks with the Z scores of the corresponding regions from 
the first dataset, the Pearson correlation coefficient was found to be 0.782. 
To obtain a final set of binding peaks, we combined the reads from the two biological replicates 
computing the Z score of each window was computed as:  
𝑍 =  𝑓𝐼𝑃1+ 𝑓𝐼𝑃2− 𝑓𝑊𝐶𝐸1− 𝑓𝑊𝐶𝐸2
�𝜎2𝐼𝑃1+ 𝜎2𝐼𝑃2+ 𝜎2𝑊𝐶𝐸1+ 𝜎2𝑊𝐶𝐸2. 
We conservatively considered all windows with a Z-score larger than 4.5 as were considered 
significantly enriched (False Discovery Rate 0.6%). The final binding peaks were obtained by 
merging consecutive windows that all passed the cut-off and by considering the “peak” to 
correspond to the top scoring window, i.e. corresponding to the summit of the ChIP-Seq signal. 
To determine the PGC-1α distribution genome-wide, peaks were annotated according in relation 
to their closest Mus musculus RefSeq transcripts. We defined peaks as: “Intronic” (peak center 
lying inside an intron); “Exonic” (peak center lying inside an exon); “Upstream of TSS” (peak 
center lying within -10 to 0 kb from the closest TSS); “Downstream of TES” (peak center lying 
within 0 to 10 kb from the closest TES); “Intergenic” (peak center located farer than 10 kb from 
the nearest transcript). Moreover, we computed the ratio between observed and expected peak 
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location distributions, obtained by generating 100 peak sets composed of 7512 random peaks 
each. 
4.3.4. Motif finding and TFBSs over-representation 
The binding peak regions were aligned to orthologous regions from other 6 mammalian species 
– human (hg18), rhesus macaque (rheMac2), dog (canFam2), horse (equCab1), cow (bosTau3) 
and opossum (monDom4) – using T-Coffee [18]. A collection of 190 mammalian regulatory 
motifs (position weight matrices or WMs) representing the binding specificities of approximate 
350 mouse TFs (in many cases, sequence specificities of multiple closely-related TFs were 
represented with the same WM) were downloaded from the SwissRegulon website [19]. TFBSs 
for all known motifs were predicted using the MotEvo algorithm [20] on the alignments of all the 
7512 peak sequences. Only binding sites with a posterior probability >= 0.1 were considered for 
the further steps of the analysis. In order to create a background set of regions to assess the 
overrepresentation of binding sites within our regions, we created randomized alignments by 
shuffling the multiple alignment columns, maintaining both the gap patterns and the conservation 
patterns of the original alignments. TFBSs were predicted on the shuffled alignments using the 
same MotEvo settings as for the original peak alignments. Over-representation of motifs in the 
PGC-1α binding peaks was calculated by comparing total predicted TFBS occurrence within 
binding peaks with the predicted TFBS occurrence in the shuffled alignments. We evaluated the 
enrichment of TFBSs for each motif x by collecting the sum 𝑛𝑥 of the posterior probabilities of its 
predicted sites in the peak alignments as well as the corresponding sum 𝑛′𝑥 in the shuffled 
alignments, and computed a Z-score: 
𝑍 =  𝑓𝑥 −  𝑓′𝑥
�𝑓𝑥 ∗
(1 −  𝑓𝑥)
𝐿𝑥
+ 𝑓′𝑥 ∗ (1 −  𝑓′𝑥)
𝐿′𝑥
 
where 𝐿𝑥 and 𝐿′𝑥 are the total lengths of the original and shuffled alignments, respectively, while 
𝑓𝑥 and 𝑓′𝑥 are given by the equations: 
𝑛𝑥 ∗  𝑙𝑥 =  𝑓𝑥 ∗  𝐿𝑥 and 𝑛′𝑥 ∗  𝑙𝑥 =  𝑓′𝑥 ∗  𝐿′𝑥 
with 𝑙𝑥 the length of motif x. 
4.3.5. Principal Component Analysis of TFBS occurrence in binding peaks 
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The input matrix N for the Principal Component Analysis (PCA) contained the total number of 
predicted binding sites Npm in each of the 7512 binding peaks p (rows) for each of the 190 
mammalian regulatory motifs m (columns). After mean centering the columns of this matrix, 
𝑁�𝑝𝑚 = 𝑁𝑝𝑚 − 〈𝑁𝑚〉, i.e. subtracting the average site count for each motif, Singular Value 
Decomposition (SVD) was used to factorize this matrix: 𝑁� = 𝑈 ∙ 𝑆 ∙  𝑉𝑇, where 𝑈 is a 𝑃 × 𝑀 
matrix whose columns are the left singular vectors of 𝑁� ; 𝑆 is a 𝑀 × 𝑀 diagonal matrix containing 
the singular values, and 𝑉𝑇 (the transpose of 𝑉) is an 𝑀 × 𝑀 matrix whose rows are the right 
singular vectors, with P the number of peaks, and M the number of motifs. The SVD was 
performed using the “svd” package of the “R” programming language. 
4.3.6. Gene expression arrays 
Whole-gene expression after 48 hours of transfection with adenovirus was measured in C2C12 
cells with Affymetrix GeneChip® Mouse Gene 1.0 ST microarrays at the Life Science Training 
core facility of the University of Basel. Raw probe intensities were corrected for background and 
unspecific binding using the Bioconductor package “affy” [21]. Subsequently, probes were 
classified as expressed or non-expressed by using the “Mclust” R package [22] and, after 
removal of non-expressed probes, the intensity values were quantile normalized across all 
samples. Using mapping of the probes to the UCSC collection of mouse mRNAs, probes were 
then associated to a comprehensive collection of mouse promoters available from the 
SwissRegulon database [19]. The log2 expression level of a given promoter was calculated as 
the weighted average of the expression levels of all probes associated to it. Log2 expression 
levels were then compared between over-expressed PGC-1α and the control GFP sample; for 
each promoter, the change in expression level across the two conditions was measured by log2 
fold change (log2FC), computed as the difference between the mean of the log2 values in PGC-
1α and the mean of the log2 values in GFP. The significance of the expression change was 
assessed by a Z score, which was computed as: 
𝑍 =  𝐸�𝑃𝐺𝐶1𝛼 −  𝐸�𝐺𝐹𝑃
�𝜎
2
𝑃𝐺𝐶1𝛼
𝑛 + 𝜎2𝐺𝐹𝑃𝑛  
where 𝑛 = 3 was the number of replicate samples, 𝐸�𝑃𝐺𝐶1𝛼 is the mean log2 expression across 
the PGC-1α samples, 𝐸�𝐺𝐹𝑃 is the mean log2 expression across the GFP samples, and 𝜎2𝑃𝐺𝐶1𝛼 
and 𝜎2𝐺𝐹𝑃 are the variances of log2 expression levels across the replicates for the PGC-1α and 
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control samples, respectively. Promoters were considered significantly up-regulated when 
log2FC >= 1 and Z >= 3, and significantly down-regulated when log2FC <= -1 and Z <= -3. 
Peaks were assigned to promoters by proximity. To assign each peak to a promoter, we 
calculated the distance from the center of the peak to the center of neighboring promoters; 
whenever the peak was closer than 10 kb from at least one promoter, it was assigned to the 
nearest promoter and, thus, to its associated gene. 
4.3.7. Gene Ontology enrichment analysis 
Gene IDs were extracted from differentially regulated promoters and divided in four groups: up-
regulated promoters with an assigned binding peak, up-regulated promoters without an assigned 
binding peak, down-regulated promoters with an assigned peak, and down-regulated promoters 
without an assigned peak. These four gene sets were used as input for the functional analysis 
tool FatiGO [23] to identify significantly over-represented Gene Ontology (GO) categories 
compared to all Mus musculus genes. Only GO terms having an FDR-adjusted p-value <= 0.05 
were considered significant. 
4.3.8. Motif activity at direct and indirect targets of PGC-1α 
To integrate the information from the PGC-1α binding peaks, we extended MARA [24] to model 
the direct and indirect regulatory effects of PGC-1α. Given the input expression data and the 
computationally predicted binding sites, MARA infers, for each of 190 regulatory motifs m, the 
activity Ams of the motif in each sample s when the motif occurs outside of a region of PGC-1α, 
and the activities A*ms of the motifs when they occur within a PGC-1α binding peak. That is, 
changes in the motif activities Ams upon over-expression of PGC-1α indicate indirect regulatory 
effects of PGC-1α on each motif m, whereas changes in the motif activities A*ms reflect direct 
regulatory effects of PGC-1α as mediated by each motif m. For each promoter p that was not 
associated with any PGC-1α binding peak (which we denote indirect targets), we modeled its 
log-expression in sample s, eps, in terms of the predicted number of TFBSs Npm that occur in the 
proximal promoter region (running from -500 to +500 relative to TSS) for each regulatory motif 
m. That is, MARA assumes the linear model: 
𝑒𝑝𝑠 = 𝑐𝑝 + ?̃?𝑠 + � 𝑁𝑝𝑚𝐴𝑚𝑠
𝑚
 
where cp is the basal expression of promoter p, ?̃?𝑠 is a sample-dependent normalization 
constant, and 𝐴𝑚𝑠 is the regulatory activity of motif m in sample s, which is inferred by the 
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model. Formally, 𝐴𝑚𝑠 quantifies amount by which the expression of promoter p in sample s 
would be reduced if a binding site for motif m were to be deleted from the promoter.  
For each “direct target” promoter p that has an associated PGC-1α binding peak, which we 
defined as promoters with a peak within 1 kb or with a peak within 100 kb that was highly 
conserved according to PhastCons score of the region [25], we model its expression in terms of 
the predicted TFBSs in the binding peak, i.e.: 
𝑒𝑝𝑠 = 𝑐𝑝 + ?̃?𝑠 + � 𝑁𝑝𝑚∗ 𝐴𝑚𝑠∗
𝑚
 
where 𝑁𝑝𝑚∗  is the number of predicted TFBSs for motif m in the peak associated with promoter p, 
and 𝐴𝑚𝑠∗  is the motif activity of regulator m in sample s when this motif occurs in the context of 
PGC-1α binding. That is, the inferred motif activities 𝐴𝑚𝑠 quantify the activities of regulatory 
motifs when they occur independent of PGC-1α binding, and the motif activities 𝐴𝑚𝑠∗  quantify the 
activities of motifs when they occur in a PGC-1α binding peak, i.e. the latter activities reflect 
direct effects of a PGC-1α while the former reflect indirect effects.  
MARA predicts activities for 190 different mammalian regulatory motifs, associated with roughly 
350 mouse TFs. Besides motif activities MARA also calculates error-bars 𝛿𝑚𝑠 for each motif m in 
each sample s. Using these, MARA calculates, for each motif m, an overall significance measure 
for the variation in motif activities across the samples analogous to a z-statistic: 
𝑧𝑚 = �1𝑆��𝐴𝑚𝑠𝛿𝑚𝑠�2𝑆𝑠=1  
For each motif we calculate both a z-score 𝑧𝑚 associated with its indirect activity changes, and a 
z-score 𝑧𝑚∗  associated with its direct activity changes. MARA also ranks the confidence on 
predicted target promoters of each motif by a Bayesian procedure that quantifies the contribution 
of that factor to explaining the promoter’s expression variation by a Chi-squared value (for 
details, see [24]). The parameters used for motif stratification were: (i) the Z score 𝑧𝑚∗  for direct 
activity changes, (ii) the Z score 𝑧𝑚 for indirect motif activity changes, (iii) the Z score 𝑧?̅?∗  for 
direct motif activity changes, computed by averaging the sample replicates and (iv) the Z score 
𝑧?̅? for indirect motif activity changes, computed by averaging the sample replicates. The latter 
two measures were used to show which direction the motif activity changes when over-
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expressing PGC-1α with respect to the control condition. All motifs m for which either the direct 
or indirect motif activities were changing significantly (𝑧 ≥ 2) were subsequently selected. 
4.3.9. De novo motif finding 
PhyloGibbs [26] was used to identify de novo motifs across the 200 top enriched PGC-1α peaks. 
The parameters used were -D 1 -z 1 -y 200 -m 10, corresponding to searching on multiple 
alignments for a single motif of length 10 with a total of 200 sites. The resulting motif was 
scanned for similarity to the other known motifs from our dataset using STAMP [27], with 
settings: Pearson Correlation Coefficient for column comparison metric, Smith-Waterman for the 
alignment method, penalty of 0.5 and 0.25 for gap opening and gap extension, respectively. 
4.3.10. Real-time PCR and target gene validation 
Putative target genes of distinct transcription factor-PGC-1α combinations were chosen 
according to three criteria: first, positive transcriptional regulation by PGC-1α by more than 2 
fold, second, presence of a PGC-1α binding peak within a 10 kb distance from the TSS and 
third, prediction of targeting by MARA with a positive Chi-squared score. The sequences of the 
primers used in real-time PCR experiments are depicted in Suppl. Table 1. Relative mRNA was 
quantified by qPCR on a StepOnePlus system (Applied Biosystems) using Power SYBR Green 
PCR Master Mix (Applied Biosystems). 
The values are presented as the mean +/- SEM. A Student’s t-test was performed and a p-value 
< 0.05 was considered as significant (*p<0.05, **p<0.01, ***p<0.001). 
4.3.11. Animals 
Mice were housed in a conventional facility with a 12-h night/12-h day cycle with free access to 
chow diet pellet and water. For the experiments, 22-23 week-old skeletal muscle-specific HSA-
PGC-1α knockout (MKO) male mice and 8 week-old PGC-1α muscle-specific transgenic (TG) 
male mice were used as previously described [6-8]. All experiments were performed according 
to the criteria outlined for the care and use of laboratory animals and with approval of the 
veterinary office of the canton Basel and the Swiss authorities. 
4.3.12. Treadmill running 
Treadmill running was performed with the TG mice on the Columbus Instruments motorized 
treadmill with an electric shock grid. The mice were acclimatized to the treadmill and then let run 
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till exhaustion. The running protocol is as follows: 10m/min for 5min with an increase by 2m/min 
every 5min until 26m/min and an inclination of 5 degrees. The speed of 26m/min was kept until 
exhaustion of the mice [7, 28, 29]. Mice were killed and tissues were collected 3h after exercise. 
4.3.13. RNA isolation of muscle tissue 
Gastrocnemius and quadriceps were used to isolate RNA by TRIzol® according to the TRIzol® 
reagent RNA isolation protocol (Invitrogen). 
4.4. Results 
4.4.1. Broad recruitment of PGC-1α to the mouse genome 
PGC-1α-dependent gene transcription has been studied in many different experimental 
contexts. In isolation, gene expression arrays however are unable to distinguish direct from 
indirect targets, or to reveal the genomic sites where PGC-1α is recruited to enhancer and 
promoter elements, i.e. by coactivating TFs that directly bind to the DNA. Thus, we first 
performed chromatin immunoprecipitation followed by deep sequencing (ChIP-Seq) of PGC-1α 
in differentiated C2C12 mouse myotubes to identify the locations where PGC-1α is bound to the 
genome. To identify genomic regions that are significantly enriched in the ChIP, we slid a 200 bp 
window across the genome comparing the local ChIP read density with the read density from a 
background whole cell extract sample. We selected all regions with a Z-statistic larger than 4.5 
as significantly enriched (FDR 0.6%, Suppl. Fig. S1A). Using this stringent cutoff, we identified 
7512 binding regions for PGC-1α via interaction with a TF genome-wide, which include binding 
regions in the promoters of known PGC-1α target genes (Fig. 1A) such as medium-chain 
specific acyl-CoA dehydrogenase (Acadm) and cytochrome c (Cycs) [30, 31]. The enrichment of 
immunoprecipitated DNA fragments from the ChIP-Seq was validated for these and other PGC-
1α target genes by semiquantitative real-time PCR (Fig. 1B). In absolute terms, the distribution 
of the ChIP-Seq peaks revealed that PGC-1α is mostly recruited at distal sites from the assigned 
targets and, to a lesser extent, to proximal regions of the gene or within an intronic sequence 
(Fig. 1C). However, when compared to randomly selected DNA regions of equal size and 
number, PGC-1α binding peaks occur twice as often within 10 kb upstream of the transcription 
start site (TSS). 
In parallel to the ChIP-Seq experiment, we furthermore analyzed gene expression patterns in 
differentiated muscle cells both in control condition and under PGC-1α over-expression. Using a 
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reference set of mouse promoters [19] and associating microarray probes to promoters by 
mapping to known transcripts, we found 1566 promoters (corresponding to 984 genes) to be 
significantly up-regulated (log2 fold change >= 1; Z score >= 3) and 1165 promoters 
(corresponding to 727 genes) to be significantly down-regulated (log2 fold change <= -1; Z score 
<= -3). Thus, similar to previous reports, PGC-1α induced and repressed the transcription of 
almost the same number of genes, respectively, indicating that the physiological function of 
PGC-1α includes both the activation and inhibition of substantial numbers of genes. 
To combine the DNA binding results from the ChIP-Seq with the data of the gene expression 
arrays, we then assigned ChIP-Seq peaks to the closest promoter (and the associated gene) 
within a maximum distance of 10 kb. In this way, about 30% of all peaks (2295 of 7512) could be 
associated with a target promoter. Inversely, for about 35% of all significantly up-regulated 
genes (341 of 984), a PGC-1α binding peak is found within 10 kb of the promoter. Since some of 
the up-regulated promoters may be regulated by more distal peaks, this is only a lower bound on 
the fraction of genes that are directly regulated. In stark contrast, only about 5% of all repressed 
genes harbor one or more PGC-1α DNA recruitment peaks in their vicinity (36 of 727) opposed 
to 95% indirectly down-regulated PGC-1α target genes (691 genes) (Fig. 1D). Moreover, the 
distribution of the distances between PGC-1α peaks and their associated promoters revealed a 
tight cluster of 532 peaks close to promoter regions for up-regulated, direct PGC-1α target 
genes (Fig. 1E) whereas the distribution of the 43 peaks associated to down-regulated genes 
was much wider, raising the possibility that the association of peaks to transcriptionally 
repressed genes might be spurious (Fig. 1F). In summary, the strong enrichment of binding 
peaks near up-regulated genes and the almost complete absence of binding peaks near down-
regulated genes suggest that direct regulation of transcription by PGC-1α is almost exclusively 
activating. We note that there is a large fraction of binding peaks (75%) that are associated to 
target genes that do not significantly alter their expression. These peaks may have been wrongly 
assigned, their functionality may be dependent on additional factors not active in these cells, or 
they may simply be spurious binding events that are not functional. We next used this 
stratification of peaks and genes to study whether direct (i.e. with an associated binding peak) 
and indirect PGC-1α target genes exert different biological function and identified Gene 
Ontology (GO) terms that were over-represented in any of the four categories. First, we 
observed that the most significantly enriched functional categories for directly and indirectly up-
regulated genes were those related to mitochondria, oxidative phosphorylation and energy 
production (Fig. 1G and Suppl. Fig. S1B). In contrast, GO analysis of indirectly down-regulated 
PGC-1α target genes revealed a high prevalence of terms related to inflammation and immune 
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response (Fig. 1H and Suppl. Fig. S1C). Assuming that the assignment of peaks to repressed 
genes is not spurious, the few directly repressed PGC-1α targets exhibit an enrichment in 
functions related to muscle contraction, in particular for genes that are linked to contractile and 
metabolic properties of glycolytic, fast-twitch muscle fibers (Fig. 1H and Suppl. Fig. S1D), as 
would be expected from the observed shift from glycolytic to oxidative fibers mediated by PGC-
1α in muscle [6]. 
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Figure 1. Genome-wide DNA recruitment of PGC-1α in mouse muscle cells. (A) PGC-1α ChIP-Seq 
binding peaks (read densities) around the TSS of the genes Acadm and Cycs obtained from the UCSC 
Genome Browser. (B) Real-time PCR validation of the ChIP enrichment measured at the promoter of a set 
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of PGC-1α target genes. Bars represent fold enrichment over that of the Tbp intron, error bars represent 
SEM. *p < 0.05; **p < 0.01; ***p < 0.001. (C) Mapping ChIP-Seq PGC-1α peaks across the genome. 
Transcription Start Site (TSS) and Transcription End Site (TES) are relative to mm9 RefSeq transcripts. 
“Intergenic”: ≥ 10 kb from the nearest transcript; “Upstream of TSS”: -10 to 0 kb from the TSS; 
“Downstream of TES”: 0 to 10 kb from the TES. Numbers between brackets indicate, for each category, 
the ratio between the percentage of PGC-1α peaks and the percentage of the same number of randomly 
distributed peaks. (D) Histogram illustrating the number of direct and indirect genes either up- or down-
regulated by over-expression of PGC-1α in muscle cells. Direct genes are those associated to promoters 
found within ±10 kb relative to the nearest peak. (E) Distribution of the distances of 532 peaks from their 
associated up-regulated gene promoters. (F) Distribution of the distances of 43 peaks from their 
associated down-regulated gene promoters. (G-H) Subset of the top significantly enriched GO Biological 
Process terms identified for directly and indirectly up-regulated (G) and down-regulated (H) PGC-1α target 
genes. 
4.4.2. Modeling the direct and indirect gene regulatory effects of PGC-1α  
As a next step, we rigorously modeled the effects of PGC-1α on its target genes in terms of the 
occurrence of TFBSs for a large collection of mammalian regulatory motifs. We previously 
introduced a general framework, called Motif Activity Response Analysis (MARA) [24], for 
modeling the gene expression profiles as a linear function of the TFBSs occurring in the 
promoters and unknown regulatory “activities” of each of the regulators. As detailed in the 
Methods, we here extended MARA to incorporate information from the PGC-1α ChIP-Seq data, 
with the aim of identifying which other TFs are involved in mediating both the direct and indirect 
regulatory effects of PGC-1α. Specifically, for all “direct target” promoters that were associated 
with a PGC-1α binding peak, we modeled the expression of the promoter in terms of the 
predicted TFBSs in the neighborhood of the binding peak, while for “indirect target” promoters 
we modeled the promoter’s expression in terms of the predicted TFBSs in the proximal promoter 
region, according to the conventional MARA approach (Fig. 2A and 2B). 
First, further supporting our analysis above, direct target promoters were almost exclusively up-
regulated and only in a few exceptional cases reached statistical significance for PGC-1α-
repressed transcripts (Fig. 2C). Among the direct motif activities, the ESRRA position weight 
matrix was the top ranking motif with a Z score of 6.04 (Suppl. Fig. 2). The corresponding TF 
estrogen-related receptor α (ERRα), an orphan nuclear receptor, has been extensively studied 
as a central binding partner for PGC-1α in the regulation of mitochondrial gene expression [30-
33]. To stratify the different motifs according to their predicted function, we then divided all motifs 
into groups according to the behavior of both their direct and indirect activity changes. Strikingly, 
all motifs exhibited one of only four different motif activity patterns. First, 6 TFs (Suppl. Fig. S2) 
were predicted to positively regulate PGC-1α target genes only in the presence of PGC-1α (Fig. 
2D). Second, we found 6 motifs (Suppl. Fig. S2) with significantly up-regulated direct and indirect 
motif activities upon PGC-1α over-expression (Fig. 2E). To our surprise, ERRα was predicted to 
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regulate PGC-1α target genes in this manner, even though in previous reports gene regulation 
by ERRα in the context of activated PGC-1α was suggested to be dependent on PGC-1α 
coactivation [30-33]. Third, we found 13 motifs (Suppl. Fig. S2) that were predicted to regulate 
PGC-1α target genes, however only in the absence of PGC-1α (Fig. 2F). Fourth, there was a 
group of 28 motifs (Suppl. Fig. S2) that showed a significant decrease of indirect motif activity 
upon PGC-1α over-expression, but no significant change of their direct motif activity, including 
NFκB (Fig. 2G), a central regulator of inflammation which is indirectly repressed by PGC-1α [33]. 
Intriguingly however, no motif was found that showed significant direct repression of target 
genes, reinforcing the hypothesis that PGC-1α-dependent gene repression is an indirect event. 
 
Figure 2. Four distinct mechanistic modes of action for gene expression regulated by PGC-1α and 
TF partners. (A) Classification of direct and indirect target genes in MARA (see Methods) (B) Distribution 
of peak distance from the closest promoter and phastCons conservation score of the peak. (C) Distribution 
of log2 expression values for all mouse promoters. Expression values were averaged across the 3 GFP 
and the 3 PGC-1α samples. Direct targets are depicted in red, indirect targets in grey. (D-G) Activity plot 
of the motifs ELF1,2,4 (D), ESRRA (E), REST (F) and NFKB1_REL_RELA (G) as predicted by MARA 
(Motif Activity Response Analysis). Red: direct targets; green: indirect targets. 
4.4.3. Nuclear receptors and activator protein-1-like leucine zipper proteins are the 
main functional partners of PGC-1α in muscle cells 
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As a next step, we analyzed the occurrence of TF DNA-binding motifs in the PGC-1α peaks 
identified by ChIP-Seq. We first performed de novo motif prediction on the top 200 peaks, using 
PhyloGibbs [26]. As shown in Figure 3A, the motif that PhyloGibbs identified matches 
significantly (E-value = 7.7834e-10, as calculated by STAMP [27]) the canonical ESRRA motif. 
In addition to the de novo prediction, we also used the same collection of 190 mammalian 
regulatory motifs used by MARA [19] to check which known TF DNA-binding motifs were 
significantly over-represented in the PGC-1α peaks relative to a set of background regions.  
Many of the most significantly enriched motifs represent variations of nuclear receptor binding 
sequences that are based on the “AGT/GTCA” core hexamer and occur either alone or in direct, 
inverted or everted repeats with variable spacing (Fig. 3B). Of these, the most significantly 
enriched motif was ESRRA, which is present in ~20% of all peaks. Moreover, among all genes 
with at least one associated binding peak within 10Kb, ~28% are associated with a peak 
containing a predicted ERRα site. Interestingly, besides the nuclear receptor motifs, we also 
found the DNA-binding element of the insulator protein CCCTC-binding factor (CTCF), and a set 
of highly similar DNA elements sharing the FOS-JUN-like recognition sequence “TGAG/CTCA” 
bound by the TFs BACH2, FOS, FOSB, FOSL1, JUN, JUNB, JUND, FOSL2, NFE2, and 
NFE2L2 among the top 15 motifs enriched in PGC-1α peaks (Fig. 3B). 
The identity of the exact nuclear receptor binding partner that is bound at each peak is difficult to 
deduce from DNA-binding motifs, since considerable promiscuity exists between receptors and 
DNA-binding elements in different configurations of hexameric repeats [34]. Moreover, non-
nuclear receptor-like TFs are less well studied in the context of PGC-1α-controlled gene 
expression. Thus, to identify which regulatory motifs are most over-represented among peaks 
that do not contain nuclear receptor-like sites, we first manually grouped all of the motifs with a 
sequence logo very similar to that of ESRRA. Next, we discarded all peaks that had one or more 
predicted TFBSs for any of the motifs in this set. With the remaining 3856 DNA sequences 
(51.33% of the peaks), we then again assessed the over-representation of each of the 190 
mammalian regulatory motifs. In this analysis, "TGAG/CTCA” recognition elements, hence FOS-
JUN-like motifs, were the most significantly enriched among these peaks (Fig. 3C). This result 
suggests that PGC-1α peaks naturally fall into two classes: those containing ESRRA-like sites, 
and those containing sites for FOS-JUN-like motifs. 
We then constructed a matrix N, whose elements Npm contain the number of predicted TFBSs 
for each motif m in each peak region p. We then performed principal component analysis (PCA) 
on this site-count matrix to identify linear combinations of regulatory motifs that explain most of 
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the variation in site-counts across the PGC-1α peaks. The first two components (out of 190 in 
total) clearly proved to be the most relevant ones, accounting for 10% and 9.6% of the total 
variation in our dataset, respectively (Fig. 3D). Figure 3E shows the projection of all motifs on 
these first two principal components, with the names of the motifs with the largest projection 
indicated in the figure.  
Whereas most motifs have projections close to zero along the first component, there is one 
group of motifs with strong negative projections (ESRRA, NR1H4, NR5A1,2, NR6A1) and one 
group of motifs with strong positive projections (BACH2, FOS_FOS(B,L1)_JUN(B,D), FOSL2, 
NFE2, NFE2L1, NFE2L2). These two sets of sites correspond precisely to the two classes of 
motifs identified above, confirming that the most significant variation in TFBSs across PGC-1α 
peaks is caused by the occurrence of either ESRRA-like motifs, or FOS-JUN-like motifs. Most 
interestingly, these two clusters of motifs reflect structurally distinct classes of TFs; the 
negatively scoring eigenmotifs are characterized by binding of nuclear receptor-type zinc finger 
domains, while the eigenmotifs with a positive score correspond to activator protein-1 (AP-1)-like 
leucine zipper domains. 
The second principal component corresponds to the strength of the binding signal for these 10 
motifs, as confirmed by the robust negative correlation (r=-0.92) between the TFBSs posterior 
sum per peak and the peak’s projection along the second principal component (Fig. 3F). 
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Figure 3. PCA reveals FOS-JUN-like leucine zippers as a new class of putative functional PGC-1α 
partners. (A) Sequence logo of the top position weight matrix discovered de novo by PhyloGibbs in the 
top 200 scoring peaks and of the corresponding canonical motif of ERRα as predicted by STAMP. (B) Top 
scoring results of motif search performed on all 7512 PGC-1α peaks with MotEvo. Motifs depicted in red 
and blue correspond to the clusters identified by PCA in panel D. (C) Top scoring results of motif search 
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performed on the 3656 “non ESRRA-like” peaks with MotEvo. (D) Fraction of explained variance of the top 
10 PCA components. (E) PCA analysis of the 7512 PGC-1α peaks. Eigenmotif scores across Principal 
Component 1 (PC1) and Principal Component 2 (PC2) are shown. Red and blue ellipses highlight motif 
clusters, as identified by PC1, of nuclear hormone receptor-like zinc finger and FOS-JUN-like leucine 
zipper proteins, respectively. (F) Correlation between Principal Component 2 scores and binding site 
posterior sum for each peak relative to the top 10 PCA motifs. “r” refers to the Pearson correlation 
coefficient. 
4.4.4. Validation of top scoring motifs reveals novel functional partners of PGC-1α 
Our analysis identified a number of so-far uncharacterized TFs as potentially functional partners 
for PGC-1α-controlled gene expression in skeletal muscle cells. In order to experimentally 
validate some of these candidates, we sorted all TFs by a number of criteria including TFBS 
over-representation in binding peaks, MARA activity upon PGC-1α over-expression, and the 
expression pattern of the TFs themselves. Table 1 shows the top 15 ranked TFs according to 
this selection. As expected, the well-known PGC-1α partner ERRα was identified as the most 
important factor. For our validation experiments, we chose the next two motifs 
(FOS_FOS(B,L1)_JUN(B,D) and ZNF143, which is also known as ZFP143) as well as three 
motifs from further down the list of the top 15 motifs (GTF2I, NFE2L2 and NFYC).  
Table 1. Global summary of all analyses performed on PGC-1α peaks. The final score is the count of 
all analyses where a certain motif passed the defined cutoffs. The motifs chosen for validation and their 
corresponding values which satisfied the cutoffs are shown in bold. 
Motif name PCAa Over-repr. in 
all PGC-1α 
peaksb 
Over-repr. in 
“non ESRRA-
like” peaksb 
MARA 
activity Z 
score 
directc 
MARA 
activity Z 
score 
indirectc 
Log2FC 
in expr. 
arrayd 
Abs. expr. 
in PGC-1α 
samplee 
Final 
ranking 
ESRRA Yes 1 182 6.04(14.78) 15.49(37.94
) 
2.31 1829.45 6 
FOS_FOS(B,L1)_JUN(B,D) Yes 5 2 0.88(2.14) 1.81(-4.34) 1.78 1508.85 5 
ZNF143  27 28 2.48(6.05) 4.65(9.68) 0.38 384.36 5 
BPTF  21 12 1.38(3.37) 2.56(-6.25) -0.56 333.34 4 
ESR1  17 50 2.33(5.69) 4.53(11.04) -0.47 232.42 4 
FOSL2 Yes 6 3 0.88(2.14) 1.51(3.65) -0.98 717.09 4 
GTF2I  34 13 2.09(5.10) 2.38(-5.80) -0.55 1207.81 4 
NFE2L2 Yes 8 5 0.57(1.38) 1.01(-2.37) -0.38 3673.63 4 
NFY(A,B,C)  96 116 2.37(5.80) 3.56(7.62) 1.07 2409.48 4 
NR5A1,2 Yes 3 188 3.53(8.66) 7.73(17.00) -0.08 80.97 4 
REST  12 6 0.48(1.15) 2.41(5.70) -0.89 328.04 4 
RREB1  15 10 1.56(3.82) 2.39(-5.42) 0.05 678.44 4 
SP1  24 22 3.99(9.76) 0.61(0.33) -0.32 751.98 4 
STAT2,4,6  29 23 0.35(0.52) 4.81(-9.67) -2.72 380.12 4 
TLX1..3_NFIC(dimer)  19 17 0.84(-2.05) 4.91(-11.97) -0.34 2339.33 4 
a Requirement for PCA: being among the top 10 most contributing motifs to PC1 and PC2. 
b Requirement for motifs over-representation: being among the top 30 significant motifs; ranking position 
shown. 
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c Requirement for MARA: have a Z-score ≥ 2.0. Numbers between brackets show the difference between 
the PGC-1α state and the GFP state, representing the direction in which the motif activity changes 
following PGC-1α over-expression. 
d Requirement for the expression array (1): having a log2 fold change value ≥ 1.0 (corresponding to 2 
folds up-regulation) 
e Requirement for the expression array (2): having an absolute expression in the PGC-1α sample ≥ 100 
 
FOS, the most up-regulated TF (log2 fold change = 1.78) among the TFs associated with the 
motif FOS_FOS(B,L1)_JUN(B,D), is a basic leucine zipper transcription factor known to 
heterodimerize with other leucine zipper proteins in order to form the AP-1 complex [35]. The 
AP-1 complex furthermore contains JUN as well as ATF proteins. Thus, to dissect the function of 
the AP-1 protein complex, we also included JUN and ATF3, the most highly expressed isoforms 
of their respective protein families in muscle cells. 
For each of these 7 TFs (ATF3, FOS, GTF2I, JUN, NFE2L2, NFYC and ZFP143), we selected a 
dozen target genes based on the Chi2 score of the MARA prediction, presence of a PGC-1α 
binding peak with at least one predicted binding site for the factor of interest, and at least a 2-
fold induction upon over-expression of PGC-1α. As summarized in Fig. 4 and Suppl. Fig. S3, 
siRNA-based knockdown of all TFs resulted in a robust reduction of the target mRNAs from -
40% to -75%. With the exception of NFYC and JUN, we found that the large majority of 
predicted target genes were down-regulated upon knockdown of the factor, confirming our 
predictions (Fig. 4). The most consistent effects were observed for FOS and ZFP143 (all targets 
down-regulated), followed by GTF2I (11 out of 12 down-regulated) and NFE2L2 and ATF3 (10 
out of 12 down-regulated). Interestingly, distinct target genes of the AP-1 complex showed 
differential responsiveness to knockdown of the three AP-1 complex components FOS, JUN and 
ATF3 (Fig. 4B, Fig. 4C and Fig. 4D). Similarly, PGC-1α-mediated induction of a majority of the 
predicted target genes for NFE2L2 (Fig. 4E), ZFP143 (Fig. 4F) and GTF2I (Fig. 4G) was 
reduced upon knockdown of the respective TF when compared to the expression in cells with 
overexpressed PGC-1α and a scrambled siRNA control. Surprisingly, only 1 of the 11 predicted 
target genes for NFYC that have been chosen for validation was significantly repressed by 
siRNA-induced reduction of this TF (Fig. 4H), suggesting that other TFs may be involved in 
mediating the regulatory effects of the NFYC regulatory motif. 
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Figure 4. Validation of TFs associated with top scoring motifs reveals novel functional PGC-1α 
partners. (A) siRNA-mediated knockdown efficiency for FOS. Bars represent fold induction over 
GFP/siCtrl value, error bars represent SEM. *p < 0.05; **p < 0.01; ***p < 0.001. See also Figure S4. (B-H) 
qRT-PCR analysis of PGC-1α target genes whose associated peak contains at least one binding site for 
the motif: FOS_FOS(B,L1)_JUN(B,D) (B-D), NFE2L2 (E), ZNF143 (F), GTF2I (G), NFY(A,B,C) (H). Bars 
represent % change compared to PGC-1α/siCtrl values. Error bars represent SEM. *p < 0.05; **p < 0.01; 
***p < 0.001. 
4.4.5. Functional interaction between PGC-1α and different compositions of the 
AP-1 protein complex 
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Our targeted validation strategy revealed that PGC-1α target genes predicted to be regulated by 
the FOS-JUN-like motif react in distinct manners to siRNA-mediated knockdown of individual 
components of the AP-1 transcription factor protein complex. For example, some genes only 
reacted to reduction of FOS (Fig. 5A), while others were responsive to the knockdown of two 
(Fig. 5B) or even all three AP-1 protein partners (Fig. 5C) that we have tested using the siRNA-
based approach. To further dissect the responsiveness of PGC-1α target genes to different AP-1 
protein complexes, we performed global gene expression arrays upon knockdown of each of the 
three TF components of the AP-1 complex. Fig. 5D depicts the number of genes that were 
induced by PGC-1α and that were, at the same time, down-regulated by the siRNA knockdown 
of any of the three AP-1 complex members. Amongst a total of 477 genes, 89% responded to 
FOS knockdown, 52% to ATF3 knockdown, and 31% to JUN knockdown. Moreover, while 37% 
of all targets responded exclusively to FOS, the fraction of targets responding exclusively to 
either JUN or ATF3 was at most 5%. This analysis shows that, whereas different target genes 
respond differently to the knockdown of distinct AP-1 components, FOS is the dominant factor in 
determining AP-1 function in these conditions. 
As shown in Fig. 3B, 341 genes were associated to a PGC-1α binding peak containing a 
predicted site for the FOS-JUN-like motif bound by the AP-1 complex. Of these genes, the 
expression of 55 was significantly induced by PGC-1α over-expression in muscle cells. In our 
siRNA-based validation experiment, we found that 47 out of these 55 PGC-1α-induced/AP-1 
predicted targets were significantly down-regulated by knockdown of the AP-1 complex 
components and we called these genes “direct PGC-1α/AP-1 targets”. The remaining 430 genes 
out of 477 (Fig. 5D) were defined accordingly as “indirect PGC-1α/AP-1 targets” that lack a 
PGC-1α peak containing a FOS-JUN-like motif, but still are regulated by PGC-1α and the AP-1 
protein components (Fig. 5E). To reveal whether these gene categories exert distinct functions, 
GO and KEGG enrichment analyses were performed. Surprisingly, the 47 direct PGC-1α/AP-1 
target genes showed a distinct and significant over-representation of the terms “response to 
hypoxia” (GO ID: 0001666; adjusted p-value: 0.0247542) and “mTOR signaling pathway” (KEGG 
ID: mmu04150; adjusted p-value: 0.030674) that were absent in the GO analysis of the 
remaining PGC-1α/AP-1 targets (Fig. 5F). Recruitment of FOS to the same regulatory regions as 
PGC-1α in the direct AP-1/PGC-1α target genes was subsequently validated by ChIP (Fig. 5G). 
These results suggest that AP-1, when interacting with PGC-1α, drives a synergic effect of 
response to hypoxia; on the other hand, when AP-1 and PGC-1α act separately, and 
furthermore through downstream intermediate TFs, they regulate the expression of genes 
involved in mitochondrial organization and energy metabolism. 
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Intriguingly, several of the predicted AP-1/PGC-1α target genes are also under the control of 
PGC-1α working with other transcription factors. For example, the vascular endothelial growth 
factor (VEGF) or, based on the gene expression arrays, 8 OXPHOS genes seem likewise to be 
under the control of AP-1 as well as ERRα in the context of elevated PGC-1α in skeletal muscle 
[31, 36]. We therefore assessed the predicted and experimental overlap of these two 
transcription factors in the regulation of AP-1/PGC-1α target genes. Interestingly, when the PCA 
analysis of the PGC-1α peaks was stratified in terms of eigenpeaks, we observed two distinct 
groups of peaks associated with AP-1/PGC-1α target genes (Fig. 5H). First, some of these 
genes exclusively harbored peaks with FOS-JUN-like TFBSs, whereas the second group 
exhibited either peaks with both FOS-JUN- and ESRRA-like TFBSs, or a combination of distinct 
peaks with either of these sites within 10 kb from their promoters (Fig. 5H). Next, we validated 
this prediction by investigating the change in expression of different AP-1/PGC-1α target genes 
in the context of reduced ERRα expression and function, elicited by a combination of shRNA-
mediated knockdown and pharmacological treatment of muscle cells with the ERRα inverse 
agonist XCT-790 [31]. In line with the PCA, two distinct groups of ERRα inhibition-sensitive (Fig. 
5I-K) and –insensitive (Fig. 5L-N) AP-1/PGC-1α target genes were found. 
Finally, since all of the experiments were performed in differentiated myotubes in culture, we 
assessed whether similar gene expression changes of the direct AP-1/PGC-1α targets involved 
in hypoxic gene regulation are also observed in skeletal muscle tissue of different gain- [6] and 
loss-of-function mouse models [7, 8] in vivo. In skeletal muscle-specific PGC-1α knockout mice, 
the expression of several of these genes was reduced significantly (Fig. 6A-F). Surprisingly 
however, some of the predicted transcripts were not altered in this loss-of-function model for 
PGC-1α, for example Nr0b2 (Fig. 6E). To further clarify the role of PGC-1α in the regulation of 
these genes, relative transcript levels were next assessed in muscle-specific transgenic mice for 
PGC-1α (Fig. 6G-L). In most cases, the genes with a reduction in their transcription in the PGC-
1α muscle-specific knockout animals were inversely elevated in the PGC-1α muscle-specific 
transgenic mice. Moreover, some of these genes were likewise induced by exercise (Fig. 6G-L) 
and at least in some cases, for example Twf2 and Nr0b2 (Fig. 6J and K), PGC-1α 
overexpression and physical activity synergistically boosted gene expression, for Nr0b2even in 
the absence of any effect of the muscle-specific PGC-1α transgene per se (Fig. 6K). 
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Figure 5. PGC-1α controls the hypoxia gene program via a functional interaction with different 
configurations of the AP-1 protein complex. (A-C) qRT-PCR analysis of Cdk15, Nppb and Slc6a19 
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mRNA levels in response to PGC-1α over-expression and either siFos, siJun or siAtf3 knockdown. Data 
are normalized to mRNA levels in GFP infected cells. Error bars represent ± SEM. *p < 0.05; **p < 0.01; 
***p < 0.001. (D) Venn diagram illustrating the overlap in number of genes up-regulated by PGC-1α and 
down-regulated by either FOS, JUN or ATF3 knockdown. (E) Histogram illustrating the number of direct 
and indirect PGC-1α/AP-1 target genes. (F) Subset of the top significantly enriched Gene Ontology and 
KEGG terms identified for the two gene groups illustrated in panel (E). (G) qRT-PCR validation of the 
ChIP enrichment of c-Fos measured at the gene of TGFβ1 (validated) and at the promoters of Nr0b2, 
Gprc5a and Dbt (predicted) target genes. Bars represent fold enrichment over PGC-1α exon2 set as 1. 
Error bars represent SEM. *p < 0.05; **p < 0.01; ***p < 0.001. (H) PCA analysis of the 7512 PGC-1α 
peaks. Eigenpeak scores across Principal Component 1 (PC1) and Principal Component 2 (PC2) are 
shown. Colored dots correspond to peaks associated to the 47 direct PGC-1α/AP-1 targets. Blue dots 
refer to genes associated to peaks containing only FOS-JUN TFBSs, while red dots refer to genes 
associated to peaks with FOS-JUN and ESRRA TFBSs, either located in the same peak or in distinct 
PGC-1α peaks. (I-K) qRT-PCR analysis of PGC-1α/AP-1 targets whose associated peaks contain an 
ESRRA binding site. The bars represent relative mRNA levels compared to AV-shGFP + AV-GFP + 
vehicle, which is set as 1. The error bars represent SEM. *p < 0.05, **p < 0.01, ***p < 0.001. (L-N) qRT-
PCR analysis of PGC-1α/AP-1 targets whose associated peaks (if any) do not contain an ESRRA binding 
site. The bars represent relative mRNA levels compared to AV-shGFP + AV-GFP + vehicle, which is set 
as 1. The error bars represent SEM. *p < 0.05, **p < 0.01, ***p < 0.001. 
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Figure 6. PGC-1α controls the hypoxic gene program in muscle in vivo. (A-F) qRT-PCR analysis of 
hypoxic genes in sedentary control (ctrl) and muscle-specific knockout mice (MKO). The control group is 
set as 1. Error bars represent SEM. *p < 0.05, **p < 0.01, ***p < 0.001. (G-L) qRT-PCR analysis of 
hypoxic genes in treadmill running mice. Control (ctrl) and muscle-specific transgenic (TG) mice were 
used under sedentary and exercise conditions. The control group sedentary is set as 1. Error bars 
represent SEM. *p < 0.05, **p < 0.01, ***p < 0.001. (M) Schematic representation depicting the 
downstream effects of the functional interaction between PGC-1α and the AP-1 complex in the context of 
the hypoxia gene program. Direct targets of PGC-1α and AP-1 are indicated in bold. 
4.5. Discussion 
Exercise-induced skeletal muscle cell plasticity is a highly complex biological program that 
involves the remodeling of a number of fundamental cellular properties. Since PGC-1α function 
has been strongly linked to the induction of an endurance-trained muscle phenotype, we here 
dissected the PGC-1α-controlled transcriptional network in muscle cells. First, our results reveal 
a broad recruitment of PGC-1α to many different sites in the mouse genome (7512 peaks), the 
majority of which were either not located within 10 kb distance from a promoter or close to a 
gene that was not regulated by PGC-1α over-expression at the time of harvest of the cells, as 
has analogously been observed in many other ChIP-Seq experiments (for example, see ref. 
[37]). Apart from the fact that PGC-1α could mediate long-range enhancer effects that were 
excluded in our peak-gene assignment, it is conceivable that PGC-1α recruitment is 
transcriptionally silent in some binding peaks because it requires the recruitment of additional 
cofactors for activation, which are not present in the conditions or cell type in which our 
experiments were performed. In addition, it is possible that a large fraction of PGC-1α binding 
peaks may be “neutral” in the sense of not having any direct role in regulating gene expression. 
Second, while an almost equally strong effect of PGC-1α on gene induction and repression has 
been reported [31], our analysis now indicates that direct PGC-1α-mediated gene expression is 
restricted almost exclusively to positively regulated PGC-1α target genes, whereas the vast 
majority of gene repression is indirect, i.e. not associated with PGC-1α recruitment within a 10 
kb distance to their promoters. Thus, the fact that almost 95% of all repressed genes were not 
linked to PGC-1α recruitment strongly implies that this coregulator primarily acts as a 
coactivator, and not as a corepressor as suggested by the data of some studies [38-40]. 
Importantly, indirect repression of PGC-1α target genes was also supported by the MARA 
prediction. The strong indirect inhibition of genes, many of which are involved in inflammatory 
processes, is predicted by MARA to be mediated by TFs such as NFκB and IRF factors. Such 
an indirect inhibition of NFκB and pro-inflammatory genes by PGC-1α in muscle cells has been 
reported previously [33]. 
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One of the main functions of PGC-1α in all cells and organs is to boost mitochondrial gene 
transcription and oxidative metabolism. Accordingly, we observed that Gene Ontology terms 
related to these pathways were highly enriched when analyzing positively regulated PGC-1α 
target genes in muscle cells. Based on previous studies, the regulation of this core function 
could have been assigned to the direct interaction of PGC-1α and ERRα binding to regulatory 
elements of these genes [31, 32]. Surprisingly, our data indicate that many of the genes that are 
involved in oxidative metabolic pathways are indirectly controlled by PGC-1α and, hence, do not 
require PGC-1α recruitment to enhancer and promoter elements. Likewise unexpectedly, the 
MARA analysis implies ERRα action on direct and indirect PGC-1α-induced target genes, i.e. in 
the presence or absence of PGC-1α coactivation. Thus, while these observations might 
obviously reflect a temporally distinct control of different PGC-1α target genes that is not 
represented in our simultaneous analysis of DNA binding and gene expression at one time point, 
it is conceivable that PGC-1α acts primarily as an upstream regulator of other factors that are 
subsequently controlling more downstream PGC-1α target genes without direct involvement of 
PGC-1α itself. 
In skeletal muscle, PGC-1α has been reported to interact with ERRs, PPARs and other nuclear 
receptors, as well as myocyte enhancer and nuclear respiratory factors to mediate 
transcriptional regulation [3]. Accordingly, ERRα and other nuclear receptor binding motifs were 
amongst the most highly significant binding elements in our present report. Importantly however, 
we also predict a number of so-far unknown TFs to functionally interact with PGC-1α and 
thereby contribute to PGC-1α-controlled gene expression in skeletal muscle. Since a complete 
functional validation of all new putative TF partners is beyond the scope of this manuscript, we 
combined the high-throughput results with several computational analyses (see Table 1) to 
select and test some of the potentially most important factors together with predicted target 
genes. Notably, in siRNA-based knockdown experiments, we could show that depletion of FOS 
and its putative AP-1 multimerization partners JUN and ATF3 as well as NFE2L2, ZFP143 and 
GTF2I in muscle cells reduced the ability of PGC-1α to positively regulate target genes. Second, 
we could provide evidence of a co-recruitment of FOS and PGC-1α to the same regulatory sites 
in the vicinity of AP-1/PGC-1α target genes, confirming a functional interaction between these 
TFs and PGC-1α. Thus, our results indicate that the coactivation repertoire of PGC-1α in muscle 
exceeds the prediction of previous studies by far. For example, even in our list of the top 15 
motifs, several predicted TFs have not yet been investigated in the context of PGC-1α-controlled 
gene expression, including BPTF, FOSL2, REST or RREB1. Future studies will aim at a more 
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detailed dissection of the global functional consequences of PGC-1α coactivation of these TFs in 
muscle cells. 
Curiously, almost all of our analyses, and in particular the principal component analysis, 
highlighted the relevance of FOS-JUN-like motifs. In fact, the largest amount of variation in 
TFBS occurrence within PGC-1α binding peaks results from either ESRRA-like or FOS-JUN-like 
motifs. The FOS-JUN-like motif, in particular, embodies the main binding elements of the AP-1 
complex, which consists of different configurations of FOS, JUN, ATF and MAF proteins [35, 41]. 
Our data comparing gene expression in cells with reduced FOS, JUN and ATF3 levels indicate 
that PGC-1α functionally interacts with the AP-1 complex in different configurations in the 
regulation of specific genes. The differential requirement observed for distinct AP-1 components 
might provide an additional layer of control for specific PGC-1α target gene regulation. 
AP-1 function itself is regulated by a variety of stimuli, including cytokines, growth factors and 
stress, and subsequently controls a number of cellular processes including apoptosis, cell 
proliferation and differentiation, stress response and hypoxia [41, 42]. Mechanistically, we 
classified PGC-1α-induced/AP-1-knocked-down targets in either direct or indirect genes. Most 
interestingly, functional analysis of these two groups of genes revealed that when AP-1 and 
PGC-1α act disjointedly, they are involved in the regulation of mitochondrial and other metabolic 
genes while, when coactivated by PGC-1α, AP-1 distinctly alters the expression of genes that 
are enriched in the ontology terms “response to hypoxia” and “mTOR signaling” (Fig. 5F). 
Intriguingly, a closer analysis of all 47 direct AP-1/PGC-1α target genes revealed 24 genes that 
are induced by hypoxia, are effectors of hypoxia or attenuate the detrimental consequences of 
hypoxia (Fig. 6M). For example, several inhibitors of the mTOR signaling pathways are included 
in this group of genes and hypoxia has been described as a suppressor of mTORC1 activity 
[43]. Another group of genes contributes to the reduction of cellular stress, detrimental 
metabolites, reactive oxygen species and increase in cellular survival to reduce potential harmful 
consequences of prolonged hypoxia [44]. Furthermore, several genes promote endothelial 
regeneration, vascular remodeling and vascularization [45]. In this context, PGC-1α has 
previously been shown to promote VEGF-induced angiogenesis in skeletal muscle in a hypoxia-
inducible factor 1α (HIF-1α)-independent, ERRα-dependent manner [36]. Similarly, PGC-1α 
regulates the hypoxic response of brown fat [46], neuronal and endothelial cells [47] even 
though the mechanisms of cellular protection exerted by PGC-1α in these experimental contexts 
have not been elucidated. Our findings now indicate that, to ensure adequate oxygen and 
nutrient supplies for oxidative metabolism in skeletal muscle cells, PGC-1α might coordinate 
metabolic needs through ERRα-induced Vegf expression with a broad, stress-induced AP-1-
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dependent hypoxia program. Such a functional convergence was found for a subset of the direct 
AP-1/PGC-1α target genes that likewise seem to be under the control of ERRα together with 
PGC-1α (Fig. 5H and I-K). Inversely, for the complementary subset of these genes, the 
functional interaction between AP-1 and PGC-1α seems distinct from the ERRα-dependent 
PGC-1α target gene regulation. Finally, in vivo evidence supports our muscle cell cultured-based 
prediction, considering that many of the AP-1/PGC-1α hypoxia-related target genes exhibit 
reduced and elevated transcript levels in PGC-1α muscle-specific knockout and transgenic 
animals, respectively. As previously demonstrated for VEGF and skeletal muscle vascularization 
[36], many aspects of the phenotypic consequences of exercise-induced muscle hypoxia occur 
in the muscle-specific transgenic mice even in the absence of physical activity. In extension of 
these studies, we now however found additional genes involved in this process that show an 
additional, or in case of Nr0b2, even an exclusive synergistic activation by exercise in the PGC-
1α transgenic animals. Thus, combined with previous descriptions of muscle plasticity in these 
mice post-exercise in regard to insulin sensitivity [29], our present findings reiterate the 
importance of bona fide exercise even in a genetic model for endurance training such as the 
PGC-1α muscle-specific transgenic animals. 
In summary, our data provide a first insight into the transcriptional network controlled by PGC-1α 
in muscle cells. While one other study of global DNA recruitment of PGC-1α has been performed 
in the human hepatoma cell line HepG2 [48], our results highlight the importance of combining 
ChIP-Seq experiment, transcriptional data together with a comprehensive computational 
modeling approach and experimental validation of predicted key regulators, in order to be able to 
discover mechanistic as well as functional outcomes of such a network. Combined with the 
knowledge of transcriptional regulation, posttranslational modifications, alternative splicing and 
recruitment of different chromatin remodeling protein complexes, a scenario can thus be 
conceived in which PGC-1α is able to control and integrate different signaling pathways using a 
multitude of different transcription factor binding partners [10, 11]. A better understanding of 
such regulatory networks will eventually allow the targeting of whole biological programs or 
specific sub-modules in pathological states of disregulation. 
4.6. Accession numbers 
The Gene Expression Omnibus (GEO) accession number for the ChIP-Seq and gene 
expression array data reported in this paper is GSE51191. 
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4.8. Supplementary information 
Suppl. Fig. S1. Peak Z score distribution and KEGG functional analysis. Related to Figure 1. (A) 
Distribution of the Z scores for all sliding windows considered by the peak-finding algorithm along the 
mouse genome. The chosen cutoff for peak calling is depicted by the dotted line. (B) Subset of the top 
significantly enriched KEGG terms identified for direct and indirect up-regulated PGC-1α target genes. (C) 
Subset of the top significantly enriched KEGG terms identified for direct and indirect down-regulated PGC-
1α target genes. (D) ChIP-Seq signal around the promoter region of the five directly down-regulated genes 
(Cacna1s, Mybph, Myh1, Myh4, Pfkfb3) involved in regulating the contractile properties of fast-twitch 
muscle fibers. 
Suppl. Fig. S2. Motif activities clustered by Z score in direct/indirect activation/repression. Related 
to Figure 2. (A) Motifs showing different types of regulation (1=yes, 0=not). 
Suppl. Fig. S3. siRNA knockdown efficiency for the putative PGC-1α partner TFs. Related to Figure 
4. (A-F) siRNA knockdown efficiency for ATF3 (A), GTF2I (B), JUN (C), NFE2L2 (D), NFYC (E) and 
ZFP143 (F) knockdown. Bars represent fold change over GFP/siCtrl levels. Error bars represent SEM. *p 
< 0.05; **p < 0.01; ***p < 0.001. 
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Suppl. Table 1. Real-time primer sequences. Semiquantitative real-time PCR primers used for 
validation experiments. 
Real-time PCR primers used for testing the efficiency of the ChIP 
Gene promoter or intron Forward primer Reverse primer 
Tbp intron TGTGAGCTCCTTGGCTTTTT ATAGTTGCCCAGCAATCAGG 
promoter of Aco2 CACCGATAGTTGCTTTCCAGATAC AACCATCTGACAGGCATAGTCAAT 
promoter of Cycs AAGGGCGCCCTCTGGGCACATC  ATCCCCGTCGCGCGCTCACCG 
promoter of Acadm CCTTGCCCGAGCCTAAAC GTCTGGCTGCGCCCTCT 
promoter of Atp5b CTGGAAACTTCCACCCTCACTA GAGAGGTTTTTGGCGGAACTA 
promoter of Idh3a GGACGGCGTCAAGGTCAAG GCCTAGGTGGCCTGTCTGTG 
100 
PGC-1α exon 2 TGAGGACCAGCCTCTTTGCCCA CGCTACACCACTTCAATCCACCC 
 
Gene or gene 
promoter 
Forward + reverse primer FOS binding site Peak position 
TGFβ1*1 F: TTTGAGACTTTTCCGCTGCT chr7:26472349-
26472356 
(see reference [49]) 
R: GGTCCTGCCTCCTTGCGA 
Nr0b2 promoter F: GGTACAGCCTGGGTTAATGAC chr4:133109008-
133109015 
chr4:133108962-
133109162 R:  ACTGCCTGGATGCCCTTTAT 
Gprc5a 
promoter 
F: TGATGTCATGAGCCTCACCC chr6:135011471-
135011478 
chr6: 135011398-
135011598 R: TAGCTGTCATTGAGGGCACT 
Dbt promoter F: AAGGGGCAAAGCAATTCAGG chr3: 116215241-
116215248 
chr3: 116215242-
116215249 
chr3: 116215152-
116215352 
chr3: 116215152-
116215352 
R: CTTAGAAAATGTGGTCAGATGCA 
   Real-time PCR primers used for testing the knockdown efficiency by siRNAs 
Gene Forward primer Reverse primer 
Rn18s AGTCCCTGCCCTTTGTACACA CGATCCGAGGGCCTCACTA 
Fos TACTACCATTCCCCAGCCGA GCTGTCACCGTGGGGATAAA 
Jun TGGGCACATCACCACTACAC TCTGGCTATGCAGTTCAGCC 
Atf3 TCTGCGCTGGAGTCAGTTAC CCGCCTCCTTTTCCTCTCAT 
Gtf2i TTCGAAGGCTTTGCAAGGAAG TTCGGGGTCCTCACTGGTTT 
Nfe2l2 AGTGGATCCGCCAGCTACTC ATGGGAATGTCTCTGCCAAA 
Nfyc CCACCAGTTCTACGACCACC GGCCTGTACAATCTGCACCT 
Zfp143 GTGGTCGGTCCTTTACCACA AAATGCCCTCCCACATCCAG 
   Real-time primers used for target gene validation   
Gene Forward primer Reverse primer 
Aim1l CCTGTTGCGTCCATAAGGGT GCTCTGAGTTCCACATCCCC 
Atp1b1 GCTACGAGGCCTACGTGCTA TGCCACAGTCCTCGAAAATC 
Atp5g1 CAGAGGCCCCATCTAAGCAG TGTCCCGGGAAATGACACTG 
Cdk15 ATGCAGTTGCTACCACCGTT CCGTGGAACTGGATGCTTCT 
Cdr2l GGAACAGGAAAACGAACGGC ACCACCGTGTACTCACGTTC 
Crb3 CCGGACCCTTTCACAAATAGC CTCTGTCTGCCGCTTTTCC 
Dot1l TGACCTCAGATGAGGAGCCA TGTCTTCGGGGGAGATTTGC 
Eef1a2 CAAGATGGACTCCACGGAAC CTGGGTTGTAGCCGATCTTC 
Eif2b4 ACGGCAAGACCCAATCAGAG AAGTTCTGCCTTACTCCGGC 
Fa2h GTGGACTGGCAGAAACCTCT TCTGAGTGGAAGAGGCGAAT 
Fabp3 CATGTGCAGAAGTGGAACGG CTCACCACACTGCCATGAGT 
Fam131c CTGGCTACGTCATCCCTTGT TCCAGCCTTTCCACTCGAT 
Gabpa GTCGAGGTGGTCATCGATCC GTAATGTGCTTGGTGCCGTC 
Gdf15 CACGCATGCGCAGATCAAAG TGTGCATAAGAACCACCGGG 
Gtpbp2 TGGAAACCTCAAAGCTCGGG GTACGGAGGGTTGTTGGCTT 
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Il1a TGCAAGCTATGGCTCACTTC GATACTGTCACCCGGCTCTC 
Inpp5j ACAAGGGCGGAGTAAGTGTG TGAAAGTTATCCTTGCGCTGT 
Jam2 GTATTACTGCGAAGCCCGGA CAACCGTTGCTATGATGCCG 
Kdm5a GTCTTCCGTGTGTCATCAGC TTAGTCGGGGCAATTCAGGT 
Ldhb GACTCCGAAAATTGTGGCCG TTCTCTGCACCAGGTTGAGC 
Lpin1 CGGCCCTCAACACCAAAAAG AATTCACCCCACAGCCAGAG 
Lrrc2 GTGGAAGGAGCTGCCTGATT AACAGCTCGATGTACGTGGG 
Met GCTGAGAAACTCTTCCGGCT AGCCGGCCCATGAATAAGTC 
Ndufa9 TTCTGTGGCTCATCCCATCG TGTAGCCCCAAACACAGTGG 
Nmnat1 GGTCGGTGATGCGTACAAGA CCACGTATCCACTTCCACCC 
Nppb GGCCTCACAAAAGAACACCC TGCCCAAAGCAGCTTGAGAT 
Nr0b2 CCTCTTCAACCCAGATGTGC GGGCTCCAAGACTTCACACA 
Osbpl1a TCCCCCAATCAGTGCATTCC GCTTCTACACTCTTGCCCCA 
Qrsl1 GTTGGATCAGGGTGCCCTAC GGGGTTTCTAACTGGCCCAA 
Rasl10b AGACCTGGAAGTGCGGCTAC GGCAGCGTGCACGTGTTT 
Rrm2 TTGCAGCGAGTGATGGCATA CCATGGCAATTTGGAAGCCA 
Samm50 TTTTGATGGACTTGGGCGGA TGAGATCGCCGCATTACCTC 
Sbno2 AGACATCCCAGACACACCTG TGAGAAGTGGAGTGCTGGAG 
Slc25a4 GGTACTTCCCCACTCAAGCC AGCAAAGTAGCGCCAGAACT 
Slc25a35 TAGTCGTGGCAATGACACCC TCCAAGATCCCCCGGTACAT 
Slc6a19 TCCACTCAACCAGAACCAGAC TGAGTCACTGATGGAAGTGGAG 
Srxn1 CCAGGGTGGCGACTACTACT AGGTCTGAAAGGGTGGACCTC 
Stard7 CTCTACGGCCGCCTGTATTC CGCCATCAAAACAGAGGCAT 
Stk19 GTCCTCACTGTCCGAGATGC CACCATGCTCAGTACAGCCT 
Syt7 ACTGGGCAAACGCTACAAGA TGCAGGCAACTTGATGGCTT 
Tbrg4 AACGACAGCCGTACATTGGT AGCTCCAGGCACTTGTCTTC 
Tfam GAGCGTGCTAAAAGCACTGG GCTACCCATGCTGGAAAAACA 
Tinagl1 TTCTTGTACCAGCGTGGCAT CCCCACCCAGTGATCTTGAC 
Tomm5 CGGAGGAGATGAAGCGGAAG TATGGAGTGACTCGCAGCAG 
Trak2 GCTGAAGAGACGTTCCGCTA ATCTCGATCCCTCTCTGCCA 
Trmt61a GCTCCTTCTCTCCGTGCATT TGCGCACATTGTAGACCTGT 
Trp53inp2 TACCCCTCCCGCCTGTTTTA CTGCCGGTGACATAAACGGA 
Ttc7b TGCTCCCCACGATCAAGAAC ATCTCCCGACTCCTCTCGTC 
Tusc2 GCAGTGCCTCCCTTCGTATT CTGCCCATTCTTGGTGACGA 
Twf2 TGCTACCTCCTCTTCCGACT ATAGCATCTTCAGCCGCACC 
VEGFα CACGACAGAAGGAGAGCAGA GGGCTTCATCGTTACAGCAG 
Wnt7b TTTCTCTGCTTTGGCGTCCT GGCCAGGAATCTTGTTGCAG 
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5.1. Abstract 
In skeletal muscle, the estrogen-related receptor α (ERRα) has been shown to play a crucial role 
in the regulation of various biological processes, which range from glucose and fatty acids 
metabolism to angiogenesis and reactive oxygen species (ROS) suppression. The peroxisome 
proliferator-activated receptor γ coactivator 1α (PGC-1α) is a transcriptional coactivator that 
controls most of these pathways through direct coactivation of ERRα, which is considered as the 
major effector of PGC-1α-induced gene expression in the skeletal muscle tissue. However, to 
which extent ERRα is required for PGC-1α modulation of energy metabolism in skeletal muscle 
has not been elucidated yet. Also, it is unknown which other transcription factors might co-occur 
in the vicinity of ERRα sites when there is no direct recruitment of PGC-1α. By combining high-
throughput experiments with computational analysis and biochemistry, we mapped the genome-
wide recruitment of ERRα to DNA in skeletal muscle and identified the subsets of targets directly 
or indirectly regulated by this nuclear receptor upon PGC-1α over-expression. Interestingly, we 
found that ERRα is required for the direct and indirect up-regulation of most of PGC-1α targets. 
In addition, we show SP1 as partner of ERRα in GC-rich regulatory elements, in the absence of 
direct coactivation by PGC-1α. Finally, as most of the regulatory effects of PGC-1α on gene 
regulation were indirect, we focused on the PGC-1α indirectly controlled targets and we were 
able to identify Nfyc and Znf143 as novel mediators of the indirectly-controlled PGC-1α effects in 
skeletal muscle. 
5.2. Introduction 
During the last decade, the transcriptional coactivator peroxisome proliferator-activated receptor 
γ coactivator 1α (PGC-1α) has emerged as a major controller of mitochondrial biogenesis and 
oxidative phosphorylation (OXPHOS) across different tissues and particularly in skeletal muscle 
[1]. In addition, PGC-1α plays a crucial role in the regulation of angiogenesis, neuromuscular 
junctions, glucose uptake and fiber type switch [2]. The expression and activity of PGC-1α can 
be induced and modulated by several physiological stimuli, including cold exposure, fasting and 
exercise [3]. In skeletal muscle, these signals converge on PGC-1α and are integrated through 
the coactivation of several transcription factors, particularly nuclear receptors, which in turn act 
as key regulators of a number of metabolic processes [2]. 
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The transcriptional network controlled by PGC-1α includes, among its members, also the 
estrogen-related receptor α (ERRα) [4]. In skeletal muscle, ERRα has been shown to play a 
fundamental role in the control of muscle glucose and fatty acids metabolism [5]; one 
mechanism responsible for this regulation is triggered by cAMP levels, which act selectively 
through protein kinase A (PKA) to increase ERRα activity and promote target genes transcription 
[6]. Moreover, as shown by several studies [4, 7], PGC-1α acts as a potent inducer and 
coactivator of ERRα, which in turn auto-regulates itself in a positive feedback loop [8]. Although 
no endogenous ligands have been identified to date for this orphan nuclear receptor, a functional 
study indicated that ERRα is constitutively active in a ligand-independent manner [9]. Moreover, 
in differentiated adipocyte cells, the PGC-1α homolog PGC-1β has been suggested to act as a 
“protein ligand” for the orphan nuclear receptor ERRα [10]. 
Recently, we have identified ERRα as the major mediator of PGC-1α-induced gene expression 
in cultured skeletal muscle cells [11]. However, to which extent the induction of PGC-1α target 
genes requires ERRα is not known. In other words, it is not entirely clear which genes are 
induced by PGC-1α and ERRα cooperatively, which genes are regulated by ERRα without a 
direct PGC-1α coactivation and, finally, which genes (if any) are controlled by PGC-1α 
independently of ERRα. In addition, although a couple of ERRα targets have been identified [8], 
a complete genome-wide study of ERRα occupancy in skeletal muscle in the context of PGC-1α 
over-expression has not been conducted so far. By comparing genomic locations occupied by 
ERRα with those occupied by PGC-1α through chromatin immunoprecipitation followed by deep 
sequencing (ChIP-Seq), we aim to identify to which regions (and, thus, to which neighboring 
genes) ERRα and PGC-1α are co-recruited, as opposed to regulatory elements where these two 
proteins bind independently from each other. Also, we analyze the genomic context which might 
be responsible for differential binding and investigate whether other transcription factors might 
be proposed as potential partners of ERRα in the case of an indirect coactivation by PGC-1α. 
5.3. Experimental procedures 
5.3.1 Cell culture and knockdown of ERRα 
C2C12 myoblasts were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS), 100 Units/ml penicillin and 100ug/ml streptomycin. After the 
cells had reached approximately 90% confluence, the differentiation of myoblasts to myotubes 
was introduced by switching the growth medium to differentiation medium (DMEM supplemented 
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with 2% horse serum) for 72 hours. For the knockdown and inactivation of ERRα, differentiated 
C2C12 cells were infected with either the sh-ERRα or sh-GFP (control) adenovirus (AV) and 
kept in culture for 4 days. These adenoviruses were a generous gift from Prof. A. Kralli from the 
Scripps Research Institute in La Jolla, California, USA. Subsequently, these cells were infected 
with either the flag-PGC-1α or GFP adenovirus and kept in culture for two additional days. The 
differentiation medium, which was used to infect cells, was supplemented with either 2µM of the 
ERRα inverse agonist XCT-790 (for cells previously infected with the sh-ERRα AV) or with the 
vehicle (0.02% DMSO, for the remaining cells). The experiments have been performed in 
biological triplicates. The RNA was isolated using TRIzol® and was performed according to the 
TRIzol® reagent RNA isolation protocol (Invitrogen).  
For the gene expression arrays, the RNAs from the following three conditions were used: shGFP 
AV + GFP AV + vehicle (0.02% DMSO); shGFP AV + flag-PGC-1α AV + vehicle (0.02% DMSO); 
shERRα AV + flag-PGC-1α AV + 2µM XCT-790. 
5.3.2. ChIP and ChIP-Seq 
Chromatin immunoprecipitation (ChIP) was performed according to the Agilent Mammalian 
ChIP-on-chip Protocol version 10.0. For every immunoprecipitation, we used approximately 
1x108 C2C12 cells, which were differentiated to myotubes and infected with flag-PGC-1α 
adenovirus. For the cross-linking, the cells were incubated in a 1% formaldehyde solution for 10 
minutes. After the lysis and sonication but before the immunoprecipitation (IP), 50µl of the lysate 
was saved for the extraction of input DNA. For the immunoprecipitation of ERRα, the magnetic 
beads (Dynabeads® Protein G, Invitrogen) were coated with the monoclonal anti-ERRα antibody 
(ERRα Rabbit Monoclonal Antibody, Clone ID: EPR46Y, Epitomics). For the ChIP of SP1, the 
magnetic beads (Dynabeads® Protein G, Invitrogen) were coated with the polyclonal anti-SP1 
antibody (ChIPAb+TMSp1 Rabbit Polyclonal Antibody, #17-601, Millipore). The ChIP was 
performed overnight on a rotating platform at 4°C. The PGC-1α ChIP-Seq data was obtained 
from previous experiments and was performed using the monoclonal anti-flag antibodies 
(Monoclonal ANTI-FLAG® M2 Antibody, Sigma) for the immunoprecipitation [11].  
5.3.3. High-throughput sequencing and read mapping 
The ERRα ChIP-Seq experiment in C2C12 cells undergoing PGC-1α over-expression was 
performed at the joint Quantitative Genomics core facility of the University of Basel and the 
Department of Biosystems Science and Engineering (D-BSSE) of the ETH Zurich in Basel. The 
DNA libraries for ERRα and the whole cell extract (WCE) were prepared using the standard 
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Illumina ChIP-Seq protocol, as described by the manufacturer. The immunoprecipitated samples 
were sequenced on the Illumina® HiSeq2000 sequencer. 
The sequenced reads underwent a quality filter which discarded all reads having Phred score >= 
20, read length >= 25 bps and ambiguous nucleotides (Ns) per read <= 2. The reads that 
passed the filter were used as input for Bowtie version 0.12.7 [12] and aligned to the UCSC 
mm9 mouse genome assembly. Moreover, to avoid any PCR amplification error which might 
have arisen during sample preparation, we removed redundant reads mapping to the same 
location with the same orientation and we kept only one read per position. Consequently, we 
obtained 2’155’507 reads for the IP and 84’175’472 reads for the WCE. 
5.3.4. Peak calling 
To detect regions that were significantly enriched in ERRα binding, we estimated the fraction of 
all ChIP reads fIP that fell within consecutive 200 bps sliding windows genome-wide and, in 
parallel, the fraction fWCE of reads from the whole cell extract that fell in a 2000 bps long window 
centered on the same position of the IP window. Using these two sets of values, we quantified 
the ChIP enrichment of each window as: 
𝑍 = 𝑓𝐼𝑃 −  𝑓𝑊𝐶𝐸
�𝜎2𝐼𝑃 +  𝜎2𝑊𝐶𝐸 
where 𝜎2𝐼𝑃 and 𝜎2𝑊𝐶𝐸 are the IP and WCE read frequency variances, given by: 
𝜎2𝐼𝑃 =  𝑓𝐼𝑃∗ (1− 𝑓𝐼𝑃)𝑁𝐼𝑃  and 𝜎2𝑊𝐶𝐸 =  𝑓𝑊𝐶𝐸 ∗ (1 − 𝑓𝑊𝐶𝐸)𝑁𝑊𝐶𝐸  
respectively. All consecutive windows having a Z-score greater than 3.5 were merged and the 
top scoring one from each window cluster was considered as the peak summit and used for 
further analyses.  
5.3.5. Transcription factor binding sites over-representation 
In order to account for the conservation of transcription factor binding sites (TFBSs) across 
related species, we aligned the ERRα binding peaks to their orthologous regions from 6 
mammalian species – human (hg18), opossum (monDom4), dog (canFam2), rhesus macaque 
(rheMac2), horse (equCab1) and cow (bosTau3) – through the software T-Coffee [13]. Using the 
MotEvo algorithm [14] on these alignments, we predicted binding sites within our peaks for a 
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collection of 190 mammalian regulatory motifs (also called weight matrices, or WMs) that was 
downloaded from the SwissRegulon database [15]. 
To assess the over-representation of the predicted binding sites (i.e. those with a posterior 
probability greater than 0.1) within the ERRα peaks, we created a set of background regions by 
shuffling the columns of the multiple alignments and maintaining, at the same time, both the 
conservation pattern and the gap patterns of the original aligned nucleotides. MotEvo was run on 
the shuffled alignments using the same settings as for the original sequences. Significant 
enrichment of binding sites for each motif x in the ERRα peaks was computed by collecting the 
sum 𝑛𝑥 of the posterior probabilities for its predicted TFBSs along ERRα peak alignments and 
the corresponding sum 𝑛′𝑥 in the shuffled alignments; we quantified the motif over-
representation as: 
𝑍 =  𝑓𝑥 −  𝑓′𝑥
�𝑓𝑥 ∗
(1 −  𝑓𝑥)
𝐿𝑥
+ 𝑓′𝑥 ∗ (1 −  𝑓′𝑥)
𝐿′𝑥
 
where 𝐿𝑥 and 𝐿′𝑥 are the total lengths of the original and shuffled alignments, respectively, while 
𝑓𝑥 and 𝑓′𝑥 are given by the equations: 
𝑛𝑥 ∗  𝑙𝑥 =  𝑓𝑥 ∗  𝐿𝑥 and 𝑛′𝑥 ∗  𝑙𝑥 =  𝑓′𝑥 ∗  𝐿′𝑥 
with 𝑙𝑥 the length of motif x. 
5.3.6. Principal Component Analysis of TFBS occurrences within peaks 
A Principal Component Analysis (PCA) was performed using the “svd” package of the R 
programming language [16]. The input data for the PCA was a p × m matrix N, composed by the 
total number of binding sites Npm predicted for each of the 3225 ERRα binding peaks p (rows) 
using our collection of 190 mammalian regulatory motifs m (columns). Singular Value 
Decomposition (SVD) was applied to the mean centered matrix 𝑁�𝑝𝑚 = 𝑁𝑝𝑚 − 〈𝑁𝑚〉 using the 
‘svd’ package of the statistical software R. 
5.3.7. Gene expression array analysis 
The .CEL files containing the raw probe intensities were processed using the Bioconductor 
package ‘affy’ [17], which corrects for background and unspecific binding. After using the ‘Mclust’ 
R package [16] to distinguish expressed from non-expressed probes, the intensity values were 
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quantile normalized across all samples and mapped to the mm9 mouse transcripts UCSC 
collection. These were further associated to a comprehensive collection of mouse promoters that 
was downloaded from the SwissRegulon database [15]. For each promoter, the log2 fold change 
(log2FC) was compared between the following conditions: over-expressed PGC-1α (treatment) 
and GFP (control); ERRα knockdown with the addition of XCT-790 (treatment) and over-
expressed PGC-1α (control). The significance of the expression change was assessed by a Z 
score, which was computed as: 
𝑍 =  𝐸�𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 −  𝐸�𝑐𝑜𝑛𝑡𝑟𝑜𝑙
�𝜎
2
𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡
𝑛 +  𝜎2𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝑛  
where 𝑛 = 3 was the number of replicate samples, 𝐸�𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 is the mean log2 expression 
across the treatment samples, 𝐸�𝑐𝑜𝑛𝑡𝑟𝑜𝑙 is the mean log2 expression across the control samples, 
and 𝜎2𝑡𝑟𝑒𝑎𝑡𝑚𝑒𝑛𝑡 and 𝜎2𝑐𝑜𝑛𝑡𝑟𝑜𝑙 are the variances of log2 expression levels across the replicates 
for the treatment and control samples, respectively. A log2FC threshold of ±0.5849625 
(corresponding, in a more commonly used notation, to 1.5 fold change, when taking the inverse 
of the linear binding ratio) and a Z score cutoff of ±3 were used to identify significantly up-/down-
regulated promoters. The criterion adopted to assign peaks to promoters was proximity. Each 
peak was assigned to its closest promoter (and, thus, to its associated gene symbol) whenever 
the distance between their central positions was smaller than 10 kb; otherwise, the peak was not 
assigned to any promoter. Hence, a peak could have been assigned to a promoter also in the 
case it was located within an intron or an exon. 
5.3.8. Ontology terms over-representation analysis 
Gene Ontology analysis was performed using the functional analysis software FatiGO [18]. Only 
ontology terms having a false discovery rate (FDR) adjusted p-value <= 0.05 for enrichment 
were considered significant. 
5.3.9. Motif activity response analysis 
The information obtained from the sequencing data and from the microarrays were integrated by 
extending ISMARA [19] in order to model the direct and indirect regulatory effects that ERRα 
and PGC-1α exert on their downstream targets. Using the input expression data and the 
computationally predicted transcription factor binding sites, ISMARA infers, for each of 190 
regulatory motifs m (associated with roughly 350 mouse TFs), the activity Ams of the motif in 
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each sample s when the motif occurs outside of a binding peak, and the activity A*ms of the motif 
when it occurs within a binding peak of either PGC-1α, ERRα or both (overlapping peaks). A 
significant change in the motif activity Ams upon knockdown of ERRα and/or over-expression of 
PGC-1α indicates an indirect regulatory effect of either ERRα, PGC-1α or both of them on the 
motif m, whereas a change in the motif activity A*ms reflects a direct regulatory effect as 
mediated by the motif m. For each promoter p that was not associated with any binding peak 
(which we denote as “indirect target”), we modeled its log-expression in sample s, eps, in terms 
of the predicted number of TFBSs Npm that occur in the proximal promoter region (running from -
500 to +500 relative to the transcription start site, orTSS) for each regulatory motif m. That is, 
ISMARA assumes the linear model: 
𝑒𝑝𝑠 = 𝑐𝑝 + ?̃?𝑠 + � 𝑁𝑝𝑚𝐴𝑚𝑠
𝑚
 
where cp is the basal expression of promoter p, ?̃?𝑠 is a sample-dependent normalization 
constant, and 𝐴𝑚𝑠 is the regulatory activity of motif m in sample s, which is inferred by the 
model. Formally, 𝐴𝑚𝑠 quantifies the amount by which the expression of promoter p in sample s 
would be reduced if a binding site for motif m were to be deleted from the promoter. For each 
“direct target” promoter p that has an associated binding peak (which could be an ERRα, a 
PGC-1α or an overlapping ERRα/PGC-1α peak) within 10 kb, we modeled its expression in 
terms of the predicted TFBSs in the binding peak, i.e.: 
𝑒𝑝𝑠 = 𝑐𝑝 + ?̃?𝑠 + � 𝑁𝑝𝑚∗ 𝐴𝑚𝑠∗
𝑚
 
where 𝑁𝑝𝑚∗  is the number of predicted TFBSs for motif m in the peak associated with promoter p, 
and 𝐴𝑚𝑠∗  is the motif activity of regulator m in sample s when this motif occurs in the context of 
either ERRα binding, PGC-1α recruitment or both. Besides motif activities MARA also calculates 
error-bars 𝛿𝑚𝑠 for each motif m in each sample s. Using these, MARA calculates, for each motif 
m, an overall significance measure for the variation in motif activities across the samples 
analogous to a z-statistic: 
𝑧𝑚 = �1𝑆��𝐴𝑚𝑠𝛿𝑚𝑠�2𝑆𝑠=1  
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For each motif we calculate a z-score 𝑍𝑚 associated with its indirect activity changes, a z-score 
𝑍𝑚,𝐸𝑅𝑅𝛼∗  associated with its direct activity changes in the context of ERRα binding, a z-score 
𝑍𝑚,𝑃𝐺𝐶1𝛼∗  associated with its direct activity changes in the context of PGC-1α recruitment and a z-
score 𝑍𝑚,𝐵𝑂𝑇𝐻∗  associated with its direct activity changes in the context of both ERRα binding and 
PGC-1α recruitment. 
5.3.10. Quantitative real-time PCR and statistical analysis 
Quantitative real-time PCR (qRT-PCR) was used to validate the efficiency of the ERRα 
knockdown and to verify that the ChIP of ERRα and the ChIP of SP1 were successful. The 
sequences of all primers, which were used for qRT-PCR, are listed in Suppl. Table 1. Regarding 
the statistical analysis of qRT-PCR data sets, the values are presented as the mean ±SEM. 
Student’s t tests were performed and a p-value < 0.05 was considered as significant. *<0.05, 
**<0.01, ***<0.001 
5.4. Results 
5.4.1. ERRα can be recruited to DNA also independently from PGC-1α 
The capability of ERRα to control the transcription of its downstream target genes has been 
postulated to be strictly dependent on the coactivation of PGC-1α, to the extent that this co-
regulator – more precisely its homolog PGC-1β – has been proposed to act as a “protein ligand” 
for ERRα [10]. To verify this assumption and to identify all regions genome-wide that are bound 
by this transcription factor in skeletal muscle, we performed a chromatin immunoprecipitation 
(ChIP) experiment followed by high-throughput sequencing (ChIP-Seq) of ERRα in differentiated 
C2C12 murine myotubes. The identified ERRα binding sites were then compared to a previously 
sequenced set of PGC-1α recruitment regions [11] obtained within the same context of 
adenovirus-induced PGC-1α over-expression. In order to identify all genomic locations 
significantly enriched in ERRα binding, we passed a sliding window along the genome and 
compared, for each consecutive window, the local IP read density with the whole cell extract 
(WCE) background read amount. All regions with a Z score bigger than 3.5 were merged in a 
final total of 3225 peaks, which included binding regions in the vicinity of known ERRα target 
genes (Suppl. Fig. S1A), like the pyruvate dehydrogenase lipoamide kinase isozyme 4 (Pdk4) 
and the isocitrate dehydrogenase 3 [NAD+] alpha (Idh3a) [20, 21]. The enrichment of IP 
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fragments from the ChIP-Seq experiment was validated for some of these ERRα target genes by 
semiquantitative real-time PCR (Suppl. Fig. S1B). 
Most surprisingly, when we compared ERRα and PGC-1α occurrences genome-wide (Fig. 1A), 
we noticed that the majority of ERRα (~60%) peaks are actually not overlapping a PGC-1α peak, 
suggesting that the so-far believed concept of symbiotic cooperation between these two proteins 
is in fact only restricted to a small percentage of their targets (~40% for ERRα and ~18% for 
PGC-1α), or that all the other ERRα peaks are non-functional. Some examples of this differential 
regulation are depicted in Fig. 1B. Moreover, of the 1321 ERRα peaks overlapping a PGC-1α 
site (that is, they share at least one base pair), the vast majority of them are well centered on the 
closest PGC-1α peak at a distance of a couple of dozen base pairs (Fig. 1C). Noticeably, a big 
fraction of ERRα peaks resides within 100 bp from the closest mouse promoter region (Fig. 1D), 
as opposed from the PGC-1α peaks which we previously found to be more distally located.  
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Figure 1. ERRα and PGC-1α are recruited to both shared and distinct sets of target genes. (A) Venn 
diagram depicting the number of ChIP-Seq binding peaks for PGC-1α (blue) and for ERRα (cyan). (B) 
PGC-1α and ERRα read densities around the TSS of the genes Btbd1, Ldhb and Tusc2 obtained from the 
UCSC Genome Browser. The first plot is an example of a gene directly regulated by ERRα, but not by 
PGC-1α; the second is directly regulated by both ERRα and PGC-1α; the third is directly regulated by 
PGC-1α, but not by ERRα. (C) Distribution of ERRα peaks relative to their closest PGC-1α peaks. (D) 
Distribution of ERRα peaks from the nearest mouse promoter region. 
5.4.2. PGC-1α induces gene transcription both dependently and independently on 
ERRα  
To integrate the results obtained from the ChIP-Seq experiment with functional data, we further 
analyzed the impact of ERRα on its downstream targets in terms of their gene expression 
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patterns in differentiated muscle cells under the following conditions: (i) shGFP-transfected cells 
over-expressing GFP; (ii) shGFP-transfected cells over-expressing PGC-1α; (iii) shERRα-
transfected cells over-expressing PGC-1α and supplemented with the ERRα inverse agonist 
XCT-790. By comparing the second with the first and the third with the second condition, we 
sought to assess both the effect of PGC-1α over-expression and the response to ERRα 
knockdown (Fig. 2A). After mapping the microarray probes to known transcripts and, through 
these, to a reference set of mouse promoters [15], we noticed that more promoters were 
significantly up-regulated (1863, corresponding to 1165 genes) than down-regulated (658, 
corresponding to 469 genes) following PGC-1α over-expression; in contrast, following ERRα 
knockdown, we observed the opposite effect: 910 promoters (corresponding to 597 genes) were 
significantly induced whereas 1952 promoters (corresponding to 1205 genes) were repressed 
(Fig. 2B). 
By combining the expression array with ERRα and PGC-1α genomic occupancy data, we 
quantified and distinguished PGC-1α directly or indirectly up-regulated target genes in two 
categories: ERRα-dependent and ERRα-independent targets. In particular, all array genes were 
defined ERRα-dependent when they were significantly repressed upon ERRα knockdown 
(compared to the PGC-1α over-expression condition) and ERRα-independent in the remaining 
cases. In the case of directly up-regulated PGC-1α targets, we noticed that ~70% of them were 
ERRα-dependent (Fig. 2C); similarly, ~62% of indirectly up-regulated PGC-1α targets were 
ERRα-dependent (Fig. 2D). We furthermore used the ERRα-dependent and -independent PGC-
1α direct or indirect target genes as input for the functional annotation tool FatiGO [18] to stratify 
these in terms of the regulatory pathways involved (Figs. 2E and 2F). As expected, most of the 
enriched terms were related to mitochondria and oxidative energy metabolism. However, we 
obtained more significantly enriched terms for ERRα-dependent than for ERRα-independent 
genes, suggesting that most of the biological pathways controlled by PGC-1α in skeletal muscle 
cells require ERRα. Interestingly, the top gene annotations were very similar among ERRα-
dependent and ERRα-independent PGC-1α targets, suggesting that the biological role of PGC-
1α in the modulation of mitochondrial function and organization is partly regulated with ERRα, 
but partly also without. As shown in Fig. 2G and Fig. 2H, we confirmed by qRT-PCR two ERRα-
dependent (Aim1l and Twf2) and two ERRα-independent (Atg9b and Ifrd1) PGC-1α target 
genes. 
For completeness, we also checked genes dependency on ERRα for PGC-1α down-regulated 
targets. Since PGC-1α is a coactivator rather than a corepressor, we assumed that the 22 
directly down-regulated genes might represent spurious peak-to-gene associations. In fact, the 
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vast majority of down-regulated genes (~95%) were indirect PGC-1α targets, confirming the 
results we previously found [11]. Out of these 447 indirectly down-regulated genes, about a 
quarter (104 targets) were dependent on ERRα – that is, significantly induced upon ERRα 
knockdown –, whereas the remaining 343 were not. 
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Figure 2. PGC-1α directly up-regulates both in a ERRα-dependent and -independent manner. (A) 
qRT-PCR analysis of PGC-1α, ERRα and Acadm mRNA levels in response to PGC-1α over-expression 
(OV) and shERRα knockdown (KD) + XCT-790. Data are normalized to mRNA levels in GFP infected 
cells. Error bars represent ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001. (B) Reverse cumulative distribution 
of log2 fold changes for all mouse promoters in the PGC-1α OV condition versus GFP control (left panel) 
and in the PGC-1α OV + shERRα KD + XCT-790 versus PGC-1α OV (right panel). Promoters are colored 
in red (up-regulation) when their fold change is bigger than 1.5 and in green (down-regulation) when their 
fold change is smaller than -1.5 (obtained by taking the inverse of the linear binding ratio). (C) Piechart 
representing the classification of directly up-regulated PGC-1α target genes in ERRα-dependent (orange) 
and ERRα-independent (yellow) targets. (D) Piechart representing the classification of indirectly up-
regulated PGC-1α target genes in ERRα-dependent (violet) and ERRα-independent (lilac) targets. (E-F) 
Subset of the top significantly enriched GO terms identified for ERRα-dependent and ERRα-independent 
PGC-1α directly (E) or indirectly (F) induced target genes. (G-H) qRT-PCR analysis of two ERRα-
dependent (G) or ERRα-independent (H) PGC-1α target genes, in response to PGC-1α OV and shERRα 
KD + XCT-790. Data are normalized to mRNA levels in GFP infected cells. Error bars represent ± SEM. *p 
< 0.05; **p < 0.01; ***p < 0.001. 
5.4.3. SP1 contributes to the up-regulation of ERRα targets in muscle cells 
As a following step, we analyzed the occurrence of transcription factor DNA-binding motifs within 
all the ERRα peaks. We used the software MotEvo [14] to predict transcription factor binding 
sites (TFBSs) for a set of 190 known mammalian regulatory motifs downloaded from 
SwissRegulon [15]. In order to explain most of the binding site variation observed across the 
ERRα peaks, we applied principal component analysis (PCA) to a site-count matrix N, whose 
elements Npm represent the number of predicted TFBSs for each motif m in each ERRα peak 
region p. Out of a total of 190, the first component was accounting for ~10% of the total variation 
in the dataset (Suppl. Fig. S2A). As shown in Figure 3A, the distribution of motif projections on 
the first two principal components clearly indicates two distinct clusters of motifs that stick out 
from the cloud of those having projections close to zero. The first group, characterized by motifs 
with negative eigenvalues along the first component, includes ESRRA and other nuclear 
receptors which have very similar logos to that of the ERRα motif; this cluster reflects the most 
abundant sites which can be found within the ERRα binding regions. Given the high promiscuity 
that exists between nuclear receptors consisting of different configurations of hexameric repeats 
[22], it might happen that the precise identity of the nuclear receptor bound at each peak is 
difficult to deduce from DNA-binding motifs and that, like in our case, a site for ERRα could be 
better matched by the position weight matrix (PWM) of another nuclear receptor. The second 
group, instead, is characterized by a set of GC-rich motifs which are usually found in the 
proximity of TSSs. The motif with the highest score along the first principal component 
corresponds to the binding affinity of the specificity protein 1 (SP1), known to be often present at 
the promoter region of many genes and to be involved in several cellular processes, including 
cell growth, cell differentiation, chromatin remodeling and apoptosis. The activity of this protein 
can be significantly affected by post-translational modifications, leading SP1 to act either as an 
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activator or as a repressor [23]. We thus asked whether SP1, in the context of ERRα binding, 
functions more as activator or as repressor on the common downstream target genes. For this 
purpose, we sought to combine the different classes of peaks (“only ERRα”, “only PGC-1α”, 
“overlapping ERRα and PGC-1α”, as defined in Fig. 1A) with the regulation of their assigned 
promoters (“up”, “down”, “non-changing”, “no promoter assigned”) in the plot shown in Suppl. 
Fig. S2B. Strikingly, whenever a site for SP1 is present within a peak, it is more likely for the 
assigned promoter to be up-regulated, strongly suggesting that in the context of PGC-1α over-
expression, SP1 plays a role as an activator; this effect is enhanced when SP1 is found in an 
ERRα peak rather than in a PGC-1α peak.  
An additional confirmation of the fact that the SP1 motif is particularly enriched in ERRα peaks is 
shown by Figure 3B, which displays SP1 as the top scoring motif when the TFBS occurrences in 
“only ERRα” peaks are compared to those predicted within “only PGC-1α” peaks. This 
observation is further supported by Figure 3C, showing the decrease in terms of TFBSs 
posterior sum for SP1, compared to the predictions in a shuffled peak set, when passing from 
“only ERRα” peaks to “overlapping ERRα and PGC-1α peaks” and finally to “only PGC-1α” 
peaks. Taken together, these results suggest not only a prevalent role of SP1 in the context of 
ERRα binding, but also that this co-occurrence at ERRα peaks is enriched when ERRα is not 
directly coactivated by PGC-1α, as SP1 occurs less often in the “only PGC-1α” peaks. Motivated 
by these results, we validated and confirmed by ChIP the presence of SP1 both at the promoters 
of the known target genes RIP140 and Fasn [24, 25] and at ERRα peaks hosting a predicted 
SP1 binding site in the proximity of four distinct protein coding genes (Fig. 3D). Another 
interesting observation from this binding sites motif search step is the difference in the number of 
SP1 TFBSs not only in the peaks, but also in the shuffled dataset (Fig. 3C); as SP1 is known to 
bind GC-rich regions, these results might reflect a different nucleotide composition between our 
three peak sets. Accordingly, we analyzed the CpG content of “only ERRα” and “only PGC-1α” 
peaks and further subdivided these peak sets into proximal and distal binding regions, where 
“proximal” is referred to peaks within 1kb from their associated gene promoter and “distal” to 
peaks located farther away. As clearly shown in Fig. 3E and Fig. 3F, the “only ERRα” peaks host 
more CpG dinucleotides with respect to “only PGC-1α” peaks; moreover, the fraction of “only 
ERRα” proximal peaks is much higher (~1/2) than the corresponding fraction of “only PGC-1α” 
peaks (~1/6). These results confirm the higher proximity of ERRα with respect to PGC-1α 
relative to their associated target genes and suggesting a different preference of ERRα binding 
to high- or low-CpG regions when recruited to proximal or distal sites, respectively. This pattern 
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was reflected when we juxtaposed all ERRα peaks to all PGC-1α peaks by comparing their 
CpG- and GC-content (Suppl. Fig. S3). 
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Figure 3. SP1 is the top transcription factor partner for ERRα in skeletal muscle. (A) PCA analysis of 
the 3225 ERRα peaks. The names of the motifs with the largest projections on the first two principal 
components are indicated. Purple and light blue ellipses highlight motif clusters, as identified by PC1, of 
nuclear hormone receptor-like motifs and SP1-like motifs, respectively. (B) Top and bottom scoring results 
of motif search obtained by comparing the TFBSs predictions within the “only ERRα peaks” with those in 
the “only PGC-1α peaks”. (C) TFBSs posterior sum for SP1 in “only ERRα”, “overlapping ERRα and PGC-
1α” and “only PGC-1α” peaks. For each dataset, TFBS occurrences were compared against binding site 
predictions performed on the corresponding background set of shuffled peaks. (D) qRT-PCR validation of 
the ChIP enrichment measured at the promoter of a set of SP1 known target genes and around the 
predicted SP1 site within the ERRα peaks associated to the genes Pdpr, Lrpprc, Acot13 and Mul1. Bars 
represent fold enrichment over that of the 18S rRNA gene, error bars represent SEM. *p < 0.05; **p < 
0.01; ***p < 0.001. (E-F) Density plot of the CpG content of “only ERRα” (E) and “only PGC-1α” (F) peaks, 
located either proximally (≤ 1 kb) or distally (> 1 kb) from the closest promoter. Each inset shows the bar 
plot of the number of “proximal” and “distal” peaks. 
5.4.4. ERRα displays different binding specificities upon dimerization and PGC-1α 
coactivation 
In the next step, we investigated whether ERRα showed distinct binding specificities across the 
three different peak groups and whether these might suggest precise preferences for a particular 
mode of binding (monomeric or dimeric) in a given genomic context. For this purpose, we used a 
novel approach for the analysis of transcription factor binding specificities, recently developed in 
our group (Omidi et al., in preparation). In particular, this method goes beyond the classical 
assumption that each nucleotide in a binding site contributes independently to the protein’s 
interaction with DNA; instead, this approach takes into account the possible interdependencies 
between different positions, observed to be not negligible in several biochemical, statistical and 
crystallographic studies [26-28]. As shown by Omidi and colleagues, incorporating these 
dependencies into sequence-specific affinity models improves predictive accuracy in many 
cases. 
Surprisingly, when we applied this approach to our three peak sets (“only ERRα”, “overlapping 
ERRα and PGC-1α” and “only PGC-1α” peaks), we noticed that, although there are internal 
dependencies between the positions 4,5,and 6 in every group, the dependencies between initial 
and final positions (1-2 and 13-14) of the motif are only observed for “overlapping ERRα and 
PGC-1α” and “only PGC-1α” peaks, but not for “only ERRα” peaks (Fig. 4A-C). Since 
dependencies at the ends of the motif can be interpreted as an indication that the TF is likely to 
bind DNA as a dimer, these results suggest that, in the absence of direct coactivation by PGC-
1α, ERRα binding sites might be found more often in a monomeric form rather than dimeric. We 
decided to go a step further and to investigate the presence of any difference in the spacing 
between potential dimers. For this purpose, we used the core recognition motif “AGGTCA” of the 
ESRRA weight matrix for building nuclear receptor dimers in direct, everted or inverted 
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configurations with a variable spacing between half-sites that ranged from 1 to 10 nucleotides. 
As shown in Figs.4 D-E, there was not a clearly preferred spacing for each particular dimer 
configuration; however, we noticed a general trend of some spacings more preferred than others 
in “only ERRα” and “overlapping ERRα and PGC-1α” peaks, as opposed to “only PGC-1α” 
peaks, suggesting the possibility that PGC-1α might coactivate several types of nuclear 
receptors with different spacing preferences between their monomers. In addition, the direct 
repeat dimer resulted as the most frequently observed configuration in all the three peak sets, 
predicted in 62.3% of the “only ERRα” peaks, in 58.9% of the “overlapping ERRα and PGC-1α” 
peaks and in 52.5% of the “only PGC-1α” peaks. 
Interestingly, when we compared the fraction of monomers over dimers across peak sets (as 
shown in Fig. 4G), we noticed that this ratio was twice as big in “only ERRα” peaks with respect 
to the “overlapping ERRα and PGC-1α” peaks, suggesting that ERRα core recognition sites tend 
to occur more often as dimer when they are coactivated by PGC-1α. Furthermore, the same 
trend was observed when we normalized the number of monomers by the sum of monomers 
and dimers in each peak set; in fact, the “only ERRα” peaks showed the highest fraction of 
nuclear receptor monomers (39%) with respect to the other two groups (Fig. 4G). Taken 
together, our results suggest that the core recognition site of ERRα occurs more often in the 
monomeric form when it is not coactivated by PGC-1α, with respect to the case when both 
ERRα and PGC-1α co-localize in the same regulatory regions; moreover, these findings leave 
open the possibility that, as a monomer, ERRα might bind with other partners than PGC-1α. 
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Figure 4. In the absence of a direct coactivation by PGC-1α, ERRα prefers to bind DNA as a 
monomer. (A-C) Motif logo showing the interdependencies between the different positions of the ESRRA 
weight matrix identified in “only ERRα”, “overlapping ERRα and PGC-1α” and “only PGC-1α”. 
Dependencies between positions are indicated by a blue curved line, while yellow ellipses highlight the 
dependencies which are in “overlapping ERRα and PGC-1α” and “only PGC-1α” peaks, but not in “only 
ERRα” peaks. (D-F) Percentage of direct, inverted and everted nuclear receptor dimers across our three 
peak sets, with spacings between half-sites ranging from 1 to 10. (G) Table showing the posterior sum 
and the fraction of nuclear receptor monomers and dimers across our three peak sets. 
5.4.5. Modeling and validating the indirect gene regulatory effects of PGC-1α in 
absence of ERRα binding 
In order to get an overview of the distinct peak distributions with regards to gene regulation, we 
stratified all differentially regulated target genes according to the types of ChIP-Seq peaks 
located in a window spanning from -10 kb from the gene’s most upstream promoter to +10 kb 
from the gene’s most downstream promoter. As shown in Figure 5A, the largest fraction of both 
up- and down-regulated genes does not have any PGC-1α and/or ERRα peaks in their 
neighborhood, suggesting that most of the differentially expressed genes are actually indirectly 
regulated by PGC-1α, in the absence of any ERRα peak. Therefore, we further investigated 
which other transcription factors might be mediating these indirect regulatory effects. For this 
reason, we extended a previously introduced framework, called Integrated System for Motif 
Activity Response Analysis (ISMARA) [19], to incorporate the ChIP-Seq data with the gene 
expression profiles (see Methods for more details) and to model these observations in terms of 
the TFBSs occurring within promoters and of the unknown regulatory “activities” of each input 
motif. In particular, after classifying promoters into distinct groups of direct or indirect targets, 
according to the presence or absence of PGC-1α and ERRα peaks, we focused particularly on 
the indirect targets group, whose top 30 motifs are listed in Figure 5B. 
The first observation is that ESRRA is still the top motif of the list; this might be due to the above 
mentioned possibility of having homologous proteins recognized by the same PWM or to the fact 
that some real ERRα binding sites were just below the detection threshold of our peak caller. 
Secondly, we realized that the most active motifs host several known partners of either PGC-1α 
or ERRα: NR5A1 (also known as SF1), NR5A2 (also known as LHR1), MEF2C, RXRs and 
ESR1. Finally and most interestingly, among the top 10 motifs we noticed two transcription 
factors, Znf143 and Nfyc, which we previously suggested to be new potential PGC-1α partners 
and to be either significantly induced by PGC-1α or among the top over-represented motifs in 
the PGC-1α peaks [11]. In line with our previous findings, for both motifs the activity inferred by 
ISMARA increased significantly upon PGC-1α over-expression and decreased following ERRα 
knockdown in the subset of promoters not assigned to any peak, although to a lesser extent for 
126 
ZNF143 with respect to NFYC (Fig. 5C). Therefore, we decided to experimentally validate these 
two potential downstream effectors of PGC-1α by performing a siRNA-based knockdown of 
Znf143 and Nfyc in C2C12 myotubes and by analyzing, through a microarray, the expression 
levels of these two candidate transcription factors and of their target genes. This experiment 
resulted in a strong reduction of the expression of the TFs, as well as the expression levels of a 
total of 128 genes for Znf143 and 73 for Nfyc, which were all significantly induced by PGC-1α 
and repressed by the knockdown of the corresponding factor. Some examples of these Znf143 
and Nfyc target genes, which were not assigned to any PGC-1α and/or ERRα peak, are shown 
in Fig. 5D. Furthermore, when we performed a Gene Ontology (GO) and KEGG over-
representation analysis on the genes having no peaks around them, induced by PGC-1α and 
repressed by the knockdown of either Nfyc (81 genes) or Znf143 (154 genes), we noticed that 
the most enriched terms are related to mitochondrial organization and energy metabolism (Fig. 
5E and 5F). These results highlight once more the central role of PGC-1α in the control of 
mitochondrial biogenesis and energy homeostasis in skeletal muscle, even in the absence of a 
direct recruitment of this coactivator. Moreover, since these gene sets represent ~15% and 
~28% of Nfyc and Znf143 targets, respectively, we conclude that these two transcription factors 
are novel partners of PGC-1α in the indirectly mediated regulation of skeletal muscle plasticity. 
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Figure 5. Prediction and validation of the indirect gene regulatory effects of PGC-1α, in the 
absence of ERRα recruitment, mediated by Nfyc and Znf143. (A) Counts of different combinations of 
PGC-1α and ERRα peaks located in the vicinity of all differentially regulated genes. (B) Top 30 active 
motifs in the promoters not associated to any PGC-1α and/or ERRα peak, as predicted by ISMARA. The 
motifs chosen for validation are highlighted in bold. (C) Activity plots of the motifs NFY(A,B,C) and 
ZNF143, as predicted by ISMARA, in the following conditions: (i) GFP over-expression, (ii) PGC-1α over-
expression and (iii) PGC-1α over-expression + shERRα knockdown + XCT-790. (D) Fold change levels, 
as measured by a microarray experiment, of Nfyc, Znf143 and 10 other genes significantly up-regulated 
by PGC-1α over-expression (OV), significantly down-regulated by either siNfyc or siZnf143 knockdown 
(KD) and without any PGC-1α and/or ERRα peak in their vicinity. (E-F) Subsets of the top significantly 
enriched GO and KEGG terms identified for Nfyc (E) and Znf143 (F) target gene sets, as defined in 
Fig.5D. 
5.5. Discussion 
The nuclear receptor ERRα has been described as an effector of PGC-1α-induced regulation of 
gene expression in all highly oxidative organs, like skeletal muscle, adipose tissue or heart [29-
31]. In skeletal muscle, PGC-1α promotes and coactivates ERRα to increase its transcriptional 
activity; in turn, these two proteins were shown to induce the expression of genes involved in 
mitochondrial biogenesis, oxidative phosphorylation and fatty acid oxidation [7, 8, 32]. Moreover, 
the induction of the vascular endothelial growth factor (VEGF) and angiogenesis in skeletal 
muscle by PGC-1α involves transcriptional activity of ERRα [33]; in addition, PGC-1α induces 
the sirtuin 3 (SIRT3) gene through ERRα to regulate the suppression of reactive oxygen species 
in skeletal muscle cells [34]. 
However, all these studies were focused on the transcription of individual genes or of a small set 
of genes. To date, it is not known, on a genome-wide scale, to which extent is ERRα required by 
PGC-1α for the regulation of these biological programs. We now answered this question by 
providing a global picture of gene expression regulation by PGC-1α and ERRα in skeletal 
muscle cells. The first evidence that ERRα can be recruited to DNA also independently from 
PGC-1α is provided by the fact that our ChIP-Seq experiment revealed binding of ERRα and 
PGC-1α to both shared and distinct sets of target genes. Indeed, while the occurrence of ERRα 
at the promoter regions of known PGC-1α target genes (Suppl. Fig. S1) confirms that PGC-1α 
coactivates ERRα to drive the expression of these genes, the observation that only a minor 
fraction of ERRα and PGC-1α peaks is overlapping suggests that the long-term believed 
concept of a symbiotic cooperation between these two proteins is actually only restricted to a 
subset of their target genes. Moreover, we showed that ERRα is required by PGC-1α to induce 
the expression of about two thirds of both its directly- and indirectly-controlled targets. These 
results confirm that ERRα is a crucial partner of PGC-1α and that it is required for the regulation 
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of most of PGC-1α targets, in order to guarantee an efficient control of processes which are 
essential for cell energy metabolism. On the other hand, PGC-1α is able to control these 
biological pathways also in the absence of its classical binding partner and, probably, through 
coactivation of alternative transcription factors. It is in fact not surprising that PGC-1α can be 
recruited to the regulatory elements of its target genes without being bound to ERRα, as several 
studies previously showed that PGC-1α is capable of binding and coactivating numerous 
transcription factors in skeletal muscle. Some examples are the nuclear respiratory factor 1 
(NRF-1) and the nuclear respiratory factor 2 (NRF-2). Upon coactivation by PGC-1α, the former 
TF induces the expression of the mitochondrial transcription factor A (mtTFA) and thus the 
transcription and replication of mitochondrial DNA [35], while the latter TF promotes the 
expression of genes involved in oxidative phosphorylation and neuromuscular junction formation 
[8, 36]. Similarly, PGC-1α regulates the activity of the myocyte enhancer factor 2C (MEF2C) to 
induce the expression of GLUT4 and thus to control glucose uptake in muscle [37]. 
Nevertheless, although it was expected that PGC-1α can regulate transcription also without 
ERRα, we were surprised to find that, symmetrically, ERRα can be recruited to DNA also without 
direct coactivation by PGC-1α. Previous studies, showing that ERRα is in a transcriptionally 
active conformation when complexed with PGC-1α in the absence of other ligands [38], led to 
the idea that this orphan nuclear receptor is activated by coactivator proteins rather than by 
small molecule ligands [39]. Here we show, on a genome-wide scale, that ERRα can bind to 
several regulatory regions without a direct coactivation by PGC-1α. 
A reasonable question at this point would be: if ERRα is often not directly coactivated by PGC-
1α, can we identify other possible partners of ERRα co-occurring at the same regulatory 
regions? By combining motif search and principal component analysis (PCA), we showed here 
that SP1 is the top over-represented transcription factor in the subset of ERRα peaks not 
overlapping any PGC-1α peak. In addition, we validated by ChIP the significant enrichment of 
SP1 at four predicted SP1 binding sites within ERRα peaks. To date, there is only one evidence 
that SP1 can interact in vivo with ERRα, as shown by a GST pull-down assay in 2006 [40], 
although it is known that the GST protein is prone to non-specific interactions [41]. Finally, 
another study identified both SP1 and ERRα as modulators of the transcriptional activity of the 
coregulator RIP140, also called Nrip1 [24]. Herewith, we provide clear evidence, by ChIP 
validation, that SP1 and ERRα are co-localized at the same regulatory regions. 
Most interestingly, we also found that SP1 tends to occur significantly more often in “only ERRα” 
peaks than in “only PGC-1α” peaks. In addition, we observed that the binding affinity of ERRα 
itself is slightly different in these distinct peak sets and that, in “only ERRα” peaks, nuclear 
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receptors (including ERRα) tend to occur more often as monomers rather than as dimers. These 
findings, which require further investigation, would suggest that ERRα might function in a dual 
way: in GC-poor regions, it is often binding DNA as a dimer and it is directly coactivated by 
PGC-1α; on the other hand, in GC-rich regions, ERRα mostly co-occurs as a monomer together 
with SP1. A previous study by Barry and coworkers showed that minor changes in the ERRα 
response element (ERRE) are sufficient to determine a different preference in the mode of 
binding (as monomer or dimer) and therefore to affect ERRα interaction with the coactivator 
PGC-1α [42]. Our study now strengthens this concept with DNA occupancy data and extends it 
to the skeletal muscle tissue on a genome-wide scale. 
Finally, we investigated which other transcription factors might mediate the regulation of indirect 
PGC-1α targets in skeletal muscle without the recruitment of ERRα to their promoters. These 
indirect PGC-1α target genes might be regulated by transcription factors or coactivators which 
are themselves induced, but not coactivated by PGC-1α. One such downstream effector of the 
PGC-1α/ERRα signaling axis is Perm1, which is induced by PGC-1α and subsequently regulates 
the expression of some PGC-1α target genes [30]. Our results now indicate that the transcription 
factors Znf143 and Nfyc might be other downstream effectors of PGC-1α. In a previous study 
[11], we showed that the knockdown of these two TFs was able to prevent the PGC-1α-
controlled up-regulation of a set of genes associated to PGC-1α peaks with binding site 
predictions for either Znf143 or Nfyc. Now, we show, by an expression array experiment, that 
two other subsets of indirect PGC-1α target genes – that is, not assigned to any PGC-1α peak – 
are significantly down-regulated by either Znf143 or Nfyc knockdown, respectively. 
In conclusion, this study describes the genome-wide map of ERRα recruitment to DNA, in the 
context of over-expressed PGC-1α in skeletal muscle. By a comparison to a previous study on 
PGC-1α occupancy, we could identify and distinguish different subsets of genes whose 
regulatory regions were either bound by ERRα, PGC-1α or both. Moreover, we discovered that 
ERRα is required by PGC-1α to induce most of its direct and indirect targets, mainly involved in 
the regulation of mitochondrial organization and energy metabolism. In addition, we propose a 
mechanism in which ERRα is coactivated mostly as a dimer by PGC-1α, whereas, as a 
monomer, it is often co-localized with SP1 in GC-rich regions. Finally, we suggest two 
transcription factors, Nfyc and Znf143, as novel potential mediators of PGC-1α indirectly 
regulated gene up-regulation. In summary, by elucidating the relationship between PGC-1α and 
ERRα, we additionally identified novel members and regulatory mechanisms of the PGC-1α-
controlled transcriptional network that modulates energy metabolism in skeletal muscle. 
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5.6. Supplementary figures and tables 
 
Suppl. Figure S1. Related to Figure 1. (A) ERRα read densities around the TSS of the known target 
genes Pdk4 and Idh3a, as displayed by the UCSC Genome Browser. (B) Real-time PCR validation of the 
ChIP enrichment measured at the promoter of a set of ERRα target genes. Bars represent fold enrichment 
over that of the TBP intron. 
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Suppl. Figure S2. Related to Figure 3. (A) Fraction of explained variance of the top 10 PCA 
components. (B) Barchart representing the different classes of peaks (“only ERRα”, “only PGC1α”, 
“overlapping ERRα and PGC1α”) together with the regulation of their associated promoters (“up”, “down”, 
“non-changing”, “no promoter assigned”). Numbers shown on top of each box represent the absolute peak 
counts. 
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Suppl. Figure S3. Related to Figure 3. (A-B) Two-dimensional histogram (shown as a heatmap) of the 
GC base content (horizontal axis) and CpG dinucleotide content (vertical axis) of all PGC-1α peaks (A) 
and of all ERRα peaks (B). The values shown on both axes are expressed as logarithms. 
Suppl. Table 1. Real-time primer sequences 
Real-time PCR primers used for ChIP validation   
Gene promoter or intron Forward primer Reverse primer 
TBP intron TGTGAGCTCCTTGGCTTTTT ATAGTTGCCCAGCAATCAGG 
promoter of Acadm CCTTGCCCGAGCCTAAAC GTCTGGCTGCGCCCTCT 
promoter of ATP5b CTGGAAACTTCCACCCTCACTA GAGAGGTTTTTGGCGGAACTA 
promoter of Idh3a GGACGGCGTCAAGGTCAAG  GCCTAGGTGGCCTGTCTGTG 
pNrip1 CACGCCATTCAGCTCTTCAG GTGACAATGGGAGGGAGGG 
pFasn CTGGAGCACAAGGAACGC GGACAGAGATGAGGGCGTC 
Pdpr CACACTCGTCGTCAACCAG GTGCGCTTGTTTGGGTCTC 
Lrpprc ACAACACCCCTCCACTTTGA CGGTGTCGCTCCTAGTTG 
Acot13 TCACTCTTTAGCGCCCCAG AAGACCGCCCTCTCTGGT 
Mul1 ACTCCATATACCGGCAGAAGG GAGCTGCCAGTGAGACCG 
   Real-time PCR primers used for testing the knockdown of ERRα 
Gene Forward primer Reverse primer 
18S AGTCCCTGCCCTTTGTACACA CGATCCGAGGGCCTCACTA 
PGC-1α TGATGTGAATGACTTGGATACAGACA GCTCATTGTTGTACTGGTTGGATATG 
ERRα ACTGCAGAGTGTGTGGATGG GCCCCCTCTTCATCTAGGAC 
Acadm AACACTTACTATGCCTCGATTGCA CCATAGCCTCCGAAAATCTGAA 
Aim1l CCTGTTGCGTCCATAAGGGT GCTCTGAGTTCCACATCCCC 
Twf2 TGCTACCTCCTCTTCCGACT ATAGCATCTTCAGCCGCACC 
Atg9b TGGCATCACATCCAGAACCT CATTGTAATCCACGCAGCGA 
Ifrd1 GACAAGAGAAAGCAGCGGTC GGTACTGCATCCCTGATCCA 
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6. Discussion 
More than a decade of studies have established the coactivator PGC-1α and its well-known 
partner ERRα as the key modulators of skeletal muscle plasticity in response to a myriad of 
factors – including exercise, caloric restriction and oxidative stress – and with major 
consequences for health (for a recent review, see [1]). To address such a complex variety of 
stimuli, these proteins interact with a multitude of chromatin remodelers and transcription factors, 
of which, most likely, only a few have been discovered so far. In this study, we expand the 
transcriptional network of PGC-1α and ERRα through a successful combination of high-
throughput techniques and computational analysis. Using a genome-wide approach, for the first 
time to our knowledge, we have mapped all the loci in skeletal muscle cells where PGC-1α and 
ERRα are recruited to. Moreover, the fruitful integration of ChIP-Seq and microarray data 
allowed us to link genomic occupancy to direct and indirect target gene regulation. 
The first focus of this study was the optimization of the several steps involved in our ChIP-Seq 
analysis pipeline. In particular, we worked out a series of artifacts one could encounter in this 
type of computational analysis. One of these is the PCR amplification error, caused by extra 
runs of amplification from only few starting DNA molecules, which may lead to problems in the 
downstream steps of the analysis. Another such artifact originates from the under-estimated 
presence of repeats in reference genomes, causing lots of sequenced reads to map all in the 
same region and giving rise to false positive peaks. Moreover, all current high-throughput 
technologies have an average error rate that is considerably higher than the classical Sanger 
sequencing [2], requiring a quality filtering step before the read mapping to the reference 
genome. In our opinion, the best way to deal with these problems was, respectively: (i) to assign 
a weight of 1 to any “stack” of reads starting at the same genomic position, (ii) to remove sliding 
windows containing an amount of background reads exceeding a given cutoff and (iii) to 
implement a read quality filter based on the FASTQ sequencing scores. In addition, to reduce 
the amount of false positive peaks called by commonly used peak finders, we implemented our 
own algorithm to evaluate local IP enrichment versus background by calculating a Z score for 
every genomic region. In the future developments of this study, we could use a more 
sophisticated noise model for the peak calling step (for example, a log-normal distribution of 
read counts) and adopt a mixture model to refine peaks and to identify individual binding events 
at higher resolution. 
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One of the our first observations from the analysis of PGC-1α and ERRα ChIP-Seq experiments 
was the fact that both these proteins can often be found in intergenic regions, which is much 
further from genes than what current literature suggests; in fact, most of the genetic and 
molecular studies on PGC-1α and ERRα identified their recruitment sites in the immediate 
vicinity (or proximal promoters) of their target genes (for example, see [3, 4]). Most interestingly, 
the majority (~57%) of our ERRα peaks – and an even higher fraction of PGC-1α peaks (~69%) 
– is not assigned to any mouse promoter within a distance of 10 kb. Because of this maximum-
distance cutoff, one limitation of our method is to consider the peak as not annotated whenever it 
is located further than this distance from the closest promoter; however, a considerable fraction 
of our peaks (~25% for ERRα and ~31% for PGC-1α) are located within an intronic region of a 
very long gene, thus being more distant than the defined cutoff from the gene’s promoter. As 
shown by several studies (for example [5]), cis-acting regulatory elements located within 
noncoding regions of genomic DNA, like introns, can loop over DNA and enable long-range 
regulatory interactions with promoter regions. In addition, we showed that a considerable fraction 
of these not annotated peaks overlap histone modifications like H3K4me1 and H3K18ac, both 
known to be present at active and inactive/poised enhancers (see chapter 3). Taken together, 
these considerations suggest the hypothesis that several of our PGC-1α and ERRα peaks might 
be located within intergenic or intronic enhancers and thus behave as distal regulatory elements. 
Another interesting outcome of our study is the confirmation of the inability of PGC-1α to directly 
repress its downstream targets expression, in contrast to what was suggested by other studies 
[6, 7]. Using a customized version of ISMARA [8], we integrated the information coming from an 
expression array of over-expressed PGC-1α versus GFP to the ChIP-Seq data; in this way, we 
were able to model, for the first time, the direct and indirect regulatory effects of PGC-1α in 
skeletal muscle. Although several motifs showed a significant decrease of their activity upon 
PGC-1α over-expression on indirect targets, no significant reduction in the activity exerted on 
direct target promoters was observed for any motif. Most interestingly, the group of transcription 
factors showing this activity pattern includes the STAT proteins, the IRFs and NFκB, all known to 
be involved in inflammatory processes. Recently, we and others have shown that PGC-1α is 
able to reduce the transcriptional activity of NFκB in vitro and in vivo [9, 10]. Our results now 
confirm that this anti-inflammatory activity of PGC-1α is exclusively indirect. Moreover, as shown 
in chapter 3, the fact that the overlap between PGC-1α non-annotated peaks and the repressive 
histone modification H3K27me3 was one of the lowest we observed (only ~4.9%), suggests that 
an alternative repressive mechanism of modifying chromatin condensation from an active to a 
repressive state can also be excluded. 
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By distinguishing direct from indirect effects of PGC-1α, we also found, unexpectedly, that many 
genes involved in the highly enriched GO terms related to oxidative metabolic pathways are 
indirectly controlled by PGC-1α, meaning that they do not require a direct recruitment of this 
coactivator to their regulatory sites. Based on previous studies, we expected the regulation of 
these pathways to be directly controlled by PGC-1α, mostly in partnership with ERRα [11, 12]. 
Surprisingly, our data indicate that ERRα is active both in presence and absence of PGC-1α 
coactivation (see chapter 4), suggesting that the nuclear receptor was already induced, most 
probably by PGC-1α itself, at the one time point when the experiment was performed. 
Altogether, these observations suggest that PGC-1α might affect oxidative metabolic pathways 
at different levels, primarily acting as an upstream regulator of other TFs (like ERRα), which are 
controlling, at later stages, more downstream PGC-1α targets without need of a direct 
coactivation by PGC-1α itself. Unfortunately, a ChIP-Seq experiment is merely a snapshot of the 
occupancy of a protein of interest at a given time point. On the other hand, taking into account 
the fact that PGC-1α is rhythmically expressed in skeletal muscle and stimulates the expression 
of clock genes like Bmal1 and Rev-erbα [13], an interesting future direction of this project would 
be the analysis of PGC-1α occupancy in skeletal muscle at different time points. This way, 
integrating these data to a time-course RNA profiling dataset like the one described in [14], we 
could identify the temporal and causal relationship between PGC-1α and all its intermediate 
effectors that lead to the activation of mitochondrial biogenesis and energy metabolism in 
skeletal muscle. 
Regarding ERRα, several studies have focused so far on the regulation of individual genes or 
small sets of genes. Our study provides, for the first time to our knowledge, a global picture of 
ERRα genome-wide recruitment in skeletal muscle cells, in the context of PGC-1α over-
expression (see chapter 5). As mentioned before, ERRα seems to be able to bind and regulate 
target gene expression also without being directly coactivated by PGC-1α. Although previous 
studies showed that ERRα is induced to high levels by PGC-1α and is present in an active 
conformation when bound to PGC-1α [15, 16], there are no evidences to date that this nuclear 
receptor can also be recruited to the DNA without a direct interaction with PGC-1α. In a report 
from Ronald Evans’ group, the authors demonstrated that the transcriptional activity of hERR1, 
the human ortholog of the murine ERRα, is potentiated in a ligand-independent manner by the 
coactivators ACTR (activator of thyroid and retinoic acid receptors), GRIP1 (glucocorticoid 
receptor interacting protein 1), and SRC-1 (steroid receptor coactivator 1) [17]. A later study in 
human breast cancer showed that the correlation between ERRα expression with that of the 
coactivator ACTR (also called AIB1) is even stronger than with PGC-1α [18]. Taken together, 
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these studies strongly suggest that, apart from PGC-1α, other coactivators could as well 
regulate ERRα transcriptional activity in skeletal muscle, therefore explaining the lack of PGC-1α 
recruitment to most of the ERRα sites. 
An obvious question at this point is the following: if PGC-1α is not coactivating at these ERRα 
peaks, what other factors is ERRα working with? As shown in chapter 5, the specificity factor 
SP1 turned out to be the most over-represented transcription factor within the peaks occupied by 
ERRα, but not by PGC-1α. Moreover, we could validate some of our SP1 binding site predictions 
and show a significant enrichment of this protein at some ERRα peaks. The few studies that 
have previously investigated the relationship between ERRα and SP1 are somehow 
contradictory. The first, in 2003, proposed that SP1 is important for ERRα transcription in 
human, although the authors did not show actual binding of the SP1 protein to the corresponding 
sites at the ERRα gene promoter [19]; two years later, a second study suggested that ERRα up-
regulates the endogenous SP1 gene expression by binding to its promoter region [20]. In 2006, 
Castet and coworkers showed by GST pull-down assay that SP1 interacts in vitro with the ERR 
proteins [21], although it is known that the GST protein is prone to non-specific interactions [22]. 
Moreover, another study showed that siRNA knockdown of SP1 reduced the transcriptional 
activity of ERRα at the P2 promoter of the coregulator RIP140 [23]. Taken together, these 
results suggest that SP1 might be a functional partner for ERRα, although the in vivo interaction 
remains to be further investigated. In this context, our study provides a genome-wide evidence 
that ERRα and SP1 are often co-occurring at the same regulatory regions and confirms the 
accuracy of these predictions by in situ ChIP validation. 
As for ERRα, also for PGC-1α the combination of high-throughput techniques and computational 
analysis methods enabled us to discover a novel transcription partner: the heterodimeric protein 
AP-1, which is involved in a number of cellular processes including differentiation, proliferation, 
apoptosis and hypoxia [24, 25]. In particular, through siRNA knockdown, we could provide 
evidence that depletion of the AP-1 members FOS, JUN and ATF3 reduced the ability of PGC-
1α to induce target gene expression. Moreover, we found that AP-1/PGC-1α targets are involved 
in the response to hypoxia pathway and showed that FOS and PGC-1α are co-recruited to the 
same regulatory sites in proximity of these target genes. Most probably, to ensure an adequate 
oxygen supply for oxidative metabolism in skeletal muscle cells, PGC-1α coordinates these 
metabolic needs through different partners: by coactivating ERRα, it induces Vegf expression 
and, thus, promotes vascularization; on the other hand, through AP-1, PGC-1α enhances the 
expression of genes involved in cell survival, oxidative stress response and reduction of 
inflammation (see chapter 4). In summary, we provide additional evidence of PGC-1α ability to 
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control and integrate different signaling pathways using a set of several transcription factor 
binding partners, of which AP-1 is a new component. In the future steps of this project, we could 
further investigate the genome-wide occupancy of AP-1 in the context of PGC-1α over-
expression and verify the effects on hypoxia of this transcription factor in vitro, by keeping 
muscle cells under different hypoxic conditions, and in vivo, by analyzing mice performances 
upon treadmill running exercise in low oxygen conditions. 
The identification of both SP1 and AP-1 as novel partners of ERRα and PGC-1α, respectively, 
was possible mainly thanks to the Principal Component Analysis (PCA) technique, that we 
applied on a large matrix containing all TFBSs predicted within each ChIP-Seq peak set. In the 
past, PCA has been extensively used for a number of biological applications and, in particular, 
for the analysis of genome-wide expression studies to reduce multi-dimensional data and to 
extract the key features explaining most of the observed variation (e.g., see [26]). In fact, as a 
feature extraction technique, PCA reduces the amount of information required to accurately 
describe a large set of data, at a relatively low computational cost. In our context, we aimed to 
identify the structure of binding site occurrences within ChIP-Seq peaks and, more precisely, the 
linear combinations of regulatory motifs that explained most of the variation in site-counts which 
we observed across our peaks. As described in the previous chapters, using PCA on our 
datasets revealed to be a very successful approach, since it allowed us to detect different types 
of peaks and, thus, to identify novel transcriptional partners for the chipped proteins of interest. 
The accuracy of our predictions was confirmed experimentally, as shown more in detail in 
Chapter 4 and Chapter 5. 
Due to the low basal expression level of PGC-1α and since we did not have a ChIP-grade 
antibody for PGC-1α, we used adenoviral vectors to introduce exogenous tagged PGC-1α 
protein in skeletal muscle cells. In the expression array, to control for the effects of this 
approach, we also measured gene expression levels upon transfection with GFP adenovirus. 
However, despite performing the appropriate controls, this artificial condition does not 
completely reflect the effects of the endogenous PGC-1α protein. Moreover, using muscle cells 
as we did, it is not possible to study physiological processes such as angiogenesis or fiber type 
switch. In the light of these observations, an interesting future development of this project would 
be the comparison of our present results with a ChIP-Seq experiment on PGC-1α occupancy in 
vivo. This approach would in fact allow the investigation of the previously mentioned biological 
processes, as well as the study of different muscle trainings and muscle-related pathologies. 
Likewise, another extension of this project could be the comparison of our data from the skeletal 
muscle environment with PGC-1α genome-wide recruitment in other highly oxidative tissues, like 
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for example brain, kidney, liver and brown adipose tissue. Afterwards, an interesting 
experimental future step could be the study of PGC-1α post-translational modifications and of 
their distinct effects on the physiology of a specific tissue.  
Apart from AP-1, a number of other factors were predicted as putative partners of PGC-1α, but 
not validated yet. A possible follow-up of this study could be the verification of these transcription 
factors and, thus, the determination of the global regulatory network through which PGC-1α 
controls skeletal muscle adaptations to internal and external stimuli. However, the transcription 
factors we used for our computational analysis are only a subset of all TFs present in a living 
cell. Indeed, a crucial factor limiting the completeness of our TFBS predictions was the fact that 
the sequence specificity of many TFs is still unknown. As estimated by Vaquerizas et al. in 2009 
[27], the number of transcription factors in mammalian genomes is about ~1400 ( 6% of the 
total number of protein-coding genes), hence much higher than our set of ~350 motifs. In 
addition to this, nuclear receptors in particular have a high degree of similarity between their 
recognition sequences. For example, as we did not have a motif for the ERRα paralogs ERRβ 
and ERRγ, it is likely that some fraction of the ERRα binding sites predicted within PGC-1α 
peaks might have actually been bound by either ERRβ or ERRγ. However, due to the decrease 
of the sequencing costs, the number of available ChIP-Seq datasets deposited in public 
databases is rapidly increasing. Using these ChIP-Seq peak sets, together with available SELEX 
data, we expect the number of known regulatory motifs to expand in the near future, allowing us 
to extend our motif search and to identify novel factors involved in skeletal muscle metabolism. 
Moreover, to improve the accuracy of our TFBSs predictions, in the next steps of this study we 
could use DNase-Seq [28] to assign to each genomic region an accessibility score and reduce 
the number of falsely predicted peaks, as in [29]. In addition, another possibility would be to 
integrate our ChIP-Seq data with Hi-C deep sequencing results. This method, which is based on 
the Chromosome Conformation Capture technique and is able to detect chromatin interactions in 
the mammalian nucleus, could be used to address the limitation of long-range peak-to-gene 
annotation mentioned earlier and, at the same time, to get an idea of higher-order chromatin 
organization in skeletal muscle cells upon different treatments and in different conditions.  
In conclusion, by combining high-throughput techniques with a comprehensive computational 
analysis, the study presented herein not only extends the repertoire of transcriptional partners 
for both PGC-1α and ERRα, but elucidates the mechanism through which PGC-1α is able to 
control the response to hypoxia in skeletal muscles. Applying our approach to other tissues or in 
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other physiological or pathological conditions could help to identify novel key players of relevant 
biological processes. 
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Appendix 
In this section, I present three manuscripts to which I contributed during the PhD. 
In the first one (Appendix 1, Eisele et al., J. Biol. Chem. (2013)), I performed: the downstream 
steps of the microarray analysis concerning gene clustering and heat map creation; GO and 
KEGG enrichment analysis; binding site prediction within a region spanning 1kb around the TSS 
of each array gene; motif over-representation within the distinct gene clusters; motif activity 
response analysis (MARA). 
In the second manuscript (Appendix 2, Pérez-Schindler et al., Mol. Cell. Biol. (2012)), I 
performed the GO analysis of NCoR1 MKO and PGC-1α mTg target gene groups and created 
the heat map of the genes in the array that were annotated either as “OXPHOS” or “TCA cycle”. 
In the third manuscript (Appendix 3, Egger et al., PLoS One (2012)), I created the heat map of a 
selection of genes involved in any of the following signaling pathways: apoptosis, DNA repair, 
inflammation or phototransduction. 
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